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1.1  HYPOTHALAMIC PITUITARY ADRENAL AXIS 
1.1.1  Normal HPA-axis regulation 
Traditional concept of the stress response 
All living species aim to maintain a complex dynamic equilibrium or homeostasis, which is constantly 
challenged by internal or external adverse stimuli, called stressors.1, 2 Stress in physiological terms is 
therefore a state in which homeostasis is threatened and which should be restored by coordinated 
physiological processes, together called the stress response. This response is essential for survival. The 
stress response is exerted by the combination of the neuronal pathways, linked to the release of 
catecholamines from the adrenal medulla and the hypothalamic pituitary adrenal (HPA)-axis control to 
release glucocorticoid production by the adrenal cortex. These immediate stress responses comprise 
many orchestrated endocrine adaptations that are presumably directed towards providing the required 
energy for the „fight or flight response‟ in a context of exogenous substrate deprivation. Indeed, 
alterations within the different hypothalamic pituitary axes bring about lipolysis, proteolysis and 
gluconeogenesis and redirect energy consumption towards those processes that mediate acute survival, 
while anabolism is postponed to more prosperous times. 
To pursue this response a complex coordination of central and peripheral systems is indispensible. 
Whenever stress occurs different afferent signals activate the central nervous system (CNS). 
Consequently the CNS causes activation of the hypothalamus which initiates the release of the 
corticotropin-releasing hormone (CRH) and arginine vasopressine (AVP) which stimulates the anterior 
pituitary corticotrophs to secrete the adrenocorticotropic hormone (ACTH). ACTH induces the 
production and release of cortisol from the adrenal gland. Cortisol itself can turnoff this activation of the 
HPA-axis by negative feedback inhibition as such preventing the deleterious effects of excessive HPA-
axis activation. (Figure 1)  
Regulation of the hypothalamus 
The hypothalamus integrates all stress signals and converts these neurologic signals into hormone 
responses. Different types of stress signals, coming from sensory receptors, somatosensorial fibers, the 
prefrontal cortex, limbic system and hippocampus can stimulate the hypothalamus to release CRH and 
AVP.3 
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Figure 1 - Normal HPA-axis regulation 
with Supra-chiasmatic nucleus (SCN), central nervous system (CNS), paraventricular hypothalamus (PVH), corticotropin-
releasing hormone (CRH), arginine vasopressine (AVP) and adrenocorticotropic hormone (ACTH). (Adapted from 4) 
CRH neurons are located in the parvocellular division of the paraventricular hypothalamus (PVH) and 
release CRH at the median eminence into the primary capillary plexus of the hypothalamo-pituitary 
portal system. Furthermore, CRH is also expressed peripherally, with high levels found in the heart and 
placenta, but also in the limbic system, uterus, immune system, gastrointestinal tract, skin and adrenal 
gland. AVP is primarily produced in magnocellular neurons of the hypothalamic paraventricular and 
supraoptic nuclei, which project to the posterior pituitary to regulate vascular tonus and diuresis. 
However, AVP is also expressed by the CRH neurons in the PVN and acts as an auxiliary ACTH 
regulator in synergy with CRH.3,5,6  
Regulation of the pituitary gland 
ACTH is synthesized in the corticotroph cells of the anterior pituitary. It is derived from the  
pro-opiomelanocortin (POMC) gene, which after translation results in a prehormone. Several 
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posttranslational modification steps are required to process the POMC-prehormone in different peptides 
such as ACTH, β-lipotropin, which in turn gives rise to γ-lipoprotein and β-endorphin, and γ-melanocyte 
stimulating hormone (MSH). ACTH itself can be cleaved into α-MSH and corticotropin-like intermediate 
peptide (CLIP).7 
After release of CRH into the hypothalamo-pituitary portal system, CRH reaches the pituitary where it 
binds to the CRH-receptor. There are two types of the CRH-receptors, but activation of the HPA-axis is 
mediated exclusively through the CRH-type 1 receptor. Binding to the receptor, which is G-protein 
coupled, causes activation of adenylate cyclase followed by an increase of cyclic AMP (cAMP) and 
protein kinase A (PKA). As such POMC gene transcription is stimulated. CRH stimulation leads to a 
biphasic response with the fast release from the pool of a pre-synthesized ACTH, and a slower 
sustained release of newly synthesized ACTH.8 Furthermore, AVP, after binding to the vasopressine 1b-
receptor (V1b-receptor) in the pituitary, can stimulate ACTH secretion weakly by itself, but synergizes 
with the effects of CRH on ACTH release.3, 5, 6 
Next, a tightly regulated immune-neuroendocrine interface regulates the ACTH secretion.  
Pro-inflammatory cytokines, such as leukemia inhibitory factor (LIF), are known to stimulate POMC 
transcription and ACTH secretion. LIF is expressed in the corticotrophs of the pituitary gland and can act 
synergistic to CRH. Different other regulations of ACTH are described such as β-adrenergic 
catecholamines, vasoactive intestinal peptide and ghrelin which are all stimulators of ACTH, while 
opioids, oxytocin and atrial natriuretic peptide act as inhibitors of ACTH release. Furthermore, ACTH 
expression is negatively regulated by glucocorticoids.7 
Feedback regulation by glucocorticoids 
The HPA-axis is tightly regulated by a feedback system, where corticosteroids rapidly inhibit both CRH 
and ACTH. Glucocorticoids are lipid soluble and can therefore freely go through the blood-brain barrier. 
In the hypothalamus and pituitary they can bind to two receptors, the mineralocorticoid receptor (MR) 
and the glucocorticoid receptor (GR).9 Glucocorticoids bind to the MR with a higher affinity than to the 
GR. As a consequence, both receptors respond to different levels of glucocorticoids. MRs are 
predominantly occupied under basal resting conditions, while GRs are occupied at the circadian peak 
and following stress. Furthermore, central MRs participate in control of the sensitivity of the 
neuroendocrine stress response system, while GRs are involved in termination of the stress response.10  
The feedback regulation appears to work at three time frames.11 Fast feedback, within seconds to 
minutes, cannot be exerted by influencing gene expression or protein synthesis, but likely works by 
inhibiting ACTH release.12 Intermediate feedback occurs within 4 hours and inhibits hypothalamic CRH 
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synthesis. At last, slow feedback involves regulation of the pituitary ACTH content by decreasing levels 
of POMC mRNA. Therefore, slow feedback inhibits basal as well as stimulus-induced ACTH secretion. 
In addition, cortisol insensitive neural pathways could play a role.13-15 Clearly, the feedback regulation of 
glucocorticoids is much more complex than the initially proposed simple closed loop feedback system.16 
Circadian and ultradian rhythm 
Besides the episodic release of cortisol in response to stress, cortisol is secreted continuously to 
maintain daily homeostasis. Both ACTH and cortisol follow a diurnal rhythm with maximum levels 
reached in the morning to anticipate wakening and daily activity, while minimal levels are observed 
during sleep. These levels fluctuate continuously and are influenced by food intake and physical activity. 
It was long assumed that this rhythm was driven by a CRH secretion rhythm. However, constant 
infusion of CRH restored the diurnal rhythm in CRH-knock-out mice suggesting that CRH, although 
necessary, is not the diurnal rhythm generator.17 Recent evidence suggests that a biological clock exists 
to allow the human body to anticipate and prepare for changes and to ensure that different physiological 
processes are coordinated. The hypothalamic supra-chiasmatic nucleus (SCN) has been suggested for 
this role, as ablation leads to complete loss of circadian rhythm.18 Recent evidence also strongly 
supports that besides the SCN as the central pacemaker, an integrated activity of the adrenal intrinsic 
oscillator and the splachnic nerves maintain the periodicity of cortisol.19 
The diurnal rhythm is constructed by ultradian pulses that vary in amplitude and frequency during the 
day, with predominantly pulse amplitude determining the circadian rhythm. Increasing evidence 
supports the importance of this pulsatile release for maintaining transcriptional responsiveness of 
glucocorticoid-dependent genes and preventing desensitization of transcriptional responses in target 
tissues.20-22 Feed-forward and feed-back interactions between ACTH and cortisol have been proposed 
to account for this ultradian rhythm.23 Further research is needed to investigate the impact of circadian 
rhythm and pulsatility, since it was suggested to play a significant role in humans health and disease.24 
1.1.2. Normal adrenal gland function 
Adrenal gland anatomy and function 
The adrenal glands are small retroperitoneal organs with a pyramidal structure, situated at the cranial 
pole of each kidney. (Figure 2 A) The gland consists of two parts, the cortex and medulla, which can be 
considered as two different organs based on their embryologic origin, function and regulation.25, 26 
The medulla represents about 10% of the total adrenal gland and has a neuro-ectodermal origin. It is 
located in the center of the adrenal gland and consists of chromaffin cells that are responsible for 
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catecholamine production. The medulla is richly innervated by preganglionic sympathetic fibers and is 
therefore an extension of the sympathetic nervous system. 
The adrenal cortex is derived from the mesoderm and organized in three concentric zones. These 
zones can be differentiated based on their morphological pattern and function. (Figure 2 B,C) Beneath 
the connective tissue capsule, the zona glomerulosa, consists of a thin region of columnar small cells 
arranged in spherical nests around the periphery of the cortex. It represents only 15% of the cortex. The 
intermediate layer, the zona fasciculata is responsible for 75% of the cortex and consists of large lipid-
laden cells which form radial cords throughout a fibrovascular network. The third zone, the zona 
reticularis is composed of anastomosing cellular cords, which form a reticulum. Cells are lipid-sparse 
and contain often the brown pigment lipofuscin.25, 26 
 
Figure 2 – Adrenal gland anatomy and histology  
(A) Schematic adrenal gland anatomy with transverse section of the adrenal gland. (B) Schematic drawing of a microscopic 
section of the adrenal gland. (C) Photograph of a hematoxylin-eosin-staining of the adrenal gland. (Adapted from Pearson 
Education Inc., Benjamin Cummings 2004 and McGraw Hill Companies Inc)  
The adrenal cortex produces three groups of steroid hormones. The zona glomerulosa secretes 
mineralocorticoids, predominantly aldosterone, which is responsible for the water and electrolyte 
balance in the body. The zona fasciculata secretes glucocorticoids, with cortisol being the most 
important one in humans. At last sex steroids are produced in the zona reticularis, which regulate sexual 
differentiation and function. In humans, this zone secretes predominantly the weak androgens 
androstenedione, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS). The 
function of these androgens is regarded as having little physiological significance when gonadal function 
is normal. The zonational difference in hormone secretion is explained by the specific and differential 
expression pattern of steroidogenic enzymes throughout the three zones.25, 26  
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Steroidogenesis 
No hormones are stored in the adrenal gland and thus their secretion always requires an activation of 
the biosynthetic pathway. The production of steroid hormones in the adrenal gland starts with 
cholesterol by a process named steroidogenesis. The principal source of cholesterol (80%) is via uptake 
of low-density lipoprotein (LDL) cholesterol from the circulation via LDL-receptor (LDLR) mediated 
endocytosis. (Figure 3) To a lesser extent, both high-density lipoprotein (HDL) cholesterol and LDL are 
taken up in the adrenal gland with the scavenger receptor B1 (SCARB1) via selective cellular uptake.27 
Selective cellular uptake describes the selective uptake of only cholesterol-esters, without internalizing 
the complete lipoprotein particle itself. HDL-uptake is more important than previously thought, since 
patients with very low levels of LDL-cholesterol have a normal cortisol production.28 The remaining 20% 
of cholesterol is generated de novo within the adrenal cortex, starting from acetyl coenzyme A (acetyl 
coA) and regulated by the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR). After uptake and production in the adrenal gland, the cholesterol molecules are esterified 
and stored in intracellular vesicles, where they reside until steroidogenesis starts.29 
Figure 3- Cholesterol uptake and storage   
with LDL-receptor (LDLR), scavenger receptor B1 (SCARB1), Hormone sensitive lipase (HSL), Acyl co-enzyme A: 
cholesterol acyltransferase (ACAT), cholesterol esters (CE), HMG co-enzyme A reductase (HMGCR), steroid acute 
regulatory protein (STAR) and cytochrome P450 cholesterol side-chain cleavage enzyme (CYP11A1) (Adapted from 27) 
Whenever cortisol is needed, cholesterol esterase (predominantly hormone sensitive lipase (HSL)) 
rapidly mobilizes cholesterol out of the lipid droplets to the cytoplasm. Thereafter cholesterol must be 
transported from the outer to the inner membrane of the mitochondria (IMM), where steroidogenesis 
starts. This transport is mediated by the steroidogenic acute regulatory protein (STAR), which is highly 
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important for cortisol production, since absence of this protein severely impairs steroidogenesis.30 
Furthermore, peripheral type benzodiazepine receptor (PBR) helps STAR to transport cholesterol to the 
mitochondria.31  
In the IMM cytochrome P450 cholesterol side-chain cleavage enzyme (CYP11A1) catalyzes the 
conversion of cholesterol to pregnenolone, which is the rate-limiting step in steroidogenesis. (Figure 4) 
Next, pregnenolone is converted to progesterone in the endoplasmatic reticulum by 3β-hydroxysteroid 
dehydrogenase (3β-HSD), followed by a hydroxylation to 17OH-progesterone through the activity of 
17α-hydroxylase (CYP17). Further hydroxylation by 21-hydroxylase (CYP21A2) results in 11-
deoxycortisol. In the final step, which occurs again in the mitochondria, 11-deoxycortisol is hydroxylated 
by 11β-hydroxylase (CYP11B) to cortisol.32 
The production of the other steroid hormones in the adrenal gland occurs in parallel and considerable 
interconversion between these pathways is possible. However, the expression of certain genes is 
restricted to specific cortical layers. As such the zona glomerulosa does not express CYP17 which is 
necessary for synthesis of 17-hydroxypregnenolone and 17-hydroxyprogesterone, while expression of 
aldosterone synthase (CYP11B2) is restricted to this zone.33 (Figure 4) 
 
Figure 4 – The Steroidogenesis  
with P450 cholesterol side-chain cleavage enzyme (CYP11A1), 3β-hydroxysteroid dehydrogenase (3β-HSD),  
17α-hydroxylase (CYP17), 21-hydroxylase (CYP21A2), 11β-hydroxylase (CYP11B)  
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Regulation by ACTH 
The primary role of ACTH is to maintain the adrenal gland size, structure and function. Binding of ACTH 
to the melanocortin-2-receptor (MC2R) on the adrenocortical cells activates adenylyl cyclase and results 
in increased cAMP concentrations, which stimulates PKA.34 PKA causes phosphorylation of different 
proteins and different nuclear transcription factors such as cAMP response element binding protein 
(CREB), which influences gene expression by binding to the cAMP response element (CRE) residing in 
the promoter regions of those genes. 
ACTH function can be divided into acute and chronic effects. Immediately after ACTH is bound, 
phosphorylation of cholesterol esterase leads to the release of cholesterol from the lipid droplets.35 
Furthermore, rapid de novo protein synthesis of STAR is required for the transfer of cholesterol to 
CYP11A1. Consequently cortisol is released within minutes after ACTH secretion.36 Different studies 
indicated that acute steroidogenesis is not dependent on new mRNA synthesis, but on the activation of 
several proteins or the synthesis of protein from pre-existing mRNA. Moreover, inhibition of 
phosphorylation impaired steroidogenesis.36 
The chronic response to ACTH requires several hours and involves increased transcription and 
posttranscriptional regulation of genes encoding steroidogenic enzymes (CYPs) and thus enhances the 
synthetic capacity of the cells.34 This regulation is complex, which is supported by the observation that 
no clear correlation exists between mRNA and protein levels.37 ACTH phosphorylates different 
transcription factors for the steroidogenic genes among which the steroidogenic factor 1 (SF-1) is 
important.38 In addition, ACTH increases the number of both the cholesterol uptake receptors (LDLR 
and SCARB1) as well as stimulates de novo production by upregulation of HMCGR, as such increasing 
adrenal cholesterol availability.28, 29, 35 Furthermore, by stimulating cholesterol esterase while inhibiting 
acyl-CoA:cholesterol acyltransferase (ACAT) it promotes cholesterol delivery to the mitochondria.39 
ACTH also has a direct stimulatory effect on the expression of its own receptor in a dose-dependent 
manner.40 Moreover, mRNA levels of MC2R accessory protein (MRAP), an essential component for 
MC2R function, are also increased after ACTH stimulation. By enhancing the expression of both MC2R 
and MRAP, the responsiveness of the adrenal cells to ACTH is amplified by its own stimulation. 
Furthermore, ACTH stimulates adrenal growth by inducing cellular hypertrophy and hyperplasia. In the 
acute phase, ACTH causes hypertrophy of the adrenal cells, while hyperplasia only occurs if ACTH 
stimulus is maintained. Induction of the proliferation occurs via the extracellular signal-regulated kinases 
(ERKs) signaling pathway.41 Both ACTH and growth factors activate this pathway, which is followed by 
phosphorylation of transcription factors that stimulate cell proliferation. Alternatively, ACTH also 
stimulates endothelin production and such influences adrenal blood flow.42 
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The multi-factorial role of ACTH in the adrenal gland was further demonstrated in POMC-deficient 
(POMC-/-) mice.  POMC-/- mice are incapable of producing ACTH because they lack the precursor 
molecule. Mutant mice showed no lipid staining on frozen sections of the adrenal glands. Furthermore 
gene expression of STAR and SCARB1 was decreased. Gene expression of CYP11A1, LDLR and 
HMGCR was unchanged or even increased, though corresponding protein levels were all decreased.43 
Furthermore, POMC-/- mice had smaller adrenal glands with loss of zonational structure.44 All together 
these data further supports that ACTH is indispensible for adrenal gland function and structure.  
Additional regulators  
Increasing evidence supports the existence of non-ACTH dependent drivers of cortisol secretion.  
First, the adrenal cortex and medulla interact in two directions: The adrenal cortex can influence the 
synthesis of catecholamines in the medulla, while the cortex also receives postganglionic nerves from 
the medulla. The adrenal medulla consists of chromaffin cells, which receive splanchnic innervations. 
These medullar nerves are predominantly catecholaminergic and peptidergic and store dopamine, 
noradrenaline and adrenaline. Furthermore,  the chromaffin cells also produce different neuropeptides, 
including opioid peptides, neuropeptide Y, vasoactive intestinal peptide and substance P, which also 
influence steroid production.45 Furthermore, it is an oversimplification that medulla and cortex are two 
separate organs since chromaffin medullar cells are found in the adrenal cortex, allowing extensive 
contact zones for paracrine interaction.26 Under non-stress conditions, splanchnic neural activity 
appears to be inhibitory, whereas during stress conditions neural activity is excitatory, explained by the 
difference in the released neurotransmitter.46 The extensive innervations also sensitize the adrenal 
gland to ACTH, play a role in the diurnal output of the adrenal gland and stimulate growth of the adrenal 
gland.47, 48  
The regulatory role of the immune system has been recognized already extensively. Pro-inflammatory 
cytokines have been shown to stimulate the HPA-axis at every level and can influence cortisol secretion 
independently of ACTH.49-51 Different cytokines can also suppress the HPA-axis and GR function. 
Beside direct stimulation of the adrenal gland by circulating cytokines, these cytokines are also 
produced within the adrenal gland by immune cells and adrenocortical cells. Furthermore, cytokines 
also influence adrenal growth and differentiation with both stimulating as well as inhibiting effects being 
described.45 
The adrenal medulla and intra-adrenal immune cells are also a source of extrahypothalamic CRH and 
extrapituitary ACTH, which could also account for the residual cortisol production without an increase in 
circulating ACTH levels.45 Other intra-adrenal regulatory pathways have been suggested, such as a role 
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for blood flow and endothelial products, a role for growth factors, a role of the intra-adrenal renin-
angiotensin system, though further research is needed.52  
The question remains whether this extra-pituitary regulation can be an exclusive pathway or is only 
additional. It has been suggested that extra-pituitary regulation can be responsible for maintaining a 
basal small reserve, maintaining normal circadian rhythm fine tuning of secretion and compensatory 
growth. The role of this pathway in chronic forms of stress has been suggested, though needs to be 
explored.45 
1.1.3 Cortisol function and metabolism 
Cortisol transport 
Immediately after cortisol is produced, it is released from the adrenal gland into the circulation. Being a 
steroid hormone, cortisol is relatively insoluble in plasma. Therefore, more than 95% of circulating 
cortisol is bound to proteins, predominantly to corticosteroid-binding globulin (CBG) and to a lesser 
extent to albumin. CBG has a high affinity for endogenous glucocorticoids, while affinity for exogenous 
glucocorticoids is less. Furthermore, CBG has a limited binding capacity and is saturated at a cortisol 
concentration of approximately 20-25 µg/dl indicating that circulating cortisol levels above this 
concentration increase the percentage of free cortisol exponentially. Albumin has a lower affinity for 
cortisol, but a higher binding capacity.26 
Recent evidence suggests that CBG is more than just a transport protein.53 It is secreted from the liver 
and follows a diurnal rhythm, opposite to the glucocorticoids diurnal rhythm. Since only free cortisol can 
be metabolized or cleared, low CBG levels also shorten the half-life of cortisol, and increase the plasma 
clearance and distribution volume of cortisol.54 Furthermore, CBG affinity is affected by different factors 
such as pH, temperature and activity of neutrophils, as such regulating free cortisol levels. During 
inflammation, local elastases produced by neutrophils increase release of the glucocorticoid from CBG 
and therefore increase free cortisol. This is further emphasized by the loss of affinity caused by 
increased temperature.53 
Importantly, routine cortisol assays measure total circulating cortisol which is determined by both free 
cortisol levels and protein-bound cortisol. However, only the unbound fraction is free to enter the target 
cells either to exert their metabolic effects or to be transformed into inactive metabolites. Currently, no 
commercial assays are available to measure circulating free cortisol levels. The gold standard to 
measure free cortisol is via ultra-filtration and equilibrium dialysis, yet these techniques are not available 
in most clinical settings and difficult to perform. As a practical alternative for direct measurement, 
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methods for estimating free cortisol levels are described and validated, with the Coolens equation being 
the most frequently used method. In this calculation, free cortisol levels are estimated based on total 
circulating cortisol levels and measured protein concentrations of CBG and albumin affinity.55 
Cortisol signal transduction 
When free cortisol, which is lipophylic, reaches the target organ, it rapidly diffuses across the cell 
membrane to enter the cytoplasm where it can bind to the GR. The GR is expressed in virtually all cell 
types. Cortisol can also bind to the MR with a 10-fold higher affinity. Though, MR expression is only 
restricted to certain tissues such as the kidney.56  
The GR is a member of the nuclear receptor superfamily and functions as a ligand-dependent 
transcription factor. In the absence of ligands, the receptors are located in the cytoplasm and bound to a 
complex of proteins that stabilize the receptor in an inactive conformation. After binding of cortisol, the 
GR is released from the proteins and translocates to the nucleus where the GR can exert its effects 
which are complex and diverse. (Figure 5) In summary, to cause activation of gene expression the GR 
can bind directly after dimerization with another GR to a glucocorticoid response element (GRE) in the 
DNA or as a monomeric protein in cooperation with other transcription factor or by tethering other 
transcription factors to the DNA-bound monomeric GR.56 Furthermore, GR can also repress gene 
transcription to a negative GRE via different ways.56, 57 (Figure  5) 
The observation that glucocorticoids also can induce effects within minutes, being too rapid to be the 
result of transcription, led to the hypothesis that glucocorticoids also have non-genomic effects. The 
non-genomic effects are diverse and increasing evidence suggests that second-messenger molecules 
and different membrane receptors are involved.58  
Multiple GR isoforms are described and occur by alternative splicing. The GRα is the active form that 
binds ligands, while the GRβ does not bind glucocorticoids and acts as a dominant negative form by 
binding with GRα and preventing GR-dimerisation. The ratio of GRα to GRβ therefore reflects the 
glucocorticoid sensitivity of a cell. Furthermore, post-translational modification of the GRα is tissue 
specific and therefore regulates tissue specific glucocorticoid action.59 
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Figure 5 - GR Signaling causes activation or repression of gene transcription. 
 Left green panel: Activation is mediated by (i) binding of GR dimers to GRE, (ii) DNA binding of GR in concert with another 
transcription factor (XY), or (iii) binding of GR to a transcription factor by a tethering mechanism.  
Right red panel: Repression is mainly achieved by (iv) direct binding of GR dimers to negative GRE (v) DNA-binding cross-
talk with another transcription factor, (vi) interference of monomeric GR with the transactivation activity of transcription factors 
by a tethering mechanism, (vii) competition for an overlapping binding site (competitive GRE), (viii) sequestration of a DNA-
bound transcription factor or (ix) competition for binding cofactors with other DNA-bound transcription factors. (From 56) 
Cortisol function 
The observation that GRs are found in almost all cells hints that cortisol has widespread effects. Indeed 
glucocorticoids are critical regulators of multiple fundamental processes, including metabolic 
homeostasis, cell proliferation and immunomodulation.60, 61 It contributes to the provision of extra energy 
to vital organs by acutely shifting carbohydrate, fat and protein metabolism and by delaying anabolism. 
This comprises increasing glucose levels and insulin resistance, activating lipolysis, inhibiting protein 
synthesis and stimulating proteolysis.  
Moreover, cortisol likely affects the hemodynamic system by intravascular fluid retention and by 
enhancing inotropic and vasopressor responses to respectively catecholamines and angiotensin II. In 
addition, glucocorticoids stimulate anti-inflammatory cytokine production and inhibit pro-inflammatory 
cytokines, cell migration and production of inflammatory mediators. These anti-inflammatory effects of 
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cortisol can be interpreted as an attempt to prevent overactivation of the inflammatory cascade. 
Furthermore, cortisol has diverse effects on bone, regulates cell growth and reproduction and influences 
the central nervous system by changing mood, food intake and behavior.26 Despite the widespread 
positive acute effects, chronic hypercortisolism predominantly induced by long-term treatment causes 
severe side effects such as diabetes, osteoporosis, hypertension and muscle atrophy.  
Cortisol metabolism 
The metabolism of cortisol is complex and differs within tissues. (Figure 6) Cortisol can be inactivated to 
cortisone via 11β-hydroxysteroid dehydrogenase (11β-HSD) type-2 mainly in kidney. However, other 
mineralocorticoid target tissues also express this enzyme such as placenta, gastro-intestinal tract, the 
salivary glands and lungs. Cortisol can also be regenerated from cortisone via 11β-HSD type-1. This 
enzyme can function in the two directions and can therefore also inactivate cortisol. The directionality is 
tissue specific and depends upon the availability of the co-factor NADPH. 11β-HSD type-1 is widely 
distributed in the body including liver, adipose tissue, gonads, bone, muscle and skin, all glucocorticoid 
target tissues.62 Both 11β-HSDs play a pivotal role in cortisol function at tissue level by influencing the 
availability of active cortisol. Only cortisol can bind to the GR and MR and exert its function. Therefore, 
conversion into cortisone inhibits binding to the receptor, which is predominantly of importance in kidney 
to prevent aldosterone-like effects by binding to the MR.62 
The principle route of irreversible cortisol breakdown is via the A-ring reductases, 5α-reductase and 5β-
reductase, which mediate the rate-limiting step in cortisol breakdown. This results in dihydro-
metabolites, which are further reduced by 3α-HSD to form the tetrahydro-metabolites. Cortisol 
breakdown via 5α-reductase occurs predominantly in liver and adipose tissue and leads to the formation 
of the metabolite 5α-tetrahydrocortisol (allo-THF). Two genes of the steroid α-reductase family (SRD5A) 
encoding for 5α-reductase are described. Type 1 is predominantly expressed in androgen-independent 
tissue, such as liver, adipose tissue, skin and brain, while type 2 predominates in androgen dependent 
tissues such as the prostate where it activates testosterone.63 
Also present in the liver, 5β-reductase degrades both cortisol and cortisone into 5β-tetrahydrocortisol 
(THF) and tetra-hydrocortisone (THE) respectively. This enzyme is encoded by the aldo-keto-reductase 
member D1 (AKR1D1) gene. Furthermore, 5β-reductase plays an essential role in bile acid synthesis, 
supported by the observation that patients with a point mutation in the 5β-reductase gene (AKR1D1) 
have low levels of cholic acids and chenodexoycholic acids.64 
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Figure 6 – Schematic overview of cortisol metabolism  
with the major metabolites depicted in boxes.  
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Other metabolizing pathways consist of 6β-hydroxylation of cortisol, the reduction of the 20-oxogroups 
or conversion of the tetrahydro-metabolites into cortols and cortolones.65 Afterwards, conjugation with 
either sulfates or glucuronides enhances solubility of the metabolites and therefore the renal secretion. 
Only 1% of circulating cortisol is excreted unaltered in the urine, while the metabolites of the A-ring 
reductases predominate.66 
Since all the metabolites are excreted in urine, enzyme activity is mostly assessed by measuring the 
ratios of the different urinary cortisol metabolites. 5α-Reductase activity is estimated by the allo-THF/F 
ratio and 5β-reductase activity by THF/F and THE/E ratios. The activity of renal 11β-HSD2 was 
estimated by the E/F ratio. The ratio (allo-THF+THF)/THE only reflects the balance of cortisol/cortisone 
interconversion.67, 68 However, investigation with specific 11β-HSD-inhibitors showed that urinary 
metabolites are not appropriate to investigate their activities and infusion of isotopically labeled cortisol, 
generating labeled metabolites, is now the golden standard to quantify 11β-HSD activity.69 
Regulation of these enzymes is complex and incompletely understood due to conflicting results. 
Furthermore, the clinical significance of the suggested regulations needs to be elucidated. Growth 
hormone and insuline growth factor-1 were described to inhibit 11β-HSD1, but to stimulate 5α-
reductase. Pro-inflammatory cytokines stimulate the expression and activity of 11β-HSD1. 
Glucocorticoids regulate both 11β-HSD1 and 2, although conflicting data exist. Insulin has been 
described either to inhibit or not affect 11β-HSD1 activity while it could stimulate 5α-reductase. 
Luteinizing hormone and follicle stimulating hormone stimulate, while progesterone inhibits 11β-HSD1. 
Thyroid hormones inhibit 11β-HSD1 and stimulate 5α-reductase.26, 62, 67 Interestingly, bile acids, both 
conjugated and unconjugated, are potent inhibitors of the cortisol metabolizing enzymes, via competitive 
inhibition at low-physiological concentrations and by suppression of gene and protein expression at 
elevated concentrations.70-72 Furthermore, different diseases can influence cortisol metabolism such as 
thyroid disorders, kidney diseases, and obesity.  
1.2  STRESS RESPONSE IN CRITICAL ILLNESS 
1.2.1 Critical illness 
Critical illness is defined as any life-threatening condition requiring support of vital organ functions to 
prevent imminent death. This condition can be evoked by a variety of insults such as multiple trauma, 
complicated surgery and severe medical illnesses. Without modern critical care medicine, critically ill 
patients would not survive.  
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Although survival from previously lethal conditions is nowadays possible, often recovery does not swiftly 
follow. Then, patients enter a chronic phase of critical illness during which they continue to depend upon 
vital organ support for weeks, while the original trigger of the critical illness has long been resolved. This 
stage is characterized by distinct endocrine and metabolic alterations which may no longer be solely 
beneficial as they may hamper recovery. An example is the relative maintenance of fat stores while 
large amounts of proteins continue to be wasted from skeletal muscle and other organs.73 This 
response may impair recovery of vital organ functions, extend weakness and hamper rehabilitation74 
and expose patients to severe, often infectious, complications.75 The understanding of the mechanisms 
determining why certain patients recover and others don‟t remains very limited, but recent studies point 
to variable abilities to remove cell damage as playing a key role.76, 77 When patients remain dependent 
upon critical care support, it is ultimately decided to withdraw care because of futility. Hence, further 
understanding the underlying pathways of recovery and investigating whether these pathways can be 
beneficially affected by treatment is of high clinical relevance.  
1.2.2 HPA-axis regulation in critical illness 
Critical illness is the ultimate form of severe physical stress and all stress responses are expected to be 
of greater magnitude in critically ill patients. As part of this stress response, elevated plasma 
concentrations of the stress hormone cortisol hallmark critical illness. The more severe the critical illness 
in human patients, and thus the higher the risk of death, the higher plasma cortisol concentrations 
appear to be.78 However, also inappropriately low plasma cortisol has been linked to increased mortality 
Moreover, circulating levels of DHEAS and aldosterone are low during both the acute and prolonged 
phase of critical illness. Traditionally, this high cortisol levels were attributed primarily to the stress-
induced activation of the hypothalamic-pituitary-adrenal (HPA) axis with a shift in production away from 
both mineralocorticoid and adrenal androgens towards glucocorticoid production.79 
Beside high total cortisol levels, increased free cortisol levels are also observed during critical illness, 
explained by decreased CBG and albumin levels.80 This hypoproteinemia could be explained by hepatic 
failure or could be induced by high glucocorticoid levels, known to increase CBG clearance. 
Furthermore, sepsis is characterized by a reduced activity and amount of CBG levels. CBG affinity is 
also decreased at the site of infection caused by increased elastase activity from the neutrophils and 
increased temperature, increasing local cortisol availability.80-84 
The biological response of cortisol is not only mediated by the free cortisol concentrations, also the GR 
function plays a role. Increasing evidence from both animal and human experiments suggests that GR 
availability, GR affinity and GR translocation are regulated during critical illness.85-90 Decreased GR 
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affinity was observed in different animal and in vitro studies and confirmed in human studies of patients 
with chronic inflammation. GR expression was shown to be reduced in white blood cells of critically ill 
patients.90 However, the expression of GR in different tissues warrants more research in critically ill 
patients. Furthermore, the clinical relevance of these cellular changes needs to be elucidated.  
High cortisol levels are traditionally attributed to an activation of the HPA-axis and therefore to increased 
cortisol production. This conclusion is based on the observation of increased circulating cortisol levels 
and on the general concept of the stress response. However, plasma hormone concentrations are not 
only influenced by hormone secretion, but are the net result of hormone secretion, distribution in 
plasma, binding to plasma proteins and plasma clearance.91 Prior to this PhD project, direct 
investigation of the cortisol production and clearance during critical illness was lacking.  
Published data on plasma ACTH concentrations in critically ill patients are scarce. This lack of data is 
likely explained by the essential requirements for correctly assaying plasma ACTH: blood samples 
should be placed on ice and spun cold prior to assay or prior to freezing plasma for later assay. Already 
in 1995, however, Vermes et al. observed that plasma ACTH concentrations in patients suffering from 
severe trauma or sepsis were only transiently elevated when compared to healthy control values, and 
dropped after a few days to values below the healthy lower limits of normality.92 Other studies 
investigated ACTH after surgery or only at one time point, which hampers general conclusions on ACTH 
during critical illness.93-95 
Low plasma ACTH in the presence of high plasma cortisol concentrations have been interpreted as non-
ACTH driven cortisol production.96 (Figure 7) Beside alternative simulators of the adrenal gland or 
increased ACTH sensitivity, this constellation could be caused by reduced cortisol breakdown 
suppressing the production of adrenocortical hormones via feedback inhibition. This mechanism was 
already suggested 50 years ago. However, prior to this PhD project, this possibility was not further 
explored.97, 98  
The studies that investigated the interaction between ACTH and cortisol during critical illness were 
based on one daily time point.93-95 Considering the fact that both ACTH and cortisol are secreted in 
pulses, one could easily miss the link between two pulses with only one time point.96 
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Figure 7 – non-ACTH dependent mechanisms of the ACTH-cortisol dissocation. (from 96) 
1.3  ADRENAL INSUFFICIENCY 
An intact HPA-axis is indispensable to survive critical illness. This was evidenced by animal experiments 
showing that mortality of sepsis is much higher after adrenalectomy.99 Yet, prolonged critical ill patients 
often appear to suffer from a failing HPA-axis, which is lethal when left untreated. Therefore, recognition 
and appropriate treatment of this condition is crucial.100 
1.3.1 Absolute adrenal insufficiency 
Etiology 
According to the underlying mechanism, absolute adrenal insufficiency, also known as Addison disease, 
can be divided into primary, secondary and tertiary causes. Primary adrenal insufficiency is caused by 
diseases of the adrenal gland itself. Lack of ACTH function or secretion due to pituitary abnormalities is 
labeled as secondary adrenal insufficiency, while insufficient AVP and CRH secretion and function can 
cause tertiary adrenal insufficiency.101 Long-term, high-dose exogenous glucocorticoid therapy is the 
most common cause of tertiary adrenal insufficiency due to suppression of the HPA axis by exogenous 
glucocorticoid.100-102 
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Diagnosis 
Adrenal insufficiency often has an insidious onset which is often missed and therefore adrenal 
insufficiency can evolve into an adrenal crisis evoked by an intercurrent illness. An adrenal crisis should 
always be ruled out in any patient with cardiovascular shock that is resistant to vasopressors. An acute 
adrenal insufficiency can also be initiated by acute adrenal hemorrhage, which is clinically presented by 
hypotension, abdominal pain, falling hemoglobin and progressive hyperkalemia. The combination with 
other non-specific signs of chronic adrenal failure can hint to acute adrenal insufficiency.100-102 
Chronic adrenal insufficiency is characterized by non-specific symptoms such as fatigue, (orthostatic) 
hypotension, weight loss, abdominal cramps, nausea, anorexia, and diarrhea. The most specific sign of 
primary adrenal insufficiency is hyperpigmentation of the skin and mucosa and craving for salt. 
Furthermore, laboratory analysis can reveal normocytic anemia, lymphocytosis, eosinophilia, metabolic 
acidosis, hypercalcemia and hypoglycemia. Signs of mineralocorticoid deficiency (hyponatremia and 
hyperkalemia) are only present in case of primary adrenal deficiency.101, 102 
Clinical suspicion of adrenal insufficiency can be confirmed by the presence of low baseline cortisol 
levels (<3µg/dl in the morning). Circulating ACTH levels should be measured to differentiate between 
primary and secondary failure with low ACTH levels being indicative of secondary adrenal insufficiency, 
while high ACTH levels point to a primary cause. Furthermore, circulating levels of renin and 
aldosterone add to the differentiation of primary and secondary failure. The ACTH-stimulation test 
confirms the diagnosis. Therefore, 250 µg of synthetic ACTH is given and the circulating cortisol levels 
at baseline and at 30 and 60 minutes after injection represents the adrenal ability to produce cortisol. 
Cortisol levels <20µg/dl after ACTH simulation are indicative of adrenal insufficiency. The use of a low 
dose ACTH-stimulation test is suggested to increase sensitivity in patients with mild adrenal 
insufficiency. Other diagnostic tests such as the insulin tolerance test, the metapyrone test, the CRH 
stimulation test and adrenal imaging could add to the differential diagnosis.100, 103 
Treatment 
Treatment of chronic adrenal insufficiency consists of substitution of the daily cortisol production by 
exogenous glucocorticoids. The current guidelines recommend 10-12 mg/m² hydrocortisone, given in 
two or three doses with a higher dose in the morning to mimic the circadian endogenous production. In 
primary adrenal failure, mineralocorticoids should be added, while the substitution of androgens is less 
clear. For all patients the use of stress-doses to prevent adrenal crisis should be implemented when a 
new major stressor such as surgery is suspected and patients should be educated to be aware of this 
risk.103 
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An adrenal crisis is life-threatening and therefore, immediate therapy should be initiated when clinically 
suspected. This treatment consists of reversal of hypotension and electrolyte disorders, combined with 
high dose glucocorticoid substitution (200 mg hydrocortisone per day) until the patient‟s condition is 
stable, and followed by a tapering down of the dose.  
Absolute adrenal insufficiency and critical illness 
In critical illness, absolute adrenal insufficiency can concomitantly be present. Adrenal insufficiency 
should be suspected when unexplained catecholamine-resistant hypotension is present, especially 
when combined with concurrent hyperpigmentation, hyponatremia or hyperkalemia. In addition, 
spontaneous adrenal insufficiency due to adrenal hemorrhage and adrenal-vein thrombosis occurs more 
frequently due to coagulation disorders related to critical illness. Furthermore, different medications 
often used in the intensive care unit (ICU) can affect cortisol production. Etomidate is known to inhibit 
cortisol production, even after a single dose. Other drugs know to influence the HPA axis are 
predominantly azoles, anticoagulants, phenobarbital, phenytoin, rifampin, opioids, chlorpromazine and 
imipramine.104 
It is generally accepted that patients with an established diagnosis of primary or central adrenal failure 
or patients on chronic treatment with systemic glucocorticoids prior to critical illness should receive 
additional coverage to cope with the acute stress.105, 106 Also, patients who are diagnosed with an acute 
Addisonian crisis in the ICU are typically treated with high doses of glucocorticoids. This therapeutic 
strategy is based on the assumption that cortisol production is several-fold increased in critical illness. 
The conventional treatment proposes the administration of a bolus of 100 mg of hydrocortisone followed 
by 50 to 100 mg every 6 hours on the first day, 50 mg every 6 hours on the second day, and 25 mg 
every 6 hours on the third day, tapering to a maintenance dose by the fourth to fifth day.105, 106  
1.3.2 Relative adrenal insufficiency 
Activation of the HPA-axis is assumed to be sometimes insufficient to cope with severe illness and to 
cover the needs for cortisol to survive. As plasma cortisol in this condition is still higher than during 
health, it has been labeled „relative adrenal insufficiency‟ (RAI),107 or more recently, 'critical illness-
related corticosteroid insufficiency' (CIRCI).108 Both terms comprise the inability to raise adrenal steroid 
production up to the level required to match the level of stress. Such „relative failure‟ could be due to a 
malfunctioning at any level of the HPA-axis and/or to resistance of the peripheral tissues to cortisol 
during critical illness.108, 109  Depending on the diagnostic criteria, the incidence varies widely. However, 
septic patients and patients with acute respiratory distress syndrome are more prone to RAI. 
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Furthermore, liver diseases and adrenal disorders frequently coincide, which led to the introduction of 
the term “hepato-adrenal syndrome”.110 
Pathophysiology 
In 1946 Hans Selye suggested that „exhaustion‟ of the adrenal cortex could occur. However, the 
underlying mechanisms still remain unknown. Pro-inflammatory cytokines are suggested to induce 
tissue resistance or inhibit ACTH function. Furthermore, impaired blood supply to the pituitary can 
induce ischemia or necrosis, which is followed by the accumulation of nitric oxide or central 
neuropeptides, leading to decreased hormone secretion.101 Additionally, different neuropeptides, 
oxidative stress, altered adrenal blood flow, substrate deficiency due to low circulating cholesterol or 
interfering medications are suggested to play a role.104 Since cholesterol production is exerted by the 
liver, patients with liver disease have defective cholesterol production, which increases the risk of 
adrenal insufficiency. Furthermore, the incidence of coagulopathy is higher in these patients leading 
more frequently to adrenal hemorrhage.110 Tissue resistance, the second part of the definition of CIRCI, 
can be explained by decreased glucocorticoid delivery or decreased glucocorticoid action. As explained 
before, due to low CBG levels and decreased CBG affinity, cortisol transport is impaired and GR 
receptor levels and affinity are affected during critical illness.  
Diagnosis 
Initial diagnosis should always be based on clinical suspicion. Hypotension refractory to fluid 
resuscitation or vasopressors is indicative of CIRCI with or without non-specific symptoms of adrenal 
failure as described previously.  
Suggested diagnostic criteria for CIRCI in critically ill patients were based on a landmark study by 
Annane et al. who identified a plasma cortisol incremental response of <9 µg/dl after injection of 250 µg 
ACTH and a high baseline cortisol level (>34 µg/dl) as most discriminative for increased risk of death.107 
However, other investigators have not all been able to replicate these findings and until now no 
consensus has been reached. Furthermore, also the dose of the stimulation test remains controversial. 
A dose of 250 µg of ACTH leads to supra-physiologic ACTH levels and could therefore overcome ACTH 
resistance. Alternatively, a 1 µg stimulation dose was suggested. However, this has not been 
extensively studied in critically ill patients and this test has not been clinically implemented in the critical 
care setting, due to conflicting results.  
Alternatively, a random total cortisol of <10µg/dl during critical illness has been suggested for the 
diagnosis of CIRCI.108 However, total plasma cortisol concentration is the net result of adrenal 
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production and secretion, distribution, binding and elimination of cortisol. Also, cortisol is secreted in a 
pulsatile manner.111 It thus seems unlikely that one could judge the adequacy of the adrenal cortisol 
production in response to critical illness merely by a single measurement of total plasma cortisol. 
Furthermore, total plasma cortisol concentrations do not reflect glucocorticoid signaling.  First, only free 
cortisol can pass the cell membrane to exert its function by binding to the GR. Critical illness acutely 
suppresses circulating levels of the binding proteins, CBG and albumin, and also alters CBG binding 
affinity via increased cleavage from CBG at inflammatory loci or by increased temperature.80-84 Hence 
plasma free cortisol may be more appropriate than total cortisol to assess HPA-axis function. However, 
plasma free cortisol assays are currently not readily available and normal ranges for plasma free cortisol 
during critical illness have not been defined. Additionally, increasing evidence from both animal and 
human experiments suggests that GR availability in different tissues, the GR affinity and translocation 
are regulated during critical illness.85-90 In septic patients, for example, the dominant negative β-isoform 
of the GR was induced from admission, which downregulates glucocorticoid action.86 Although these 
changes could be adaptive or maladaptive, they preclude conclusions about „adequacy‟ of cortisol 
availability and function during illness. Finally, assays that are commonly used to quantify plasma 
cortisol concentrations are often inaccurate and very substantially112 indicating that it is virtually 
impossible to define CIRCI based on one cut-off value in clinical practice without better standardizing 
the methodology. It may be necessary to use mass spectrometry for this purpose.113, 114  
It was recently suggested that measuring interstitial cortisol levels could be interesting to assess the 
amount of active tissue cortisol levels in critically ill patients.115, 116 For this purpose, a microdialysis 
catheter is inserted into the subcutaneous adipose tissue. However, edema is frequently present and 
regional blood flow varies in critically ill patients.117 Hence, the benefit of this invasive technique could 
be questioned.  
Recent guidelines from the surviving sepsis campaign now no longer recommend the use of the ACTH 
stimulation test to diagnose CIRCI.118 They suggest to use a random cortisol level <18 μg/dl in a patient 
with septic shock and clinical suspicion of adrenal failure as an indication for initiation of steroid 
therapy.118  
Treatment 
Although the concept of CIRCI is widely accepted, it remains highly debated whether or not it should be 
treated with exogenous glucocorticoids and if so, with which doses. Indeed, randomized controlled 
studies generated conflicting results. The first large trial by Annane et al.119 investigated 300 patients 
with septic shock on vasopressor therapy. All patients were randomly assigned to be treated with 
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placebo or 200 mg hydrocortisone plus 50 µg fludrocortisone. In all patients an ACTH stimulation test 
was performed. They observed that the glucocorticoid treatment reduced the duration of vasopressor 
therapy and caused a 10% absolute risk reduction of 28 days-mortality in those patients who did not 
respond sufficiently to the ACTH stimulation test. However, the study was criticized based on different 
methodological aspects, such as the use of etomidate and statistical issues. 
To settle controversy, a new large multi-center randomized-controlled double-blind trial investigated 499 
patients to evaluate the impact on 28 days-mortality of placebo versus 200 mg hydrocortisone daily for 5 
days after which a tapering period followed.120 This study confirmed that hydrocortisone treatment 
increased shock reversal in all patients. However, hydrocortisone did not improve survival, neither in the 
non-responders to ACTH stimulation, nor in the entire population. Moreover, an increased incidence of 
septic shock relapse was observed. Again, concerns were raised since the study was underpowered, 
weakening the overall conclusions. Since then no adequately designed study was performed to resolve 
the remaining questions. 
In view of the controversy, recent guidelines from the surviving sepsis campaign now recommend, 
although with a weak level of recommendation, to only treat patients with hypotension refractory to 
vasopressor or fluid resuscitation. A dose of 200 mg hydrocortisone via continuous infusion is desirable, 
with a quick tapering down of the dose whenever vasopressors are no longer needed. Furthermore, 
they do not advise glucocorticoid treatment for patients with sepsis without shock.118 
1.4  REMAINING QUESTIONS 
Despite the general agreement that adequate HPA-axis function is crucial for survival in critical illness, 
important lack of knowledge currently retains further improvement of both diagnosis and treatment of 
adrenal failure in critical illness. Moreover, even the fundamentals of cortisol and ACTH regulation 
during critical illness are not fully understood. It is imperative that we explore ACTH and cortisol 
secretion during critical illness to gain more insight in the so-called ACTH-cortisol dissociation. Despite 
different suggestions in the literature, research is lacking to explain this dissociation. A better 
understanding of the underlying pathophysiology will allow us to better refine subgroups that may 
benefit from glucocorticoid therapy and increase survival.  
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AIM AND STUDY OBJECTIVES 
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AIM 
The main objective of this doctoral thesis was to explore the regulation of cortisol secretion and 
metabolism during critical illness in order to gain more insight in the pathophysiology of adrenal 
insufficiency that occurs in ICU patients. 
 
GENERAL HYPOTHESIS 
The general hypothesis of this doctoral thesis postulates that during critical illness reduced cortisol 
breakdown, rather than continuously stimulated cortisol secretion, contributes to maintaining the 
elevated plasma cortisol concentrations. Negative feedback inhibition, exerted by high circulating 
cortisol levels would then explain low ACTH levels. When ACTH deprivation sustains, adrenal integrity 
and function could be negatively affected, predominantly in the prolonged phase of critical illness. 
 
SPECIFIC STUDY OBJECTIVES 
This hypothesis was tested by means of the following specific study objectives: 
(1) To investigate cortisol production and breakdown in relation to circulating ACTH and cortisol 
levels via 5 clinical studies in which blood, urine and tissue samples of critically ill patients and 
matched healthy controls are compared. Therefore, we determined (i) daily ACTH and cortisol 
levels during the first week of ICU stay; (ii) plasma cortisol clearance, breakdown and 
production during deuterated-steroid tracer infusions; (iii) plasma clearance of 100 mg 
hydrocortisone; (iv) urinary cortisol metabolites and (v) mRNA and protein expression in liver 
and adipose tissue to assess the major cortisol-metabolizing enzymes. 
 
(2) To study ACTH and cortisol hormonal secretory dynamics during critical illness, and how both 
are interrelated, via mathematical analyses of repeated sampling time-series obtained from 
patients and matched healthy control subjects. Besides other methodologies (Approximate 
entropy, CrossApproximate entropy and the dose response relationship), deconvolution 
analysis was used to derive secretion profiles from the plasma concentration profiles. 
 
(3) To identify the impact of sustained ACTH deprivation on the adrenal glands during critical 
illness. Since ACTH exerts a profound trophic effect on the adrenal gland and its steroidogenic 
potential, adrenal glands were harvested within 24h after death from ICU-non-survivors and 
from sudden out-of-hospital deaths, to investigate these key ACTH effects. 
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DURING CRITICAL ILLNESS 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Boonen E, Vervenne H, Meersseman Ph, Andrew R, Mortier L, Declercq PE, 
Vanwijngaerden YM,  Spriet I, Wouters PJ, Vander Perre S, Langouche L, Vanhorebeek I, Walker BR, 
Van den Berghe G. Reduced cortisol metabolism during critical illness. N Engl J Med 
2013;368(16):1477-1488 
41 
 
3.1  ABSTRACT 
Background: Critical illness is often accompanied by hypercortisolemia, which has been attributed to 
stress-induced activation of the HPA-axis. However, low ACTH levels have also been reported, which 
may be due to reduced cortisol metabolism. 
Methods: In a total of 158 patients in the intensive care unit and 64 matched controls, we tested five 
aspects of cortisol metabolism: daily ACTH and cortisol levels; plasma cortisol clearance, metabolism 
and production during infusion of deuterium-labeled steroid hormones as tracers; plasma clearance of 
100 mg of hydrocortisone; levels of urinary cortisol metabolites and levels of messenger RNA and 
protein in liver and adipose tissue, to assess the major cortisol-metabolizing enzymes.  
Results: Total and free circulating cortisol levels were consistently higher in patients than in controls, 
whereas ACTH levels were lower (P<0.001 for both comparisons). Cortisol production was 83% higher 
in the patients (P=0.02). There was a reduction of more than 50% in cortisol clearance during tracer 
infusion and after the administration of 100 mg of hydrocortisone (P≤0.03 for both comparisons). All 
these factors accounted for an increase by a factor of 3.5 in plasma cortisol levels in patients, as 
compared with controls (P<0.001). Impaired cortisol clearance also correlated with lower cortisol 
response to ACTH stimulation. Reduced cortisol metabolism was associated with reduced inactivation 
of cortisol in the liver and kidneys, as suggested by urinary steroid ratios, tracer kinetics and 
assessment of liver-biopsy samples (P≤0.004 for all comparisons). 
Conclusions: During critical illness, reduced cortisol breakdown, related to suppressed expression and 
activity of cortisol-metabolizing enzymes, contributed to hypercortisolemia and hence ACTH 
suppression. The diagnostic and therapeutic implications for critically ill patients are unknown.  
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3.2  INTRODUCTION 
Critical illness, an example of severe acute physical stress, is often accompanied by hypercortisolemia 
that is proportionate to the severity of illness.1,2 This observation has traditionally been attributed to 
stress-induced activation of HPA-axis and increased ACTH-driven cortisol production.3 However, this 
stress response may not be sufficient for a good prognosis in patients with relative adrenal 
insufficiency.4-7 Moreover, Vermes et al.8 reported only transiently elevated levels of ACTH during critical 
illness, whereas cortisol remained high, a paradoxical dissociation between cortisol and ACTH levels 
that has also been observed in other stress conditions.9  
In addition to alternative activators of cortisol production, such as proinflammatory cytokines,9,10 another 
explanation for hypercortisolemia in the presence of suppressed ACTH could be reduced cortisol 
removal. The principal routes of cortisol clearance occur in the liver (through A-ring reductases [5β-
reductase and 5α-reductase]) and kidneys (through 11β-hydroxysteroid dehydrogenase type 2 [11β-
HSD2] which converts cortisol to cortisone). This removal is offset by the regeneration of cortisol from 
cortisone through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in liver and adipose tissue.11,12 
The regulation of these enzymes is complex.12,13 In addition, in critically ill patients, elevated circulating 
levels of bile acids could be powerful suppressors of the expression and activity of cortisol metabolizing 
enzymes.14-17 
We hypothesized that cortisol metabolism is reduced during critical illness, contributing to sustained 
hypercortisolemia with enhanced negative-feedback inhibition of ACTH.    
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3.3  MATERIALS & METHODS 
To test our hypothesis, we performed five clinical studies comparing 158 consecutively screened 
patients in ICU with 64 demographically matched controls (Table 11 and Table-S1 in the Supplementary 
Appendix).18,19 In these studies, we measured daily levels of ACTH and cortisol; plasma cortisol 
clearance, metabolism and production during infusion of deuterium-labeled steroid hormones as tracers; 
plasma clearance of 100 mg hydrocortisone; urinary cortisol metabolites and levels of messenger RNA 
(mRNA) and protein in liver and adipose tissue to assess major cortisol-metabolizing enzymes.  
Excluded from the study were patients and controls who had predisposing risk factors for HPA-axis 
dysfunction, who were receiving contraindicated drugs or who were undergoing extracorporeal 
membrane oxygenation or therapy with a circulatory-assist device (for details, see Supplementary 
Appendix, Methods S1-S2; Table-S2). All samples were stored at -80°C.   
All study protocols and written consent forms were approved by the Institutional Ethical Review Board of 
the KU Leuven (ML1094/ML2707, ML1820/ML2707, ML4190/ML2112, ML6625, ML5754). All 
participants or their representatives provided written informed consent.  
Plasma ACTH and cortisol time course 
Morning blood was collected daily from 47 patients for 7 days after admission and from 12 controls 
(Table 1). Samples were collected in pre-chilled EDTA tubes, placed on ice and centrifuged at 4°C. 
Total levels of cortisol (Immunotech, Prague, Czech Republic) and CBG (DiaSource, Louvain-la-Neuve, 
Belgium) were quantified on radioimmunoassay and ACTH levels on double-monoclonal 
immunoradiometric assay (Brahms Diagnostics, Berlin, Germany).20,21 
Plasma cortisol clearance and production   
A total of 11 patients and 9 controls (Table 1) received intravenous deuterated cortisol ([9,11,12,12-²H4]-
cortisol, D4-cortisol, Cambridge Isotopes)22 as a 0.7 mg priming bolus followed by continuous infusion of 
0.35 mg/h for 3 hours between 10 a.m. and 1 p.m. to achieve steady state in the circulation.11,23,24 After 
100 minutes of D4-cortisol infusion, participants also received deuterated cortisone ([1,2-²H2]-cortisone, 
D2-cortisone, Cambridge Isotopes)25 as a 0.08 mg priming bolus, followed by continuous infusion of 
0.1053 mg/h. Blood samples were obtained 5 minutes before D4–cortisol infusion and at intervals of 60, 
120, 140, 160, 165, 170, 175 and 180 minutes after infusion. 
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Table 1: Characteristics of study patients and controls 
 
  
                    
  
Plasma ACTH-Cortisol 
Time Course Study 
D4-Cortisol  
Tracer Study 
Plasma Clearance of a 
Therapeutic Dose of 
Cortisol Study 
Cortisol Metabolizing 
Enzymes 
Urine Study 
Cortisol Metabolizing 
Enzymes 
Tissue Biopsy Study 
  
Patients 
(n=47) 
Controls 
(n=12) 
Patients 
(n=11) 
Controls 
(n=9) 
Patients 
(n=20) 
Controls 
(n=8) 
Patients 
(n=36) 
Controls 
(n=15) 
Patients 
(n=44) 
Controls 
(n=20) 
Demography and anthropometry          
     Gender (no. male (%)) 27 (57) 5 (42) 7 (64) 5 (56) 8 (40) 5 (63) 25 (69) 9 (60) 28 (63) 14 (70) 
     Age (yr) (mean±SD) 63.7 ± 18.0 60.4 ± 4.7 68.5 ± 8.3 62.6 ± 4.1 64.4 ± 13.2 60.3 ± 4.3 66.4 ± 10.8 61.1 ± 8.3 71.2 ± 12.0 70.4 ± 11.6 
     BMI (kg/m2) (mean±SD) 26.2 ± 4.2 24.4 ± 3.4 28.5 ± 4.9 25.2 ± 4.1 26.3 ± 5.8 24.1 ± 1.8 26.7 ± 5.4 25.2 ± 5.3 24.8 ± 3.6 25.0 ± 2.6 
Admission severity of illness score          
     APACHE II (mean±SD) 28 ± 10  29 ± 11  34 ± 7  31 ± 6  29 ± 9  
Patients characteristics at study time           
     SIRS (no. (%)) 20 (43)  7 (64)  20 (100)  22 (61)  35 (80)  
     Sepsis (no. (%)) 16 (34)  5 (45)  15 (75)  17 (47)  26 (59)  
     CRP (mg/l) (mean±SD) 107 ± 86  199 ± 131  143 ± 106  109 ± 81  185 ± 91  
     Requiring Inotropes (no. (%)) 6 (13)  3 (27)  8 (40)  2 (7)  24 (55)  
     Requiring Vasopressors (no. (%)) 17 (36)  7 (64)  20 (100)  19 (53)  30 (68)  
     24h Urine Output (liter) (mean±SD) 1.8 ± 1.0  1.6 ± 0.5  0.9 ± 0.7  1.7 ± 0.7   1.0 ± 1.3  
     Blood Lactate (mmol/l) (mean±SD) 0.93 ± 0.28  1.18 ± 0.35  2.54 ± 2.84  1.27 ± 1.85  3.50 ± 1.16  
     Treated with Opioids (no. (%)) 28 (60)  10 (91)  15 (75)  16 (44)  34 (77)  
     On Therapeutic Anticoagulation (no. (%)) 5 (11)  0 (0)  0 (0)  0 (0)  2 (5)  
Clinical Outcomes           
     Days in ICU (mean±SD) 18 ± 16  26 ± 16  24 ± 32  22 ± 25  14 ± 17  
     Day of Sampling (mean±SD) 1 to 7  7 ± 5  9 ± 15  10 ± 17  14 ± 17  
     ICU Mortality (no. (%)) 6 (13)  2 (18)  7 (35)  5 (14)  44 (100)  
The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Acute Physiology and Chronic Health Evaluation II (APACHE II) ranges from 0 to 71, with 
higher scores indicating greater severity of illness.18  CRP: C-Reactive Protein, CO: Cardiac Output.  SIRS: Systemic Inflammatory Response Syndrome, determined by the BONE criteria.19 
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In pre-infusion samples, plasma levels of ACTH (as described above) and levels of tumor necrosis 
factor α (TNF-α) and interleukin 6 (IL-6) were measured by means of enzyme-linked immunosorbent 
assay (ELISA) (Invitrogen, Camarillo, USA). Plasma concentrations or tracer/tracee ratios of 
endogenous cortisol and cortisone, 9,11,12,12-[2H]4-cortisol (D4-cortisol), [9,12,12-²H3]-cortisol (D3-
cortisol), and 1,2-[2H]2-cortisone (D2-cortisone) were quantified by Liquid-Chromatography-tandem-
Mass-Spectrometry (LC-MS/MS), with modification to the technique previously described.11,25 Ten 
patients underwent a short ACTH-stimulation test (injection of 250 µg Synacthen®) within 24 hours after 
tracer infusion. 
Cortisol kinetics were calculated from mean values in steady-state (t = +160 to +180 min). D4-cortisol 
clearance was calculated by dividing the D4-cortisol infusion rate by the steady-state concentration. 
Cortisol rate of appearance, a composite of adrenal cortisol secretion and extra-adrenal cortisol 
regeneration, was calculated as the D4-cortisol infusion rate divided by the D4-cortisol/cortisol ratio. 
Cortisol regeneration by 11β-HSD1 was estimated by the rate of appearance of D3-cortisol, calculated 
as the D4-cortisol infusion rate divided by the D4-cortisol/D3-cortisol ratio. Cortisone kinetics were also 
calculated from mean values in steady-state (t = +160 to +180 min). Net cortisone rate of appearance 
was calculated after adjustment for differences in substrate cortisol concentration as D2-cortisone 
infusion rate divided by [D2-cortisone/cortisone ratio]x[plasma cortisol]. The calculated rate of 
appearance is 'net' because the tracer D2-cortisone is converted to D2-cortisol by 11β-HSD1 reductase, 
and then recycled back to D2-cortisone by 11β-HSD2 dehydrogenase; similar recycling occurs between 
endogenous cortisol and cortisone. As a result, the dilution of D2-cortisone by endogenous cortisone 
underestimates the total 11β-HSD2 dehydrogenase activity by an amount that is proportional to this 
'recycling' of tracer. However, when comparing subjects in whom there is no difference in 11β-HSD1 
reductase activity (quantified by D3-cortisol generation, as above) then the extent of recycling of  
D2-cortisone tracer can be assumed not to be different, and any differences in net rate of appearance of 
cortisone can be attributed to 11β-HSD2 dehydrogenase. These circumstances applied in our 
comparison of ICU patients and controls. 
Plasma clearance of a therapeutic dose of cortisol 
A total of 20 patients and 8 controls (Table 1) received a 100 mg intravenous bolus hydrocortisone 
(Solu-Cortef).  Blood samples were taken every 10 minutes for 1 hour and then every hour for 4 
hours. Cortisol was quantified by radioimmunoassay, as described above. Plasma clearance of cortisol 
was estimated by dividing the hydrocortisone dose by the area-under-the-curve of the plasma cortisol 
concentrations over time (estimated from 0 to infinity) and cortisol distribution volume was estimated by 
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dividing the calculated clearance by the elimination rate constant.26,27 Plasma half-life, a composite 
measure of clearance and distribution volume, was estimated by dividing ln2 by the elimination rate 
constant, calculated from the slope of the regression line of the log-transformed cortisol concentration 
over time.27 
Activity of cortisol metabolizing enzymes   
We collected 24-hour urine samples from 36 patients and 15 controls, followed by a morning blood 
sample (Table 1). Patients requiring renal replacement therapy were excluded. We used LC-MS/MS to 
estimate levels of urinary Cortisol (F), cortisone (E), 5α-tetrahydrocortisol (allo-THF),  
5β-tetrahydrocortisol (THF) and tetrahydrocortisone (THE), which were subsequently quantified on Gas-
Chromatography-Mass-Spectrometry (GC-MS).28 α-Reductase activity was estimated by the allo-THF/F 
ratio and 5β-reductase activity by THF/F and THE/E ratios. The activity of renal 11β-HSD2 was 
estimated by the E/F ratio and the overall activity of 11β-HSDs by (allo-THF+THF)/THE ratio, reflecting 
the balance of cortisol/cortisone interconversion.28-32 In addition, total bile acids in the serum samples 
were quantified by means of enzymatic cycling (Diazyme, Poway, California).  
Tissue Expression of Cortisol Metabolizing Enzymes 
For this study, we investigated liver and adipose tissue biopsies collected immediately after death from 
44 non-surviving patients (Table 1) who had not been treated with exogenous glucocorticoids during 
ICU stay.33,34 The postmortem biopsy samples of liver (lower right quadrant) and abdominal 
subcutaneous and omental adipose tissue were harvested within minutes after death [adipose tissue  
16 (10-24) min; liver 25 (17-40) min].  Blood samples were collected in the morning on the day of death. 
For comparison, liver and adipose tissue biopsies and blood samples were collected from 20 matched 
control patients undergoing elective abdominal surgery for restorative rectal resection. Tissue samples 
were snap-frozen in liquid nitrogen and stored at -80°C until analysis. Blood samples were centrifuged 
and frozen at -20°C and stored at -80°C.  
Total mRNA was purified from liver and adipose tissue using Qiazol lysis reagent (Qiagen, Hilden, 
Germany) and subsequently purified with RNAeasy Mini columns (Qiagen). Samples were treated with 
DNase to remove all genomic DNA, and 0.5 µg total mRNA was reverse-transcribed using random 
hexamers. Copy DNA (cDNA) levels of 11β-HSD1, 5α-reductase type-1 and 5β-reductase were 
quantified in real time with the TaqMan gene expression assays using the StepOnePlus System 
(Applied Biosystems, Carlsbad, CA), for highly accurate quantification of mRNA levels. Individual 
samples with a copy number coefficient of variation greater than 20% were reanalyzed. Data are 
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expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and as a fold 
difference from the mean of the control patients. Primers and probe for 5α-reductase type-1 detection 
were developed using Primer Express software (Applied Biosystems) and generated by Eurogentec 
(Liege, Belgium): forward, 5‟-GGAATCTGTCTAGGAGCCCTCTCT-3‟; reverse, 5‟-
TCCCCAAGTTCTCCACTTACACA-3‟; probe, 5‟-AAACTTGCCAACCTTCGTGTCAGGTGCT-3‟. For 
11β-HSD1, 5β-reductase and GAPDH, assays from Applied Biosystems were used (Hs01547870_m1, 
Hs00818881_m1 and 4310884E). 
To quantify protein expression, liver samples were weighed and homogenized in lysis buffer with 
phosphatase and protease inhibitors, using ceramic beads and a Precellys 24 homogenizer (6000 rpm, 
45 sec, Bertin Technologies, Villeurbanne, France). Protein content was determined using Coomassie 
Protein Assay Reagent (Pierce Biotechnology Inc., Rockford,IL). An equal amount of protein was loaded 
for each sample and homogenates were separated by denaturating SDS-PAGE and immunoblotted with 
specific antibodies against 5β-reductase (ab89166, Abcam, Cambridge, UK), against liver 11β-HSD1 
(pc544, The Binding Site, Birmingham, UK), against adipose tissue 11β-HSD1 (ab39364, Abcam, 
Cambridge, UK), against 5α-reductase (sc20658, Santa Cruz Biotechnology, Heidelberg, Germany) and 
with species-specific HRP-conjugated secondary antibodies (P0447, P0448 and P0163, Dako, 
Heverlee, Belgium). Signals were quantified using ImageQuant software, and normalized for 
cytokeratin (CK)-18 protein expression (liver) and GAPDH protein expression (adipose tissue) and as a 
fold change of the mean of the control patients. The CK-18 antibody was purchased from Abcam 
(ab668, Cambridge, UK) and the GAPDH antibody from Ambion (AM4300, Austin, USA). Enzyme 
activity of 11β-HSD1 and 5β-reductase was determined in vitro in hepatic tissue, and enzyme activity of 
11β-HSD1 was determined in adipose tissue.35 Total cortisol was quantified with the use of 
chemiluminescence (Immulite2000-Immunoassay; Diagnostic Products Corporation, Los Angeles, CA) 
and total bile acids were measured as described above.  
Statistical Analyses 
All data are presented as means ± standard deviation (SD) or medians (interquartile ranges(IQR)). We 
used Wilcoxon rank-sum test for data that did not have a normal distribution and unpaired Student‟s t-
tests for normally distributed data. Proportions were compared with the use of chi-square tests. 
Associations were analyzed with linear regression after transformation to normal distribution when 
required. We used analysis of variance to calculate the significance of Pearson‟s determination 
coefficients (r2). A two-sided P value of less than 0.05 was considered to indicate statistical significance. 
All statistical analyses were performed with JMP software, version 9.0.0 (SAS Institute Inc., Cary, USA).  
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3.4  RESULTS 
Differences between patients and controls applied to survivors and non-survivors and were not 
influenced by illness severity, illness duration at the time of blood or tissue sampling, or status with 
respect to the use of opioids or anticoagulant agents (Tables S2 trough S6 in the Supplementary 
Appendix). 
Plasma ACTH and cortisol time course 
In the presence of elevated total cortisol levels (averaged over 7 days, P=0.01) patients had lower 
ACTH levels than did controls (P<0.001) (Figure 1). Levels of cortisol did not correlate with ACTH 
levels.   
Figure 1- Plasma ACTH and Cortisol Time Course 
Means and standard errors for ACTH and cortisol from day 1 to 7 in ICU are depicted for patients (dark grey) (N=47). The 
light grey area represents the interquartile range of values in healthy controls (N=12). The overall mean cortisol over the 7 
days was 16.8±7.8 µg/dl for patients and 11.9±2.3 µg/dl for controls (P=0.01). The overall mean ACTH over the 7 days was 
16.9±9.5 pg/ml for patients and 49.6±37.9 pg/ml for controls (P<0.001). For conversion of ACTH to SI units (pmol/l) multiply 
by 0.22. For conversion of cortisol to SI units (nmol/l) multiply by 27.6. 
Mean levels of CBG were lower in the patients than in the controls with values for patients on day 1 of 
31.610.4 mg/l (P=0.001) and on day 7 of 47.411.6 mg/l (P<0.001), as compared with a single 
measure of 67.88.7 mg/l in the controls. As a consequence, calculated median free cortisol levels were 
higher in the patients than in the controls with values for patients on day 1 of 1.0 µg/dl (IQR 0.4-2.7) and 
on day 7 of 0.9 µg/dl (0.6-1.6), as compared with a single measure of 0.4 µg/dl (0.3-0.4) in the controls 
(P≤0.001 for both comparisons).  
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Plasma cortisol clearance and production  
Steady-state concentrations and enrichments of D4-cortisol and D2-cortisone were achieved from 60 
minutes onward. In the patients, as compared with the controls, endogenous cortisol levels were 
increased by a factor 3.5 (P<0.001), and the rate of appearance of cortisol (hereafter referred to as 
cortisol production) was increased by 83% (P=0.02), but pre-infusion ACTH levels were reduced by 
65% (P=0.03) (Figure 2 A,B,C).   
There was no significant difference in cortisol production between patients who were treated with 
catecholamines and those who were not treated with catecholamines (2.7±1.3 mg/h and. 2.9±1.4 mg/h, 
respectively; P=0.86). 
In the patients, as compared with the controls, plasma levels of TNF-α were increased by 49% 
(P=0.001) and plasma IL-6 were increased by more than a factor of 200 (P<0.001). Cytokine levels 
correlated positively with cortisol production (R²=0.26 and P=0.02 for TNF-α and R²= 0.30 and P=0.01 
for IL-6); there also was a positive correlation after correction for ACTH levels, (R²=0.28 and P=0.03 for 
TNF-α and R²= 0.30 and P=0.02 for IL-6). Consistent with these correlations was the finding that 
patients with the systemic inflammatory response syndrome (SIRS)19 had 90% higher cortisol 
production than those who did not have the syndrome (3.4±1.1 mg/h vs. 1.8±1.1 mg/h, P=0.04); the 
latter not differ significantly from that of controls (P=0.39).  
In the patients, as compared with the controls, D4-cortisol levels during infusion were 57% higher 
(P=0.04) and plasma clearance of D4-cortisol was reduced by 53% (P=0.03) (Figure 2 D,E). Reduced 
cortisol clearance did not correlate with markers of organ perfusion (Table S7 in the Supplementary 
Appendix).  
We tested whether decreased cortisol clearance was associated with evidence of adrenal insufficiency 
in relation to reduced ACTH stimulation. A lower cortisol response to ACTH stimulation in the patients 
correlated both with lower cortisol production and with lower D4-cortisol clearance (Figure 2 F,G). 
Patients with a cortisol response to ACTH <21µg/dl, a level that is considered indicative of absolute 
adrenal insufficiency,36 had substantially lower D4-cortisol clearance (0.15±0.02 l/min) than did patients 
who had a normal response to ACTH (0.28±0.11 l/min; P=0.01). Cortisol production in patients with 
adrenal insufficiency (1.4±0.5 mg/h) was indistinguishable from that in controls, whereas it was elevated 
(3.0±1.3 mg/h) in patients with a normal response to ACTH (P=0.03). Circulating levels of cortisol 
before ACTH stimulation were similar in these two groups of patients (9.5±1.5µg/dl and 11.5±6.5 µg/dl, 
respectively; P=0.51).  
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Figure 2 - Results of D4-cortisol tracer infusion  
Panel A and D: Plasma levels of endogenous cortisol and of D4-cortisol tracer reached steady state during study period in 
patients (N=11) and controls (N=9). Means and standard errors are depicted for patients (dark grey) and controls (white/light 
grey). For conversion of cortisol to SI units (nmol/l) multiply by 27.6. For conversion of D4-cortisol to SI units (nmol/l) multiply 
by 27.3. Panel B depicts Rate of Appearance of Cortisol. Panel C depicts pre-infusion plasma ACTH levels. For conversion 
of ACTH to SI units (pmol/l) multiply by 0.22. Panel E depicts D4-clearance. Bar charts in panels B, C and E represent 
means and standard errors. Panels F-G show the correlation between Plasma Clearance of D4-cortisol and Rate of 
Appearance of Cortisol with plasma cortisol responses, 60 minutes after ACTH injection (250 µg) amongst patients. The 
shaded area represents 95% confidence interval. 
Tracer analysis also allowed dissection of the contribution of 11β-HSD enzymes to altered cortisol 
clearance.11,25 The patients had a lower net rate of appearance of cortisone than the controls 
(0.07±0.02 mg/h for every µg/dl vs. 0.14±0.07 mg/h for every µg/dl, P=0.01). However, there was no 
significant between-group difference in the level of regeneration of cortisol by 11β-HSD1, as measured 
by the rate of appearance of D3-cortisol (0.42±0.12 mg/h and 0.49±0.12 mg/h, respectively; P=0.23). 
These findings are consistent with impaired conversion of cortisol to cortisone by 11β-HSD2. 
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Plasma clearance of a therapeutic dose of cortisol 
We tested whether altered cortisol metabolism in critically ill patients occurs at supra-physiological 
concentrations after the administration of therapeutic hydrocortisone. The calculated plasma clearance 
after the administration of 100 mg of hydrocortisone in the patients was 60% lower than that in the 
controls, with a distribution volume that was 37% higher (Figure 3). Cortisol clearance was even more 
suppressed in non-survivors (0.02±0.01l/min) than in survivors (0.05±0.03 l/min; P=0.03). The plasma 
half-life of the 100 mg bolus was a mean 7-fold longer in patients than controls (Figure 3), even more 
pronounced in non-survivors [9.4 (8.9-31.2) hour] than in survivors [5.6 (3.1-7.5) hour] (P=0.03). 
 
Figure 3 - Plasma Clearance of a Therapeutic Dose of Cortisol 
Cortisol half-life (hour) was determined in 20 patients and 8 controls. Panel A depicts the means and standard errors of the 
plasma cortisol concentration time course after injection of 100 mg hydrocortisone in patients (dark grey lines) and controls 
(light grey lines). Panel B depicts the half-life. For conversion of cortisol to SI units (nmol/l) multiply by 27.6. Panel C and D 
depict the plasma clearance and the volume of distribution, respectively, of a 100 mg dose of hydrocortisone. Bar charts in 
panels B-D represent means and standard errors.  
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Activity of cortisol metabolizing enzymes  
We addressed the contribution of 11β-HSDs enzymes and A-ring reductases to impaired cortisol 
clearance in patients. There were no correlations of urinary levels of cortisol metabolites and creatinine 
clearance or daily urine output, which was similar in patients (1936±655 ml/24h) and controls 
(1713±734 ml/24h) (P=0.29).37,38  LC-MS/MS analysis suggested substantial changes in relative 
excretion of cortisol metabolites (Table S8 in Supplementary Appendix). These findings were further 
quantified on GC-MS, which showed that the daily urinary excretion of cortisol was increased by a factor 
of 3.2 in the patients, as compared with the controls, and urinary excretion of cortisone was 73% higher 
in the patients (P<0.001 for both comparisons). In contrast, levels of allo-THF and THF were similar in 
patients and controls, whereas the levels of THE were reduced by 69% in the patients (P<0.001) (Table 
S9 in Supplementary Appendix). Decreased levels of 11β-HSD2 were confirmed in the patients, in 
whom the ratio of urinary E/F, which reflects the renal 11-HSD2 level and the ratio (THF+allo-
THF)/THE, which reflects the conversion of cortisol to cortisone, was markedly altered in favor of cortisol 
(Figure 3A and 3B). In addition, the ratios reflecting activities of A-ring reductases were markedly 
reduced in patients, as compared with the controls (Figure 4 C,D,E). Non-survivors had lower estimated 
5α-reductase activity than survivors (0.6 [0.2-0.8] versus 1.4 [0.8-4.2]; P=0.01) but similar 5-reductase 
activity (5-THF/F 1.2 [0.2-2.5] vs. 1.9 [1.3-3.3]; P=0.14). Levels of total bile acids were increased by a 
factor of 2.4 in the patients, as compared with the controls. (10.9±2.5 µmol/l versus 4.6±1.8 µmol/l; 
P=0.04) and correlated inversely with urinary ratios reflecting A-ring reductase activities (Figure 4 
F,G,H). 
Tissue Expression of Cortisol Metabolizing Enzymes 
To test the inferences from urinary metabolite ratios and tracer kinetics, we studied cortisol metabolizing 
enzymes in tissue biopsy samples. Circulating levels of total cortisol in the patients were three times as 
high as those in the controls (24.3 µg/dl [19.6-30.3] versus 7.4 µg/dl [4.9-14.7]; P<0.001). Levels of total 
bile acids were substantially higher in the patients than in the controls (P<0.001) (Figure 5A) and 
correlated positively with cortisol (R²=0.26; P<0.001). 
In liver specimen from the patients, the mRNA and protein expression of 5β-reductase was reduced by 
80 to 91% as compared with controls (Figure 5 B,C), and enzyme activity was reduced by 58%  
(0.022 pmol/min/mg [0.012-0.029] versus 0.053 pmol/min/mg [0.033-0.067] (P=0.01). The mRNA levels 
correlated positively with protein expression of 5β-reductase (R²=0.46; P<0.001), which in turn had a 
negative correlation with circulating cortisol levels (Figure 5 D). The level of total bile acids correlated 
inversely with the mRNA and protein expression of 5β-reductase (Figure 5 E;F).  
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Figure 4 - Activity of cortisol-metabolizing enzymes estimated from ratios of cortisol metabolites in 24h-urine 
Enzyme activities were estimated for 36 patients and 15 controls based on urinary metabolites quantified using GC-MS. 5α-
Reductase activity was estimated by the allo-THF/F ratio and 5β-reductase activity by THF/F and THE/E ratios. The activity 
of renal 11-HSD2 was estimated by the E/F ratio and the overall activity of 11-HSDs by (allo-THF+THF)/THE ratio, 
reflecting the balance of cortisol/cortisone interconversion. Bar charts represent means and standard errors.  The shaded 
area represents 95% confidence interval. 
 
Figure 5 - Tissue expression of cortisol metabolizing enzymes in relation to circulating cortisol and bile acids. 
Twenty controls and 44 patients were studied. Bar charts represent means and standard errors. For conversion of cortisol to 
SI units (nmol/l) multiply by 27.6. The mRNA data are expressed, normalized to GAPDH, as a fold difference from the mean 
of the controls. Protein data are expressed normalized for CK-18 protein expression, as a fold difference from the mean of 
the controls.  
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The liver mRNA level of 5α-reductase was reduced by 77% in patients, as compared with controls  
(0.23 [0.12-0.36] vs. 1.01 [0.66-1.65]; P<0.001). The hepatic mRNA 5α-reductase level also correlated 
negatively (albeit more weakly than 5β-reductase) with circulating bile acids (R2=0.22, P<0.001) and 
cortisol (R2=0.13; P=0.005).  
Levels of 11β-HSD1 mRNA in liver were reduced by 80% in patients as compared to controls  
(0.20 [0.12-0.37] vs.1.01 [0.62-1.36]; P<0.001) whereas 11β-HSD1 protein and enzyme activity were 
unaltered. These levels were unrelated to the elevated cortisol levels, despite an inverse correlation with 
bile acids (R2=0.26; P<0.001 for mRNA and R2=0.16; P=0.005 for protein).  
Levels of 11β-HSD1 mRNA in omental adipose tissue were reduced by 73% in patients as compared 
with controls (0.27 [0.16-0.46] vs. 1.00 [0.60-2.09]; P=0.003) and by 82% in subcutaneous adipose 
tissue (0.18 [0.07-0.30] vs. 1.00 [0.56-2.17]; P<0.001). These levels were unrelated to elevated cortisol 
levels, despite an inverse correlation with bile acids (subcutaneous adipose tissue R2=0.28; P=0.008). 
Levels of 11β-HSD1 protein and in vitro enzyme activity in adipose tissue were unaltered. 
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3.5  DISCUSSION 
In our study, elevated cortisol levels in critically ill patients were only partially explained by an increase 
of 83% in cortisol production as compared with controls. Since ACTH levels were paradoxically low in 
the patients, a pituitary-independent mechanism was suggested. We showed that impaired cortisol 
clearance contributed to hypercortisolemia, as suggested by studies conducted in the 1950s before the 
advent of ICUs.39,40 Reduced cortisol clearance could be explained by suppressed levels of A-ring 
reductases and 11β -HSD2.  
In other circumstances of reduced cortisol metabolism, such as congenital 11β-HSD2 deficiency,41 
negative feedback on the HPA-axis results in compensatory downregulation of cortisol secretion, with 
lower ACTH levels and adrenocortical atrophy. Elevated levels and production of cortisol in patients 
treated in the ICU must reflect an ongoing stimulus to cortisol secretion. In the presence of low ACTH, 
increased ACTH sensitivity might play a role. However, this seems unlikely during critical illness as 
cortisol responses to ACTH stimulation are not increased. More likely candidates are neuropeptides, 
catecholamines or cytokines,10 especially since cytokine levels were substantially elevated and were 
positively correlated with cortisol production. The role of cytokines is further corroborated by the finding 
that only patients with pronounced inflammation had levels of cortisol production that were higher than 
the levels in controls, whereas cortisol clearance was suppressed regardless of the inflammatory status. 
It remains to be investigated whether adrenocortical atrophy is associated with a sustained reduction in 
the activation of ACTH receptors on adrenocortical cells in patients with reduced cortisol clearance, 
predisposes to adrenocortical atrophy remains to be investigated. However, such a mechanism would 
explain the high incidence of adrenal vascular instability in surgical patients with prolonged critical 
illness42 and is supported by our observation that the patients with the least response to ACTH 
stimulation had the lowest cortisol production and the lowest cortisol clearance, despite a similar 
baseline cortisol level as compared with the other patients. 
Although in isolation each of the separate studies is suggestive, the corroboration of the findings with 
the use of multiple approaches is helpful for making conclusions. Urinary excretion of cortisol was 
elevated in the critically ill patients, but cortisol metabolites were normal or low, despite increased 
cortisol production; this pattern is quite different from that in Cushing‟s syndrome.30,43 The ratios of 
urinary cortisol metabolites suggested reduced activity of the A-ring reductases in the critically ill 
patients and a net suppression of cortisol to cortisone conversion. This interpretation was corroborated 
by low mRNA and protein levels and low activity of the A-ring reductases in liver-biopsies samples. 
Unfortunately, kidney samples were unavailable to quantify 11-HSD2. However, the stable isotope 
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study showed impaired cortisone generation in the critically ill patients, indicating suppressed 11β-HSD2 
activity. Moreover, 11β-HSD1 protein and enzyme activity in biopsy samples and in vivo D3-cortisol 
generation were unaltered, so it is unlikely that altered regeneration of cortisol from cortisone played a 
role in the patients.  
Although hypoperfusion of cortisol-metabolizing organs could theoretically reduce cortisol breakdown, 
this factor does not explain our findings.  In contrast, bile acids are known to be competitive inhibitors 
and transcriptional suppressors of cortisol metabolizing enzymes.14-16 Observations in patients and 
animals with cholestasis support the inhibition of glucocorticoid metabolism by bile acids.14,15,44 The 
negative correlation between the expression and activity of the A-ring reductases and circulating bile 
acid levels suggested that elevated levels of bile acids may reduce cortisol metabolism in critically ill 
patients, a hypothesis that should be further investigated.   
Our studies have some limitations. First, it would have been ideal to document all the changes in one 
single patient population; this was not feasible, in part due to ethical reasons. However, the five groups 
of patients were matched, and the results of all studies corroborated our hypothesis of reduced cortisol 
breakdown. Second, biopsy samples were obtained on autopsy, which may have introduced bias. 
However, reduced cortisol clearance was clearly also present in the patients who survived. 
These findings have important clinical implications. The contribution of reduced cortisol breakdown to 
hypercortisolemia during critical illness changes our understanding of the stress response. Reduced 
inactivation of cortisol may be important not only to increase circulating levels but also to potentiate 
cortisol levels and activity within the vital tissues that express inactivating enzymes. More pragmatically, 
the data suggest that “stress-doses” of hydrocortisone (200 mg/day), which are advocated to replace 
cortisol production in critically ill patients who are presumed to suffer from adrenal failure, are at least 
three-fold too high.21 Finally, our data suggest that a low cortisol response to ACTH stimulation does not 
necessarily reflect adrenal failure, since cortisol production in critically ill patients is not subnormal and 
the suppressed clearance maintains hypercortisolemia. Our results may therefore help to explain why 
studies investigating the effect of the daily administration of 200 mg hydrocortisone in patients with 
sepsis (on the basis of a low cortisol response to ACTH stimulation), have had conflicting results.5,7  
In conclusion, in critically ill patients in the ICU, reduced cortisol breakdown appeared to contribute to 
abnormal blood cortisol in critical illness. This finding has potential implications for the diagnosis of 
adrenal failure and its treatment in the ICU setting.   
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SUPPLEMENTARY APPENDIX 
Methods S1.  Details of selection of patients and controls 
Healthy controls 
For the in vivo studies, healthy men and women were recruited among the relatives and friends of the 
research team and selected based on BMI, age and gender, to match with the patient groups.  
They were invited to participate after screening for exclusion criteria and investigation of their medical 
history: 
- Treatment with glucocorticoids, other steroids or anti-steroid chemotherapy by any route in the 
previous 3 months  
- Recent treatment with azoles, phenytoin, rifampicin, glitazones, imipramine, barbiturates or 
phenothiazines  
- Cerebral or pituitary disease  
- Adrenal dysfunction (Cushing‟s syndrome or Addison‟s disease) 
Before the start of the study each healthy volunteer was examined by a medical doctor to confirm their 
healthy psychological and physical condition. The study was started after written informed consent was 
given.  
For the biopsy studies, the controls were 20 matched patients undergoing elective abdominal surgery 
for restorative rectal resection.  These were also consecutive patients, gender and age-matched who 
were invited to participate after screening for exclusion criteria (such as described above) before they 
were approached for consent.   
Patient selection 
During the time frames of the different clinical studies, consecutive adult (age ≥ 18y) patients were 
screened for eligibility on a daily basis, from the population present in 5 ICUs (total of 73-beds) from 2 
departments (medical and surgical) in 1 University Hospital (University Hospital of Leuven).  
Exclusion criteria 
- Predisposing factors of adrenal insufficiency  
 Cerebral disease with intracranial hypertension threatening the neuroendocrine system  
 Pituitary disorders including (pan)hypopituitarism  
 Known adrenal disease (Cushing‟s syndrome or Addison‟s disease)  
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 Treatment with glucocorticoids, other steroids or anti-steroid chemotherapy within the 
last 3 months  
  Intubation with etomidate within the last 72 hours  
 Other drugs predisposing to glucocorticoid insufficiency160: azoles, phenytoin, 
rifampicin, glitazones, imipramin, phenothiazine, phenobarbital 
 Liver failure 
- Patients not critically ill enough 
 Patients not requiring mechanical ventilation  
 Patients expected to be discharged from ICU within the next 24 hours 
- Patients on Extra-Corporeal Circulatory assist devices 
- Patients with a planned intervention during the study period. 
- No arterial line in place 
- Ethical restrictions 
 Do not resuscitate (DNR) order 
 Patients expected to die within the next 24 hours  
 Declined participation 
The patients were matched for demographical and illness-related characteristics with the previous 
studies. Inevitably the study on the clearance of a therapeutic dose of hydrocortisone was done in even 
more severely ill patients, those for whom clinicians considered it necessary to treat with hydrocortisone.  
Also the study of the biopsies was done in the sickest patients, as these were the non-survivors only.   
To exclude a biased selection of patients, we also analyzed the difference in the patient characteristics 
of those who were included in the study versus those not included and it is clear that, as intended, the 
studied patients do represent the severely ill patients in ICU. Demographical characteristics were 
comparable (Table S1). 
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Methods S2. Consort diagrams of all studies 
Study 1: Plasma ACTH-Cortisol Time Course Study 
 
 
Study 2: D4-Cortisol Tracer Study 
 
 
 
ICU-stay < 7days
N=381
Drugs interfering with adrenal function*
N=69
Logistic, ethical and matching reasons **
N=70
Patients not requiring mechanical ventilation or ready for discharge
N=10
Diseases predisposing to adrenal dysfunction 
(Intracranial lesions/hypertension, pituitary disorders, liver failure) 
N=4
Total adult patients participating in RCT 
during the study period
N=581
Total Study Patients
N=47
Drugs interfering with adrenal function*
N=185
Logistic, ethical and matching reasons **
N=74
Patients not requiring mechanical ventilation or ready for discharge
N=59
Diseases predisposing to adrenal dysfunction 
(Intracranial lesions/hypertension, pituitary disorders, liver failure) 
N=0
Total adult patients admitted during 
study period
N=329
Total Study Patients
N=11
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Study 3: Plasma Clearance of a Therapeutic Dose of Cortisol Study  
 
 
 
Study 4 Cortisol Metabolizing Enzymes Urine Study 
 
 
 
 
Drugs interfering with adrenal function*
N=59
Logistic, ethical and matching reasons **
N=79
Patients not requiring mechanical ventilation or ready for discharge
N=33
Diseases predisposing to adrenal dysfunction 
(Intracranial lesions/hypertension, pituitary disorders, liver failure) 
N=4
Total adult patients requiring initiating of glucocorticoid 
treatment during study period
N=195
Total Study Patients
N=20
Patients on renal replacement therapy or no bladder catheter
N=105
Drugs interfering with adrenal function*
N=206
Logistic, ethical and matching reasons **
N=11
Patients not requiring mechanical ventilation or ready for discharge
N=57
Diseases predisposing to adrenal dysfunction 
(Intracranial lesions/hypertension, pituitary disorders, liver failure) 
N=10
Total adult patients admitted during 
study period
N=425
Total Study Patients
N=47
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Study 5: Cortisol Metabolizing Enzymes Tissue Biopsy Study 
 
 
 
*  All types of glucocorticoids or anti-steroid chemotherapy, etomidate, azoles, phenobarbital, phenytoin, rifampicin, 
glitazones, imipramine, phenothiazine  
** Planned surgical or diagnostic intervention, no arterial line, DNR code, circulatory assist devices, unavailability of the 
researchers, and matching with previous studies, declined participation 
(excluded in order of listing) 
Drugs interfering with adrenal function*
N=92
No biopsy available
N=263
Diseases predisposing to adrenal dysfunction 
(Intracranial lesions/hypertension, pituitary disorders, liver failure) 
N=5
Non-survivors of 2 RCTs
N=404
Total Study Patients
N=20
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Table S1: Extended characteristics of study patients and controls 
  
Plasma ACTH-Cortisol 
Time Course Study 
D4-Cortisol  
Tracer Study 
Plasma Clearance of a 
Therapeutic Dose of 
Cortisol Study 
Cortisol Metabolizing 
Enzymes 
Urine Study 
Cortisol Metabolizing 
Enzymes 
Tissue Biopsy Study 
  
Patients 
(n=47) 
Controls 
(n=12) 
Patients  
(n=11) 
Controls  
(n=9) 
Patients  
(n=20) 
Controls  
(n=8) 
Patients  
(n=36) 
Controls 
(n=15) 
Patients 
(n=44) 
Controls 
(n=20) 
Demography and anthropometry   
 
      
     Gender (no. male (%)) 27 (57) 5 (42) 7 (64) 5 (56) 8 (40) 5 (63) 25 (69) 9 (60) 28 (63) 14 (70) 
     Age (yr) (mean±SD) 63.7 ± 18.0 60.4 ± 4.7 68.5 ± 8.3 62.6 ± 4.1 64.4 ± 13.2 60.3 ± 4.3 66.4 ± 10.8 61.1 ± 8.3 71.2 ± 12.0 70.4 ± 11.6 
     BMI (kg/m2) (mean±SD) 26.2 ± 4.2 24.4 ± 3.4 28.5 ± 4.9 25.2 ± 4.1 26.3 ± 5.8 24.1 ± 1.8 26.7 ± 5.4 25.2 ± 5.3 24.8 ± 3.6 25.0 ± 2.6 
Admission characteristics   
 
      
     APACHE II (mean±SD) 28 ± 10  29 ± 11 
 
34 ± 7  31 ± 6  29 ± 9  
     SIRS (no. (%)) 43 (91)  10 (91) 
 
20 (100)  36 (100)  35 (80)  
     Sepsis (no. (%)) 17 (36)  5 (45) 
 
11 (55)  20 (56)  17 (39)  
     Diagnostic group on admission (no. (%))    
 
      
       Cardiovascular 22 (47)  4 (36) 
 
8 (40)  7 (19)  16 (36)  
       Respiratory/Esophageal-lung surgery 1 (2)  1 (9) 
 
6 (30)  4 (11)  6 (14)  
       Abdominal/Gastro-intestinal/Hepatic 6 (13)  2 (18) 
  
4 (20)  13 (36)  7 (16)  
       Other 18 (38)  4 (36) 
 
2 (10)  12 (33)  15 (34)  
Patients characteristics at study time           
     SIRS (no. (%)) 20 (43)  7 (64)  20 (100)  22 (61)  35 (80)  
     Sepsis (no. (%)) 16 (34)  5 (45)  15 (75)  17 (47)  26 (59)  
     CRP (mg/l) (mean±SD) 107 ± 86  199 ± 131  143 ± 106  109 ± 81  185 ± 91  
     Last CO before Study (l/min) (mean±SD) 5.5 ± 1.2  5.4 ± 1.4  5.2 ± 1.5  6.9 ± 3.3  NA  
     Requiring Inotropes (no. (%)) 6 (13)  3 (27)  8 (40)  2 (7)  24 (55)  
     Requiring Vasopressors (no. (%)) 17 (36)  7 (64)  20 (100)  19 (53)  30 (68)  
     24h Urine Output (liter) (mean±SD) 1.8 ± 1.0  1.6 ± 0.5  0.9 ± 0.7  1.7 ± 0.7    1.0 ± 1.3  
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     Blood Lactate (mmol/l) (mean±SD) 0.93 ± 0.28  1.18 ± 0.35  2.54 ± 2.84  1.27 ± 1.85  3.50 ± 1.16  
     Treated with Opioids (no. (%)) 28 (60)  10 (91)  15 (75)  16 (44)  34 (77)  
     On Therapeutic Anticoagulation (no. (%)) 5 (11)  0 (0)  0 (0)  0 (0)  2 (5)  
Clinical Outcome    
 
      
     Days in ICU (mean±SD) 18 ± 16  26 ± 16 
 
24 ± 32  22 ± 25  14 ± 17  
     Day of Sampling (mean±SD) 1 to 7  7 ± 5 
 
9 ± 15  10 ± 17  14 ± 17  
     ICU Mortality (no. (%)) 6 (13)  2 (18) 
 
7 (35)  5 (14)  44 (100)  
     Hospital Mortality (no. (%)) 10 (21)  4 (36) 
 
9 (45)  6 (17)  44 (100)  
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Table S2: Characteristics of patients selected and patients not selected for each study 
 
Plasma ACTH-Cortisol Time 
Course Study 
D4-Cortisol Tracer Study 
Plasma Clearance of a 
 therapeutic dose of Cortisol 
study 
Cortisol Metabolizing 
Enzymes Urine Study 
Cortisol Metabolizing 
Enzymes Tissue Biopsy 
Study 
           
  
Patients  
selected  
for study 
Patients  
not selected  
for study 
Patients  
selected 
 for study 
Patients  
not selected  
for study 
Patients  
selected  
for study 
Patients  
not selected  
for study 
Patients  
selected  
for study 
Patients  
not selected  
for study 
Patients  
selected  
for study 
Patients  
not selected  
for study 
 (n=47) (n=534) (n=11) (n=318) (n=20) (n=175) (n=36) (n=389) (n=44) (n=360) 
Demography and anthropometry           
Gender (no.( % male)) 27 (57) 341 (64) 7 (64) 197 (62) 8 (40) 94 (54) 25 (69) 247 (64) 28 (63) 227 (63) 
Age (yr) (mean ± SD) 63.7 ± 18.0 63.0 ± 14.1 68.5 ± 8.3 62.6 ± 16.0 64.4 ± 13.2 61.3 ± 15.2 66.4 ± 10.8 57.4 ±16.8 71.2 ± 12.0 64.5 ± 15.2 
BMI (kg/m2) (mean ± SD) 26.2 ± 4.2 26.4 ± 5.2 28.5 ± 4.9 25.3 ± 4.9 26.3 ± 5.8 26.4 ± 6.2 26.7 ± 5.4 26.4 ± 5.8 24.8 ± 3.6 24.6 ± 5.1 
Admission characteristics           
APACHE II (mean ± SD) 28 ± 10 23 ± 11 29 ± 11 23 ± 9 34 ± 7 21 ± 9 31 ± 6 24 ± 10 29 ± 9 36 ± 13 
SIRS (no. (%)) 43 (91) 508 (95) 10 (91) 165 (52) 20 (100) 82 (47) 36 (100) 245 (57) 35 (80) 298 (83) 
Sepsis (no. (%)) 17 (36) 122 (23) 5 (45) 84 (26) 11 (55) 37 (21) 20 (56) 155 (36) 26 (59) 238 (66) 
Diagnostic group on admission (no.)           
     Cardiovascular 22 (47) 329 (62) 4 (36) 116 (36) 8 (40) 44 (25) 7 (19) 108 (28) 16 (36) 36 (10) 
     Respiratory/Esophageal -lung surgery 1 (2) 82 (15) 1 (9) 63(20) 6 (30) 38 (22) 4 (11) 80 (21) 6 (14) 145 (40) 
     Abdominal/Gastro-intestinal/Hepatic 6 (13) 55 (10) 2 (18) 57(18) 4 (20) 46 (26) 13 (36) 60 (15) 7 (16) 54 (15) 
     Other 18 (38) 68 (13) 4 (36) 82 (26) 2 (10) 47 (27) 12 (33) 141 (36) 15 (34) 125 (35) 
Clinical Outcome           
Days in ICU (mean ± SD) 18 ± 16 8 ± 14 26 ± 16 12 ± 20 24 ± 32 11 ± 20 22 ± 25 32 ± 44 14 ± 17 16 ± 18 
ICU mortality (no (%)) 6 (13) 32 (6) 2 (18) 39 (12) 7 (35) 15 (9) 5 (14) 52 (13) 44 (100) 360 (100) 
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Table S3: Main results for ICU survivors and non-survivors versus controls.  
  Controls ICU survivor ICU non-survivor P-value P-value 
  mean±SD mean±SD mean±SD 
Control vs  
ICU-survivor 
ICU-survivor vs 
 non-survivor 
Plasma ACTH and cortisol time course      
    Mean Plasma ACTH (pg/ml)  49.6±37.9 16.9±9.7 17.1±9.1 <0.001 0.83 
    Mean Plasma Total Cortisol (µg/dl) 11.9±2.3 16.8±7.8 17.3±8.7 0.01 0.73 
    Free Cortisol day 1 (µg/dl) 0.4±0.1 1.8±2.1 2.8±4.0 0.001 0.93 
    Free Cortisol day 7 (µg/dl) 0.4±0.1 1.3±1.3 1.4±0.8 <0.001 0.28 
Cortisol kinetics during stable isotope tracer infusions 
    Plasma Cortisol at steady state (µg/dl)  2.9±1.3 9.1±4.1 14.7±2.7 0.002 0.07 
    Rate of Appearance of Cortisol (mg/h) 1.5±1.5 2.6±1.4 3.7±0.4 0.05 0.28 
    Plasma Clearance of D4-cortisol (liter/min) 0.5±0.3 0.3±0.1 0.26±0.06 0.03 0.83 
    Plasma D4-cortisol (µg/dl) 1.7±1.1 2.7±1.0 2.3 0.6 0.03 0.83 
    Net rate of appearance Cortisone (mg/h per µg/dl) 0.14±0.07 0.07±0.02 0.07±0.0006 0.008 0.90 
    Rate of appearance of D3-cortisol (mg/h) 0.5±0.1 0.4±0.1 0.4±0.1 0.42 0.28 
Plasma clearance of a therapeutic dose of cortisol 
    Plasma Clearance of Cortisol (liter/min) 0.10±0.02 0.05±0.03 0.02±0.01 0.001 0.03 
    Cortisol Half-life (h) 1.8±0.3 9.4±10.0 17.9±13.0 <0.001 0.03 
Activity of cortisol metabolizing enzymes estimated by ratios of urinary cortisol metabolites 
    11β-HSD2 (E/F) 0.7±0.2 0.5±0.3 0.3±0.3 0.01 0.13 
    overall-11β-HSD (THF+allo/THE) 1.3±0.4 6.9±6.3 4.1±2.6 <0.001 0.35 
    5α-reductase (alloTHF/F)  4.9±2.6 2.3±1.8 0.5±0.3 0.002 0.01 
    5β-reductase (THF/F) 4.6±1.3 3.0±2.9 1.3±1.4 0.001 0.14 
    5β-reductase (THE/E)  11.4±3.7 2.6±2.2 2.9±2.5 <0.001 1.00 
Tissue expression of cortisol metabolizing enzymes 
 NA NA 
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Table S4: Main results for duration of stay in ICU at sampling 
Plasma ACTH and cortisol time course    
    NA     
Cortisol kinetics during stable isotope tracer 
infusions 
 R² * P-value 
    Plasma Cortisol at steady state (µg/dl)  <0.001 0.96 
    Rate of Appearance of Cortisol (mg/h)  0.02 0.70 
    Plasma Clearance of D4-cortisol (liter/min)   0.10 0.34 
    Plasma D4-cortisol (µg/dl)  0.17 0.21 
    Net rate of appearance of Cortisone (mg/h per µg/dl)   0.15 0.24 
    Rate of appearance of D3-cortisol (mg/h)   0.15 0.24 
Plasma clearance of a therapeutic dose of cortisol    
    Plasma Clearance of Cortisol (liter/min)  0.003 0.81 
    Cortisol Half-life (h)  0.03 0.42 
Activity of cortisol metabolizing enzymes estimated 
by ratios of urinary cortisol metabolites 
   
    11β-HSD2 (E/F)  0.11 0.05 
    overall-11β-HSD (THF+alloTHF/THE)  0.04 0.23 
    5α-reductase (alloTHF/F)  0.007 0.63 
    5β-reductase (THF/F)  <0.001 0.94 
    5β-reductase (THE/E)  <0.001 0.94 
Tissue expression of cortisol metabolizing 
enzymes 
   
    5α-reductase mRNA levels liver  0.03 0.27 
    5α-reductase mRNA levels omentum  0.03 0.54 
    5α-reductase mRNA levels subcutaneous fat  0.008 0.75 
    5β-reductase mRNA levels liver  0.01 0.40 
    5β-reductase protein levels liver  0.01 0.39 
 
* R² for correlation between ICU day of sampling and the different variables listed 
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Table S5: Main results for severity of illness (APACHE II) 
Plasma ACTH and cortisol time course R² * P-value 
    Mean Plasma ACTH (pg/ml)  0.02 0.39 
    Mean Plasma Total Cortisol (µg/dl) 0.01 0.41 
    Free Cortisol day 1 (µg/dl) 0.009 0.53 
    Free Cortisol day 7 (µg/dl) 0.03 0.28 
Cortisol kinetics during stable isotope tracer infusions   
    Plasma Cortisol at steady state (µg/dl) 0.09 0.37 
    Rate of Appearance of Cortisol (mg/h) <0.001 0.97 
    Plasma Clearance of D4-cortisol (liter/min)  0.06 0.45 
    Plasma D4-cortisol (µg/dl) 0.002 0.89 
    Net rate of appearance of Cortisone (mg/h per µg/dl)  0.11 0.30 
    Rate of appearance of D3-cortisol (mg/h)  0.07 0.41 
Plasma clearance of a therapeutic dose of cortisol   
    Plasma Clearance of Cortisol (liter/min) 0.11 0.15 
    Cortisol Half-life (h) 0.01 0.56 
Activity of cortisol metabolizing enzymes estimated by 
ratios of urinary cortisol metabolites 
  
    11β-HSD2 (E/F) 0.02 0.38 
    overall-11β-HSD (THF+allo/THE) <0.001 0.97 
    5α-reductase (alloTHF/F) 0.07 0.13 
    5β-reductase (THF/F) 0.002 0.75 
    5β-reductase (THE/E) 0.08 0.10 
Tissue expression of cortisol metabolizing enzymes   
  NA NA 
 
* R² for correlation between APACHE-II score and the different variables listed 
 
  
71 
 
Table S6: Main results for unavoidable predisposing factors of adrenal dysfunction in critical 
illness 
OPIOIDS    
  
Opioids 
(mean±SD) 
No Opioids 
(mean±SD) 
P-value 
Plasma ACTH and cortisol time course N=28 N=19  
    ACTH levels on day 7 (pg/ml) 21.7±21.2 26.4±18.5 0.06 
    Total Cortisol levels day 7 (µg/dl)  17.2±9.4 18.2±10.0 0.80 
    Free Cortisol levels day 7 (µg/dl) 1.3±1.3 1.3±1.1 1.00 
Cortisol kinetics during stable isotope tracer 
infusions 
N=10 N=1  
    Plasma Cortisol at steady state (µg/dl)  10.0±4.6 11.3 1.00 
    Rate of Appearance of Cortisol (mg/h)  2.8±1.4 2.5 0.87 
    Plasma Clearance of D4-cortisol (liter/min) 0.3±0.1 0.2 0.42 
    Plasma levels D4-cortisol (µg/dl) 2.5±0.9 3.4 0.42 
    Net rate of appearance of Cortisone (mg/h per 
µg/dl) 
0.08±0.02 0.05 0.15 
    Rate of appearance of D3-cortisol (mg/h) 0.4±0.1 0.3 0.26 
Plasma clearance of a therapeutic dose of 
cortisol 
N=15 N=5  
    Plasma Clearance of Cortisol (liter/min)  0.03±0.02 0.05±0.04 0.33 
    Cortisol Half-life (h)  12.8±11.3 11.1±13.6 0.40 
Activity of cortisol metabolizing enzymes by 
urinary metabolites  
N=16 N20  
    11β-HSD2 (E/F) 0.5±0.4 0.4±0.3 0.70 
    overall-11β-HSD (THF+allo/THE) 8.0±7.8 5.4±4.1 0.55 
    5α-reductase (alloTHF/F) 2.0±2.0 2.0±1.7 0.40 
    5β-reductase (THF/F) 2.6±3.3 2.8±2.3 0.62 
    5β-reductase (THE/E) 2.0±1.9 3.2±2.4 0.12 
Tissue expression of cortisol metabolizing 
enzymes 
N=34 N=10  
    5α-reductase mRNA levels liver 0.7±1.9 0.3±0.2 0.87 
    5α-reductase mRNA levels omentum 0.9±0.8 1.5±1.4 0.43 
    5α-reductase mRNA levels subcutaneous fat 1.0±0.7 0.8±0.3 0.93 
    5β-reductase mRNA levels liver 0.3±0.8 0.2±0.3 0.61 
    5β-reductase protein levels liver 0.2±0.4 0.7±1.5 0.01 
     
ANTI-COAGULANT THERAPY    
  
Therapeutic 
anticoagulants 
(mean±SD) 
No therapeutic 
anticoagulants 
(mean±SD) 
P-value 
Plasma ACTH and cortisol time course N=5 N=42  
    on ACTH levels day 7 22.8±10.1 23.7±21.1 0.58 
    on endogenous cortisol levels day 7 (yes vs. no) 17.1±8.8 17.6±9.8 0.95 
    Plasma CBG day 7 (mg/l)  45.7±5.7 47.6±12.1 0.78 
    Free Cortisol day 7  (µg/dl) 1.3±1.1 1.3±1.2 0.95 
Cortisol kinetics during stable isotope tracer 
infusions 
  
 none on therapeutic anticoagulants  
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Plasma clearance of a therapeutic dose of 
cortisol 
   
 none on therapeutic anticoagulants  
   
Activity of cortisol metabolizing enzymes 
estimated by ratios of urinary cortisol 
metabolites 
  
 none on therapeutic anticoagulants  
Tissue expression of cortisol metabolizing 
enzymes 
N=2 N=42  
    5α-reductase mRNA levels liver 0.3±0.2 0.6±1.7 0.87 
    5α-reductase mRNA levels omentum 3.0±0.0 0.9±0.8 0.13 
    5α-reductase mRNA levels subcutaneous fat 0.2±0.0 0.2±0.1 0.89 
    5β-reductase mRNA levels liver 0.1±0.2 0.3±0.7 0.80 
    5β-reductase protein levels liver 0.05±0.06 0.30±0.86 0.63 
 
Most known predisposing factors for adrenal dysfunction were excluded. The only predisposing drugs 
that could not be excluded, as often required during critical illness, were anticoagulants and opioids. To 
check if they affect our conclusions, we looked for differences between treated and non-treated patients. 
We could confidently exclude potential confounding by such treatments.  
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Table S7: Results in relation to markers of organ hypoperfusion 
D4-cortisol plasma clearance (liter/min)  
  R² * P-value  
Cardiac Output (liter/min) 0.22 0.34  
Blood Lactate (mmol/l) 0.11 0.31  
24h Urine Output (liter) 0.02 0.66  
  Treatment No treatment P-value 
  mean ±SD mean ±SD  
Inotropes  0.27±0.19 0.25±0.07 0.88 
Vasopressors  0.22±0.06 0.32±0.15 0.27 
Opioids 0.26±0.11 0.17±0 0.42 
Therapeutic anticoagulants none on therapeutic anticoagulants 
     
Cortisol plasma clearance after a therapeutic hydrocortisone dose (liter/min) 
  R² * P-value  
Cardiac Output (liter/min) 0.36 0.15  
Blood Lactate (mmol/l) 0.11 0.14  
24h Urine Output (liter) 0.10 0.15  
  Treatment No treatment P-Value 
  mean ±SD mean ±SD  
Inotropes  0.03±0.02 0.05±0.03 0.26 
Vasopressors  All on vasopressors 
Opioids 0.03±0.02 0.05±0.04 0.33 
Therapeutic anticoagulants none on therapeutic anticoagulants 
* R² for correlation between cardiac output, blood lactate or 24h urine output and cortisol plasma clearance in the tracer 
study and after a therapeutic hydrocortisone injection. 
Since cardiac output and organ perfusion may determine removal and metabolism of a substance, 
reduced cortisol clearance in critical illness could be influenced by a change in these parameters. 
Therefore, we looked to the association of indirect markers of organ perfusion with plasma cortisol 
clearance in the two studies. First, we analyzed whether cortisol clearance correlated with cardiac 
output. There was no correlation at all. Second, we looked whether cortisol clearance was associated 
with the need of treatment for low cardiac output (catecholamines such as adrenalin, dobutamine, 
isuprenaline or non-catecholamine inotropes such as phosphodiesterase inhibitors etc.) or with the need 
for vasopressors (cathecholamines such as noradrenalin or dopamine, or non-catecholamines such as 
vasopressin etc.).  Again, there was no relation at all.  Third, if the reduced cortisol clearance were the 
consequence of a general hypoperfusion state, one would expect also a correlation between cortisol 
clearance and plasma lactate (marker of global oxygen debt) or urine output (a marker of kidney 
perfusion).  None of this was the case. Hence, reduced cortisol clearance in critical illness could not be 
explained by a general hypoperfusion state.   
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Table S8: Urinary metabolites by LC-MS/MS 
Metabolite Patients (n=36) Controls (n=15) P-value 
 median (IQR) median (IQR)  
F* 21.6 (12.9-30.8) 4.2 (2.5-6.1) <0.001 
E* 6.7 (4.1-10.1) 4.7 (3.1-6.7) 0.06 
allo-THF* 1.5 (0.9-3.5) 1.5 (0.8-2.3) 0.48 
THF* 3.8 (2.2-8.2) 4.2 (2.2-6.8) 0.99 
THE* 6.7 (3.1-17.6) 15.2 (10.6-27.1) 0.004 
*relative amounts (area/area internal standard) 
 
Table S9: Urinary metabolites by GC-MS 
Metabolite Patients (n=36) Controls (n=15) P-value 
 median (IQR) median (IQR)  
F (µg/24h)  886 (534-1620) 273 (188-333) <0.001 
E (µg/24h) 312 (252-424) 180 (145-211) <0.001 
allo-THF (µg/24h) 1155 (450-2842) 1198 (992-1422) 0.80 
THF (µg/24h) 1779 (726-4629) 1362 (957-1493) 0.22 
THE (µg/24h) 663 (328-1003) 2145 (1520-2426) <0.001 
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CHAPTER 4 
 
REDUCED NOCTURNAL ACTH-DRIVEN 
CORTISOL SECRETION DURING CRITICAL ILLNESS 
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Adapted from: Boonen E, Meersseman Ph, Vervenne H, Meyfroidt G, Guïza F, Wouters PJ, Veldhuis  
JD, Van den Berghe G. Reduced nocturnal ACTH-driven cortisol secretion during critical illness.  
Am J Physiol Endocrinol Metab  (in press) 
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4.1  ABSTRACT 
Background: During critical illness, cortisol metabolism was recently found to be reduced. We 
hypothesize that such reduced cortisol breakdown may suppress pulsatile ACTH and cortisol secretion 
via feed-back inhibition. 
Methods: To test this hypothesis, nocturnal ACTH and cortisol secretory profiles were constructed by 
deconvolution analysis from plasma concentration time-series in 40 matched critically ill patients and 8 
healthy controls, excluding diseases or drugs that affect the HPA-axis. Blood was sampled every 10 
minutes between 21:00h and 06:00h to quantify plasma concentrations of ACTH and (free) cortisol. 
Approximate entropy, an estimation of process irregularity, cross-approximate entropy, a measure of 
ACTH-cortisol asynchrony, and ACTH-cortisol dose-response relationships were calculated. 
Results: Total and free plasma cortisol concentrations were higher at all times in patients than controls 
(all P<0.04). Pulsatile cortisol secretion was 54% lower in patients than controls (P=0.005), explained by 
reduced cortisol burst mass (P=0.03) whereas cortisol pulse frequency (P=0.35) and non-pulsatile 
cortisol secretion (P=0.80) were unaltered. Pulsatile ACTH secretion was 31% lower in patients than 
controls (P=0.03), again explained by a lower ACTH burst mass (P=0.02), while ACTH pulse frequency 
(P=0.50) and non-pulsatile ACTH secretion (P=0.80) were unchanged. ACTH/cortisol dose-response 
estimates were similar in patients and controls. ACTH and cortisol approximate entropy was higher in 
patients (P≤0.03), as were ACTH/cortisol cross-approximate entropy (P≤0.001).  
Conclusions: Hypercortisolism during critical illness coincided with suppressed pulsatile ACTH and 
cortisol secretion and a normal ACTH/cortisol dose-response. Increased irregularity and asynchrony of 
the ACTH and cortisol time-series supported non-ACTH-dependent mechanisms driving 
hypercortisolism during critical illness.   
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4.2  INTRODUCTION 
The stress hormone cortisol is an essential component of the „fight or flight‟ adaptation to the stress of 
illness and trauma. Whenever the human brain senses a stressful event, the HPA-axis is activated via 
the release of CRH from the hypothalamic paraventricular nucleus into the portal circulation, which 
stimulates the anterior pituitary corticotrophs to secrete ACTH in turn driving cortisol synthesis and 
secretion from the adrenal cortex. Feedback inhibition exerted by cortisol at the pituitary and the 
hypothalamic level controls its own release.  
The release of ACTH and cortisol occurs predominantly in discrete pulses superimposed upon a non-
pulsatile hormonal release with a slower diurnal pattern so that minimal levels are present during sleep 
and maximal levels around awaking.1 Several groups have reported that in patients suffering from 
critical illness, an extreme example of physical stress, high circulating cortisol levels are present in the 
face of low rather than high ACTH plasma concentrations.  This constellation is referred to as the 
„ACTH-cortisol dissociation‟2-4 and has been interpreted as ACTH-independent factors driving cortisol 
release.5   
We showed via a stable isotope tracer study that the elevated morning plasma cortisol concentrations 
during critical illness are only to a limited extent explained by increased cortisol production. In patients 
with excessive inflammation, this cortisol production was found to correlate with the plasma 
concentrations of pro-inflammatory cytokines. Critically ill patients not suffering from excessive 
inflammation did not show elevated cortisol production at all, although the plasma cortisol 
concentrations were as high as in patients with excessive inflammation. In contrast, cortisol metabolism 
was found to be reduced irrespective of the inflammatory status, via suppressed expression and/or 
activity of the A-ring reductases and of 11β-HSD2.2 
In these previous studies, only single sample plasma ACTH concentrations were reported. This 
precludes analysis of ACTH secretory dynamics and of its relationship with cortisol secretion during 
critical illness. We hypothesized that reduced cortisol breakdown during critical illness can elevate 
circulating cortisol to levels that are able to suppress pulsatile ACTH secretion via feedback-inhibition. If 
the responsiveness of cortisol secretion to a given ACTH concentration is unaltered during critical 
illness, such suppressed pulsatile ACTH secretion could then proportionately reduce pulsatile cortisol 
release in the face of elevated plasma cortisol concentrations. Such an additional regulator of the HPA 
axis will expectedly increase the irregularity and asynchrony of the ACTH and cortisol time series.  
To test this hypothesis, the dynamics of ACTH and cortisol secretion, analyzed via nocturnal time series 
of repeated (every 10 minutes) blood samples, were compared between critically ill patients and 
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demographically matched healthy control subjects. First, pulsatile and non-pulsatile ACTH and cortisol 
secretory profiles were constructed from the plasma concentration time series by deconvolution 
analysis.6 Second, with a complementary analytical model, the cortisol secretory dose-response to 
ACTH was quantified by coupling effector concentrations to time-delayed glandular secretion rates.7 
Third, the presence of alternative regulators of ACTH and cortisol was appraised by the approximate 
entropy (ApEn) of the respective time series, an estimation of process irregularity, and by cross-ApEn, a 
quantitation of ACTH-cortisol asynchrony.6 Finally, plasma concentrations of free cortisol and of the pro-
inflammatory cytokines IL-6 and TNF-α were quantified and correlated with the deconvolved ACTH and 
cortisol secretion rates and with the (cross-)ApEn to assess their potential role as regulators of the HPA-
axis dynamics during critical illness. 
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4.3  MATERIALS AND METHODS   
Patient and study samples 
Overnight serial blood samples were taken from critically ill patients and demographically matched 
healthy controls. Baseline characteristics are described in Table 1.8,9 The study protocol and consent 
forms were approved by the Institutional Ethical Review Board of the KU Leuven (ML6625). The study 
was registered at International Standard Randomized Controlled Trial Number Register (Number 
ISRCTN49306926). Written informed consent was obtained from the patients‟ next of kin and from the 
healthy volunteers. 
During the time frame of the study, consecutive adult (age ≥ 18y) patients were screened for eligibility 
on a daily basis, from the population present in 5 ICUs (total of 73 beds), both medical and surgical, in 
the University Hospitals of KU Leuven. Patients with diseases predisposing to HPA axis dysfunction or 
treated with drugs affecting the HPA-axis were excluded (glucocorticoids within the last 3 months, 
etomidate or azoles within the last 72 hours).10  
Healthy men and women were selected based on BMI, age and gender, to match with the patient group. 
They were invited to participate after screening for exclusion criteria, as mentioned above. Before the 
start of the study each healthy volunteer was examined by a medical doctor to confirm a healthy 
physical and psychological condition. The volunteers were admitted to a room adjacent to the ICU, to 
control for environmental factors. Lights went out between 22:00h and 23:00h, ambulation was 
permitted to the lavatory only and eating or drinking was not allowed.  
Undiluted 2 ml blood samples were withdrawn from an arterial line every 10 minutes during 9 hours 
(21:00h-06:00h), allowing detection of cortisol release episodes of which the timing is  
non-randomly coupled to that of prior and simultaneous ACTH release episodes.11 For critically ill 
patients, blood was sampled via the arterial catheter already in place as part of standard intensive care 
management. In healthy control subjects an arterial catheter was inserted into the arteria radialis.  
A Venous Arterial blood Management Protection system (VAMP®, Edwards Lifesciences, Irvine, USA) 
was connected to the arterial catheter to allow sampling without unnecessary blood waste. Total blood 
loss per patient/control did not exceed 110 ml. 
All samples were collected in pre-chilled EDTA-tubes and immediately placed on ice. After 
centrifugation (233g, 10 min) at 4°C, plasma samples were frozen at -20°C and stored at -80°C until 
further analysis.  
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Table 1: Characteristics of study patients and controls     
  
  
  
  Patients (N=40) Controls (N=8) P-value 
Demography and anthropometry 
  
  
     Gender (no. male (%)) 30 (75) 6 (75) 1.00 
     Age (yr) (mean ± SD) 59.1 ± 16.9 55.6 ± 4.5 0.27 
     BMI (kg/m2)a (mean ± SD) 25.9 ± 4.8 24.2 ± 2.3 0.14 
Admission Characteristics 
  
  
     Diagnostic group on admission (no. (%))       
       Cardiovascular 9 (22.5) 
 
  
       Respiratory/Esophageal-lung surgery 7 (17.5)     
       Abdominal/Gastro-intestinal/Hepatic 19 (47.5) 
 
  
       Other 5 (12.5)     
     APACHE II b (mean±SD)  36 ± 5 
 
  
Patient characteristics at study time       
     Day of Sampling (median (IQR)) 3.5 (2.0-5.0) 
 
  
     SIRSc (no. (%))  28 (70)     
     Sepsis (no. (%)) 18 (45) 
 
  
     Treatment with catecholaminesd (no. (%)) 26 (65)     
     Treatment with opioidsd (no. (%)) 30 (75) 
 
  
     Treatment with anti-coagulantsd (no. (%)) 6 (15)     
     Treatment with sedatives (no. (%)) 10 (25) 
 
  
     Treatment with hypnotics (no. (%)) 13 (33)     
     Plasma creatinine (mg/dl) (median (IQR)) 1.1 (0.6-2.2) 
 
  
     24h urinary volume (ml)  (median (IQR)) 1225 (750-1950)     
     Creatinine clearancee (ml/min) 52.7 (22.5-98.3) 
 
  
     Renal Replacement Therapy (no. (%)) 4 (10)     
Clinical Outcomes 
  
  
     Duration of stay in ICU (median (IQR)) 14 (9.3-22.5)     
     Hospital Mortality (no. (%)) 7 (18) 
 
  
 
aBMI: body-mass index. bAcute Physiology and Chronic Health Evaluation II (APACHE II) ranges from 0 to 71, with higher 
scores indicating greater severity of illness.8 cSIRS: Systemic Inflammatory Response Syndrome, determined by the BONE 
criteria.9 dOther drugs known to affect the HPA-axis were excluded:10 glucocorticoids, other steroids, anti-steroid 
chemotherapy, etomidate, azoles, phenytoin, rifampicin, glitazones, imipramin, phenothiazine, phenobarbital. ecreatinine 
clearance: (urinary creatinine level * 24h urinary volume)/(plasma creatinine level *1440) (missing values in 30% of patients). 
Plasma concentrations of ACTH and cortisol for deconvolution analysis 
Total plasma cortisol concentrations were quantified with a high-specificity and high-sensitivity 
radioimmunoassay (Immunotech, Prague, Czech Republic). Plasma ACTH was quantified by a high-
sensitivity and high-specificity double-monoclonal immunoradiometric assay (Brahms Diagnostics, 
Berlin, Germany).  
Analyses were performed according to the manufacturer‟s instructions.  For the determination of ACTH, 
300 µl of plasma was used and one extra calibrator of a lower concentration (2.4 pg/ml) was prepared 
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by dilution of the lowest kit calibrator (4.8 pg/ml) with zero serum to increase sensitivity. All samples 
from one patient/control were processed in the same assay run.  
Plasma free cortisol concentrations to estimate negative feedback inhibition on ACTH 
Plasma CBG and albumin concentrations were quantified in samples taken on five time points spread 
over the time course of the study. Plasma CBG was quantified with a commercially available 
radioimmunoassay (Riazen, Louvain-la-Neuve, Belgium). Plasma albumin was measured by the 
bromocresol green method with the Quantitative Colorimetric Albumin Determination assay (BioAssay 
Systems, Hayward, CA).  
Based on total plasma cortisol, CBG and albumin concentrations free cortisol levels were calculated 
with the Coolens method, previously validated in critical illness.12,13 Since CBG and albumin have a long 
plasma half-life, repeated measurement of plasma concentrations is not meaningful. Therefore plasma 
concentrations of CBG and albumin were quantified at several time points spread over the study period 
(at 21:30h, 23:40h, 01:30h, 03:40h and 05:30h). With use of the Coolens method,12 and using plasma 
CBG and albumin concentrations, free plasma cortisol concentrations were calculated. 
Coolens Formula:  Free cortisol =     
 
      
      with   Z 
 
  
 + 
   
       
 
With G = plasma CBG concentration (in µmol/l), T = plasma total cortisol concentration (in µmol/l), K = affinity of CBG for 
cortisol = 3.107M-1  and N = ratio of albumin bound cortisol to unbound cortisol which is 1.74 for a normal albumin 
concentration of 43 g/l.  
As albumin levels are affected by critical illness, we adapted the Coolens Formula for individual albumin 
concentrations based on the following rationale:  N” = 
    
  
 x individual albumin conc (g/l). 
Adapted Coolens Formula  
 Free cortisol = (0.01 7 +   -T 
1
2 (1+  )
)
2
+ T * 
1
 1+   *  
-0.01 7 + ( -T)
1
2 (1+  )
     
Plasma free cortisol concentration for the other time points of the study period was calculated with use 
of the average ratio of free over total plasma cortisol concentration in the 5 samples in which CBG and 
albumin was measured. 
Plasma cytokine concentrations 
Plasma TNF-alpha and IL-6 concentrations were quantified on a single morning sample with commercial 
ELISAs (Invitrogen, Camarillo, USA). 
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Data analysis of time series 
In order to allow quantification of cortisol secretory profiles from plasma concentration time series, and 
to estimate the cortisol secretory response to any given ACTH concentration, total plasma cortisol 
concentrations were required.6,7 Plasma free cortisol concentrations were determined as this is the 
active hormone fraction that mediates cortisol effects and thus also feedback inhibition.  
ACTH and total cortisol plasma concentration time series were transformed into secretion profiles by 
using a multiple parameter deconvolution analysis implemented in Matlab (MathWorks Inc, Natick, 
USA).14 This method is designed to extract the two overlapping signals; basal (non-pulsatile) secretion 
rate and intermittent secretory bursts (number and mass) from the raw time series, based on a fixed 
half-life.  For ACTH a normal half-life was used for patients and controls.15 For cortisol, a distinct half-life 
for patients and controls was used, as recently determined.2 Mathematical coupling, or multi-parameter 
interdependence, is an important issue, and in older deconvolution methods limits parameter exactness. 
In the present model, as shown by comparison with earlier versions,6 parameter estimation is good from 
known synthetic time series, due to the selection of a limited number of variables which are conceptually 
largely independent on a biological basis. 
Dose-response estimates of ACTH-cortisol drive were calculated as recently described7 and consist of a 
six-parameter logistic function, relating time-varying ACTH concentrations to delayed glandular cortisol 
secretion rates with allowable stochastic variability due to dynamical biological parameters. Specific 
dose-response outcome parameters are: (a) efficacy (asymptotic maximal ACTH-stimulated cortisol 
secretion rate); (b) potency (defined algebraically by a negative exponential term and functionally by the 
ACTH concentration driving half-maximal cortisol secretion (EC50)); (c) adrenal sensitivity (maximal 
positive slope of the ACTH-cortisol dose-response relationship). The six-parameter model contains two 
potencies (onset and offset) and a lag time (inflection point) to accommodate allowable down-regulation 
of ACTH drive represented by a right-shifted inhibitory adaptation of the dose-response process after 
the peak response to an ACTH concentration pulse.16,17 As a consequence, in the two-potency model 
an onset EC50 and recovery or down-regulated EC50 can be calculated.  
Approximate entropy (ApEn) and cross-ApEn were calculated as previously reported.18,19 ApEn is the 
likelihood that runs of patterns that are close for a number of observations remains close on next 
incremental comparisons20 and evaluates the consistency of subpatterns in sequential measurements 
and estimates the relative contribution of confounding factors, with a larger ApEn corresponding to 
greater irregularity and thus more confounders. Additionally, cross-ApEn appraises the asynchrony 
between the patterns of two time series, which is expected to increase when additional regulators are 
present. It can be calculated in two directions, the forward cross-ApEn appraising feedforward regulation 
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from ACTH to cortisol and the reverse cross-ApEn estimating feedback regulation from cortisol to 
ACTH.18,21,22  
Statistical analyses 
It was a priori decided to study 40 critically ill patients and 8 demographically matched healthy controls, 
in order to account for a larger variability in hormonal secretion rates among patients than among 
controls. With this sample size, a difference in pulsatile cortisol secretion of 50% could be detected 
with a power of 80% and a two-tailed α-error level of 5%.  
Statistical analyses were performed with JMP (version10.0) (SAS Institute Inc., Cary, USA). Data are 
presented as means±SD or medians (IQR), as appropriate. We used the nonparametric Wilcoxon rank-
sum test for not-normally distributed data and unpaired Student‟s t-test for normally distributed data 
obtained after log-transformation where required. Comparison of proportions was done by chi-square-
testing. Associations between parameters were analyzed with linear regression analysis, after 
transformation to obtain an approximate normal distribution when required. The Pearson determination 
(R2) coefficient was calculated and its significance analyzed by Analysis of Variance. Two-sided P-
values ≤0.05 were considered statistically significant. Data were presented as box-plots where boxes 
represent medians and IQR and whiskers are 10th and 90th percentile.  
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4.4  RESULTS 
In healthy control subjects, diurnal rhythm was present for ACTH and cortisol, with higher plasma 
concentrations present in the early morning hours, while there was no diurnal rhythm detectable in 
patients (Figure 1). Plasma free and total cortisol concentrations were constantly higher in patients than 
in controls (all P<0.04) and ACTH concentrations were comparable in patients and controls until 04:50h 
after which they were lower in patients (all P<0.04) (Figure 1). In line with results from previous studies, 
morning (at 06:00h) ACTH levels were lower [12.4 pg/ml (6.6-19.2)] in patients than controls [27.5 pg/ml 
(17.0-30.6)] (P=0.002) and morning cortisol levels were higher in patients [12.97.7 µg/dl] than controls 
[9.42.1µg/dl] (P=0.01). 
Plasma CBG concentrations were constantly lower in patients (29.59.7µg/ml) than in controls 
(41.85.4 µg/ml; P<0.0001). Moreover, plasma albumin concentrations were also lower in patients 
(2.81.2g/dl) than controls (4.70.4; P<0.0001) in all samples. Consequently, calculated free cortisol 
was 8-fold higher in patients [1.6 (0.7-2.2) µg/dl] than controls [0.2 (0.1-0.3) µg/dl; P<0.0001] (Figure 1). 
86 
 
 
Figure 1 - ACTH and total and free cortisol plasma concentrations 
Plasma ACTH and total cortisol concentrations in 40 patients (dark grey) and 8 controls (light grey) are depicted in the two 
upper panels, with boxplots representing medians and interquartile ranges. Plasma ACTH concentrations were lower in 
patients than controls from 04:50h onwards. Plasma total and free cortisol concentrations (lower panel) were always higher 
in patients than controls. Free cortisol was calculated with the Coolens method after determining plasma CBG and albumin 
concentrations at 21:30h, 23:40h, 01:30h, 03:40h, and 05:30h (filled bars in lower panel). From the average ratio free 
cortisol/total cortisol, free cortisol concentrations were estimated for the other time points (dashed bars in lower panel). P-
values for group comparisons were determined by the Wilcoxon rank-sum test. For conversion of ACTH to SI units (pmol/l) 
multiply by 0.22. For conversion of cortisol to SI units (nmol/l) multiply by 27.6. 
87 
 
Deconvolution analysis of the ACTH time series revealed 31% lower pulsatile ACTH secretion in 
patients than controls (P=0.03), explained by a lower mass per ACTH burst (P=0.02) with unaltered 
ACTH pulse frequency (P=0.50), illustrated for one representative patient and one control in Figure 2.  
 
 
Figure 2 - Illustrative ACTH and cortisol profiles  
Illustrative plasma ACTH and cortisol concentration time series obtained by blood sampling every 10 min from 21:00h to 
06:00h in one patient (depicted in dark grey) and one control subject (depicted in light-grey).  Top: Measured (continuous 
curves) and model-estimated (interrupted curves) plasma concentration profiles.  Bottom: Estimated instantaneous secretion 
rates.  For conversion of ACTH to SI units (pmol/l) multiply by 0.22. For conversion of cortisol to SI units (nmol/l) multiply by 
27.6.  
Non-pulsatile secretion was similar in patients and controls (P=0.80) (Figure 3 A-D). There was no 
correlation between plasma total or free cortisol concentrations and ACTH secretion. 
Deconvolution analysis of the cortisol time series revealed 54% lower pulsatile cortisol secretion in 
critically ill patients than in controls (P=0.005), explained by a lower mass per cortisol burst (P=0.03) 
with a comparable cortisol pulse frequency (P=0.35), illustrated for one representative patient and one 
control in Figure 2. Non-pulsatile cortisol secretion was unaltered (P=0.80) (Figure 3 E-H). There was no 
correlation between cortisol secretion and plasma (total and free) cortisol concentrations. 
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Figure 3 - ACTH and cortisol deconvolution results 
Panels A and E represent pulsatile ACTH and cortisol secretion rates during the study period in patients (N=40) and in 
control subjects (N=8). Panels B and F depict the mass per ACTH and cortisol burst; panels C and G the number of ACTH 
and cortisol pulses and panels D and H the non-pulsatile ACTH and cortisol secretion rates during the study period. Boxes 
represent medians and interquartile ranges and whiskers are 10th and 90th percentile. P-values for group comparisons were 
determined by the Wilcoxon rank-sum test. For conversion of ACTH to SI units (pmol/l) multiply by 0.22. For conversion of 
cortisol to SI units (nmol/l) multiply by 27.6. 
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The plasma ACTH-concentration/cortisol-secretion dose response was similar in patients and controls  
(Table 2).  
Table 2: ACTH and Cortisol Dose Response     
  
  
  
  Patients (N= 40) Controls (N=8) P-value 
Exponential Potency Onset -7.7 (-12.6 - [-3.8]) -6.9 (-9.4 - [-3.9]) 0.69 
Exponential Potency Recovery -19.4 (-39.3 - [-10.9]) -39.7 (-40.0 - [-18.8]) 0.08 
EC50 onset 15.3 (7.7 - 25.7) 9.0 (6.8 - 16.9) 0.15 
EC50 recovery 34.1 (18.5-97.6) 44.2 (36.8-64.7) 0.40 
Sensitivity 0.51 (0.19-1.25) 0.67 (0.39-0.91) 0.76 
Efficacy (µg/dl per min) 0.75 (0.14-1.55) 0.24 (0.11-0.59) 0.11 
Inflection point (10-min intervals*) 1.0 (1.0-3.0) 2.6 (1.0-2.9) 0.60 
 
Data are expressed as median (IQR) 
*number of 10-min samples between onset and offset of the cortisol response to an ACTH pulse 
The ApEn of the ACTH plasma concentration time series was 25% higher (P=0.03) and of cortisol 92% 
higher (P<0.0001) in patients than in controls. (Figure 4 A-B) The forward cross-ApEn was 37% higher 
(P=0.001) and the reverse cross-ApEn 68% higher in patients than in controls (P=0.0001) (Figure 4 C-
D). Furthermore, the average plasma free cortisol concentration correlated positively with ACTH and 
cortisol ApEn (R²=0.11; P=0.01 and R²=0.32; P<0.0001 respectively) and with both cross-ApEns (Figure 
4 E-F). 
During critical illness, morning plasma concentrations of TNF-α and IL-6 were higher in patients [TNFα: 
26.1 pg/ml (16.0-38.1) and IL6: 78.5 pg/ml (35.1-226.0)] than in healthy controls [TNFα: 8.8 pg/ml (6.2-
11.9); P=0.0002 and IL6: 5.6 pg/ml (5.6-5.6); P<0.0001]. Both cytokine levels correlated inversely 
though weakly with pulsatile cortisol secretion (TNF-α: R²=0.09; P=0.03 and IL-6: R²=0.22; P=0.0009). 
Furthermore, plasma concentrations of both these cytokines correlated positively with cortisol ApEn 
(TNF-α: R²=0.14; P=0.007 and IL-6: R²=0.28; P<0.0001). 
All the observed differences between patients and controls applied to survivors as well as non-survivors, 
and were not explained by variation in severity of illness, illness duration at sampling or by drugs such 
as opioids, catecholamines, insulin or anticoagulant treatment (data not shown).10 
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Figure 4 - ApEn and cross-ApEn for ACTH and cortisol system regularity 
Panels A and B depict the ApEn of the ACTH and cortisol time series, with high levels indicating higher system irregularity, in 
patients (N=40) and in control subjects (N=8). Panel C depicts the cross-ApEn from ACTH to cortisol, a marker of 
feedforward regulation. Panel D depicts the cross-ApEn from cortisol to ACTH, a marker of feedback regulation. Boxes 
represent medians and interquartile ranges and whiskers are 10th and 90th percentile. P-values for group comparisons were 
determined by the Wilcoxon rank-sum test.Panel E and F depict the positive correlation between plasma free cortisol 
concentrations and the two cross-ApEn parameters in patients (dark grey) and control subjects (light grey) (black line). The 
positive correlation was maintained when analyzed among patients only (dark grey line). P-values for correlation were 
determined by Analysis of Variance. 
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4.5  DISCUSSION 
We documented that hypercortisolemia during critical illness coincided with suppressed nocturnal 
pulsatile ACTH and cortisol secretion rates, whereas the cortisol secretory response to any given 
plasma ACTH concentration was unaltered. These findings speak against the classical dogma of an 
activated HPA axis in response to critical illness and instead suggest feedback-inhibition exerted by 
circulating cortisol. The increased irregularity and asynchrony of the ACTH and cortisol time series 
further support such non-ACTH-dependent mechanisms contributing to hypercortisolism during critical 
illness that is elevated through alternative pathways. These comprise reduced plasma clearance of 
cortisol and inferentially also altered splanchnic innervation and local factors within the adrenal glands 
driving cortisol release.23  
Several studies have reported low plasma ACTH levels in the presence of elevated plasma cortisol in 
single samples of ICU patients, which has been referred to as the „paradoxical ACTH-cortisol 
dissociation‟ of critical illness.2-4 However, plasma hormone concentrations in single samples give little 
information about the dynamics of hormonal secretion. To document the dynamics of ACTH and cortisol 
secretion during critical illness, we transformed nocturnal plasma hormone profiles into deconvolution-
derived hormonal secretion profiles, which demonstrated that pulsatile ACTH and cortisol secretion are 
both suppressed during critical illness. Also in septic rats, it was recently shown that after an initial 
activation suppression of ACTH occurs, possibly mediated by reduced orexin expression in the lateral 
hypothalamus.24 In our study, suppressed pulsatile ACTH still appeared to drive the (smaller) cortisol 
pulses in critical illness. Indeed, the pulses of both ACTH and cortisol secretion were reduced in size but 
not in number, and the ACTH-cortisol dose-response relationships were maintained as during health.  
Suppressed rather than increased nocturnal pulsatile ACTH and cortisol secretion during critical illness 
is surprising in relation to the classical understanding of the HPA axis stress response. It is generally 
assumed that critical illness, considered to be a condition of severe physical stress, results in several 
fold-increased cortisol production, an assumption that explains why doses of hydrocortisone given to 
substitute a failing adrenal gland during critical illness are more than 6-times higher (+/-200mg/day) than 
substitution doses for healthy subjects (+/-30mg/day).25,26 We previously reported that the rate of 
appearance of cortisol, calculated with a stable isotope tracer infused during daytime, was only 1.8-fold 
higher in critically ill patients than in healthy matched controls, in the presence of low morning plasma 
ACTH values.2 The current observation that overnight pulsatile cortisol secretion, calculated by 
deconvolution analysis, is not elevated at all during critical illness, and was actually lower than in healthy 
matched subjects, is likely explained by the loss of diurnal rhythm during critical illness. The nocturnal 
profiles indeed captured the early morning rise of ACTH and cortisol secretion in healthy subjects, which 
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was clearly absent in patients. Ideally, 24h profiles should be constructed in order to quantify the 24h 
differences between patients and controls. This, however, represents a major challenge in the ICU 
without disturbing the diagnostic and therapeutic activities that are required for the daytime care of these 
patients. However, the nocturnal cortisol secretion documented in this study was only half that of healthy 
controls. Furthermore, we previously showed that and as the cortisol production rate during the day, 
documented with isotopes, was not even a doubling of that of healthy subjects.2 All together, it can be 
estimated that 24h cortisol production rates during critical illness may not be, or at best only moderately, 
increased.  
The co-occurrence of elevated plasma total and free cortisol concentrations with suppressed ACTH and 
cortisol secretion rates implies that alternative regulators of cortisol dynamics must be involved during 
critical illness. This is corroborated by the lack of relation between plasma total and free cortisol levels 
and cortisol secretion, while (free) cortisol levels did correlate positively with the increased irregularity 
and asynchrony, as shown by increased ApEn and cross-ApEn values. Increasing evidence supports 
the existence of non-ACTH mediated regulation of cortisol production which involves cortico-medullary 
interactions, the neural input, the immune system, the vascular supply, growth factors and the 
intraglandular renin-angiotensin and CRH-ACTH systems.27 This is further supported by the discovery of 
ectopic expression of membrane hormone receptors, which are functionally coupled to steroidogenesis 
by mimicking the cellular events triggered by ACTH receptor activation.28 
Identifying the role of such non-ACTH dependent mechanisms in critical illness remains a challenge. 
Pro-inflammatory cytokines have been shown to drive cortisol secretion independently of ACTH and are 
known to be increased in critical illness.29-31 In the current study the correlation between the elevated 
cytokine levels with the measures of irregularity and asynchrony might suggest such a role for 
cytokines, although the studied cytokines were found to correlate inversely, not positively, with cortisol 
secretion. A previous study also showed that injection of LPS reduces entropy measures, rendering a 
major role of circulating cytokines less likely.32 Since cytokines are also produced locally within the 
adrenal gland by immune cells and adrenocortical cells, circulating levels alone may not account for the 
residual cortisol production. Next, the impact of sympatho-adrenomedullary system on the adrenal 
cortex was established in animal models showing that splanchnic innervation may directly drive cortisol 
secretion and stimulate the adrenal ACTH-sensitivity.33,34 Critical illness is hallmarked by an increased 
sympathetic tone.35 However, we observed that the adrenocortical sensitivity to ACTH was unaltered 
during critical illness. Also, exogenous catecholamines did not affect cortisol secretion rendering a major 
role of catecholamines less likely. However, adrenal nerves are catecholaminergic and peptidergic and 
these store, besides catecholamines, a wide variety of neuropeptides, including opioid peptides, 
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neuropeptide Y, vasoactive intestinal polypeptide, CRH and substance P.27 The role of locally active 
neuropeptides during critical illness should be further investigated.23 In addition, cortisol sensitive and 
insensitive neural pathways could play a role.36-38 Finally, the adrenal medulla and intra-adrenal immune 
cells are a source of extrahypothalamic CRH and extrapituitary ACTH, which could also account for the 
residual cortisol production without an increase in circulating ACTH levels. However, a stimulatory effect 
on cortisol secretion of such local factors was not supported by the presented data as nocturnal cortisol 
secretion was lower, not higher in patients than in healthy controls.  
The current observations of a reduced pulsatile ACTH secretion and a reduced pulsatile cortisol 
secretion, in the presence of elevated plasma levels of cortisol could be a consequence of the 
substantially suppressed metabolic clearance of cortisol during critical illness.2 Elevating circulating 
cortisol by reduced breakdown may cause a tonic negative feedback inhibition on ACTH secretion. Such 
a mechanism would predominantly affect ACTH pulsatility via reducing the mass per ACTH pulse,39-41 
as observed here, in turn leading to suppressed pulsatile cortisol secretion.  
The loss of pulsatility in the ACTH and cortisol secretory profiles observed during critical illness may 
have important implications. Indeed, the pulsatile nature of cortisol secretion prevents desensitization of 
transcriptional responses in target tissues and the pulsatile nature of ACTH release provides more 
effective signaling for the activation of the adrenal cortex than a constant ACTH stimulus.42-44 However, 
it is unknown whether it is the ACTH pulse amplitude or the pulse frequency that determines 
adrenocortical responsiveness. As ACTH pulse frequency during critical illness was unaltered, and the 
amplitude of the ACTH pulses was not completely lost, it is unclear whether the latter suffices to 
maintain adrenal cortex integrity/functionality or could contribute to adrenal atrophy in the prolonged 
phase of critical illness. Likewise, one could speculate that the loss of pulsatility in the cortisol secretory 
profiles may play a role in the tissue-specific cortisol resistance observed during critical illness.45,46 This 
requires further investigation.  
The previous studies on the relationship between ACTH and cortisol during critical illness have reported 
only single sample measurements, which precluded conclusions on the dynamics of the secretory 
profiles and the coupling between the two hormones. A strength of our study is that it used time series 
of sampling every 10 minutes for 9 hours, previously found to allow accurate analysis of such 
dynamics.11 Interestingly, we found that the low values for ACTH in the morning blood samples were 
quite representative for the suppressed pulsatile ACTH secretion. The presented study also has some 
limitations. First, the study was performed overnight only, which precludes robust conclusions about the 
24h secretory profiles, as elaborated on above. Second, although a normal night atmosphere was 
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pursued, healthy controls may have experienced a certain stress level because of the arterial line, the 
ICU context, and a disrupted sleep pattern evoked by frequent blood sampling.  
In conclusion, nocturnal pulsatile secretion of ACTH and cortisol was found to be jointly suppressed 
during critical illness with a normal ACTH-cortisol dose response. The increased irregularity and 
asynchrony of the ACTH and cortisol time series further support non ACTH-dependent mechanisms 
driving hypercortisolism during critical illness.   
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5.1 ABSTRACT  
Background: Adrenal insufficiency is considered to be prevalent among critically ill patients, although 
the pathophysiology, diagnostic criteria and optimal therapeutic strategy remain controversial. During 
critical illness, reduced cortisol breakdown contributes substantially to elevated plasma cortisol and low 
plasma ACTH concentrations. Considering the trophic impact of ACTH on the adrenal cortex, we 
hypothesized that with longer duration of critical illness, subnormal ACTH adrenocortical stimulation 
may occur, which may predispose to adrenal insufficiency.  
Methods: Adrenal glands were harvested ≤24h of death from 13 patients who died after a long ICU-
stay [median 16 IQR (13-21) days], from 27 patients who died after a short ICU-stay [2 (1-5) days] and 
from 13 control subjects who died suddenly out-of-hospital. Prior glucocorticoid treatment was excluded. 
Microscopic adrenocortical zonational structure was evaluated by H&E staining. The amount of adrenal 
cholesterol-esters was determined by Oil-Red-O staining and mRNA expression of ACTH-regulated 
steroidogenic enzymes was quantified after mRNA quality control.  
Results: The adrenocortical zonational structure assessed by H&E staining was disturbed in patients as 
compared with controls (P<0.0001), with indistinguishable adrenocortical zones only present in long 
ICU-stay patients (P=0.003 vs. controls). Adrenal glands from long ICU-stay patients, but not those of 
short ICU-stay patients, contained 21% less protein (P=0.03) and 9% more fluid (P=0.01) than those 
from controls, while they tended to weigh less for a comparable adrenal surface area.  There was 78% 
less Oil-Red-O staining in long ICU-stay patients than in controls (P=0.03) and also 78% less than in 
short-stay patients (P=0.03), the latter similar to controls (P=0.31). The mRNA expression of MC2R, 
SCARB1, HMGCR, STAR and CYP11A1 was at least 58% lower in long ICU-stay patients than in 
controls (all P≤0.03), and of MC2R, SCARB1, STAR and CYP11A1 at least 53% lower than in short 
ICU-stay patients (all P≤0.04), whereas gene expression in short-stay patients was similar to controls.  
Conclusions: Depletion of adrenocortical cholesterol esters and reduced expression of ACTH-
regulated steroidogenic genes in prolonged, but not acute, critical illness suggest that sustained lack of 
ACTH-effect may contribute to risk of adrenal insufficiency in long-stay ICU patients.  
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5.2 INTRODUCTION  
Critical illness, an example of severe physical stress, is hallmarked by increased circulating levels of the 
stress hormone cortisol. We have shown that, in contrast to previous understanding, these high levels 
are to a large extent explained by reduced cortisol breakdown, while cortisol production is only 
moderately increased, if at all.1  Furthermore, plasma ACTH was shown to be low throughout at least 
the first week of critical illness,1 possibly explained by negative feedback inhibition. Whereas reduced 
cortisol breakdown could be interpreted as a beneficial adaptation of the body to maintain 
hypercortisolemia in an “economic” way -- limiting the need for energy-consuming cortisol production in 
times of low energy availability -- sustained low ACTH levels could negatively affect structure and 
function of the adrenal cortex. Indeed, ACTH exerts important trophic and structural effects on the 
adrenal cortex2 and depletion of ACTH in experimental models causes adrenal atrophy.3 Furthermore, 
ACTH is responsible for both short- and long-term regulation of steroidogenesis.4   
Cortisol cannot be stored in the adrenal gland, so its availability depends on rapid synthesis within the 
adrenal gland in case of stress. Cortisol is synthesized from cholesterol in the zona fasciculata of the 
adrenal cortex. The principal source of cholesterol for the adrenal glands is circulating low-density 
lipoprotein (LDL) cholesterol and to a lesser extent high-density lipoprotein (HDL) cholesterol, which is 
taken up via the LDL-receptor (LDLR) and the HDL-receptor [scavenger-receptor class B, member 1 
(SCARB1)] respectively. Twenty percent of the cholesterol required for adrenal cortisol synthesis is 
newly produced within the adrenal cortex via 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).5 The 
cholesterol molecules are stored as cholesterol esters in intracellular vesicles, where they reside until 
steroidogenesis starts. Whenever more cortisol is needed, a cholesterol esterase rapidly mobilizes 
cholesterol out of the lipid droplets to the cytoplasm, from where it is transported to the inner membrane 
of the mitochondria (IMM).5,6 This transport is mediated by the steroidogenic acute regulatory protein 
(STAR).7,8 Within the IMM, cytochrome P450 cholesterol side-chain cleavage enzyme (CYP11A1) 
catalyzes the conversion of cholesterol to pregnenolone, which is the rate-limiting step in 
steroidogenesis. Afterwards, multiple enzymes regulate the further conversion of pregnenolone to 
cortisol.7  
Within minutes after onset of stress, ACTH acutely activates its receptor, the melanocortin 2 receptor 
(MC2R), on the adrenal cortex which causes the release of cholesterol from the lipid droplets and 
increases STAR expression.4 The more long-term impact of ACTH on the adrenal cortex involves 
increased transcription and translation of genes encoding proteins for cholesterol uptake (SCARB1, 
LDLR), for cholesterol synthesis (HMGCR) and for steroidogenesis (STAR and CYP11A1)] as such 
enhancing the synthetic capacity of the cells by providing a reserve pool for acute steroid 
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demand.4,5,7,9,10 In addition, ACTH has a direct stimulatory effect on the expression of its own receptor 
(MC2R) which amplifies the adrenal responsiveness to ACTH.11 Considering the extensive acute and 
chronic impact of ACTH on the adrenal cortex, persistently low ACTH concentrations profoundly affect 
the structure and function of the adrenal cortex. This is illustrated by the phenotype of pro-
opiomelanocortin (POMC)-deficient mice, characterized by loss of adrenocortical zonational structure, 
adrenocortical lipid depletion, reduced ACTH signaling and adrenal atrophy.3,12 
We hypothesized that low plasma ACTH concentrations during prolonged critical illness are associated 
with reduced trophic ACTH effects on the adrenal cortex, reflected by less lipid droplets and reduced 
expression of ACTH-regulated enzymes. Such effects could predispose to symptomatic adrenal failure 
in the prolonged phase of critical illness.13 To test this hypothesis, we studied adrenal glands, harvested 
postmortem, from patients who died in the ICU after a short or a prolonged critical illness and compared 
these with adrenal glands from individuals who died acutely out-of hospital. We quantified alterations in 
size, weight and microscopic structure of the adrenal glands, the adrenocortical storage of cholesterol-
esters and mRNA expression of different key ACTH-regulated proteins of the steroidogenic pathway.  
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5.3 MATERIALS & METHODS 
Patients and study samples 
From patients who died in the ICU and for whom an autopsy was requested by the attending physician, 
adrenal glands were harvested for this study. Patients who were on chronic glucocorticoid treatment 
during the preceding 3 months or who had received acute glucocorticoid treatment within 7 days prior to 
the day of death were excluded.  For comparison, adrenal glands were harvested at the occasion of a 
planned autopsy from individuals who suddenly died out-of-hospital, further referred to as “control 
subjects”, in collaboration with the emergency and forensic departments of the Leuven University 
Hospital. Control subjects who were known to suffer from chronic illnesses or were treated with 
glucocorticoids were excluded.  All adrenal glands were harvested within 24h of death. 
The Leuven University Hospital permits postmortem tissue sampling for academic purposes whenever a 
patient or his/her legal representative consented upon hospital admission. This is performed via a 
hospital-wide information and consent procedure, requiring active opting-out when not consenting, with 
opting-out remaining possible until time of death. The study protocol was approved by the Institutional 
Ethical Review Board of the KU Leuven (ML6625). The study was registered at International Standard 
Randomized Controlled Trial Number Register (Number ISRCTN49306926).  
We wanted to investigate the impact of duration of critical illness. To this end, control subjects who died 
suddenly out-of-hospital were compared with patients who died after a long ICU-stay (>7days) and with 
patients who died after a short ICU-stay (≤7 days). The sample size was determined by the a priori 
calculated need of at least 13 patients in each group, in order to detect a difference in lipid staining of 
about 50% in long ICU-stay patients, with a power of 80% and certainty of 95%.  Harvesting continued 
until this minimal number was reached and all patients who did not have any exclusion criteria and from 
whom adrenal glands were harvested within 24 hours after death were kept in the study. 
Processing of adrenal glands 
Immediately after harvesting, adrenal glands were processed for the different analyses. After cleaning 
from adherent fat, adrenal glands were weighed and photographed to estimate surface area with  
Image J 1.44p software (Wayne Rasband). Adrenal tissue intended for paraffin embedding was 
immediately placed in 6% paraformaldehyde. Adrenal tissue intended for cryostat sectioning were snap-
frozen in liquid nitrogen cooled isopentane, while tissue intended for gene expression was immediately 
snap-frozen in liquid nitrogen and stored at -80°C until the time of analysis. All the analyses were 
performed on the left adrenal gland of each patient.  
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To quantify water content, approximately 50mg of adrenal gland tissue was weighed before and after 
20h of lyophilisation (SpeedVac Concentrator, Thermo scientific). The difference in weight divided by 
the start weight represented the water fraction of the tissue. To determine the total protein content, 
adrenal samples (approximately 100mg) were weighed and homogenized in 4x NP40-glycerol lysis 
buffer with phosphatase and protease inhibitors, using ceramic beads and a Precellys 24 homogenizer 
(6000 rpm, 45 sec, Bertin Technologies, Villeurbanne, France). Protein content was quantified using 
Coomassie Protein Assay Reagent (Pierce Biotechnology Inc., Rockford, USA).  
Microscopic analysis of the adrenocortical zonational structure  
After embedding in paraffin, 5 µm-thick sections were stained with hematoxylin and eosin (HE). To 
evaluate adrenocortical zonational structure, HE-sections were scored semi-quantitatively based on the 
identification of the three zones in the adrenal cortex at a 5 x magnification using a Leica DM3000 
microscope. Two investigators, blinded for group allocation, evaluated all sections separately and any 
discrepancy between them was resolved by consensus. Adrenocortical zonational structure was graded 
as follows: „0‟ when the three adrenocortical zones were clearly distinguishable, „1‟ for those with a 
moderately distorted zonational structure and „2‟ when the different zones were no longer 
distinguishable.  
Quantification of cholesterol-ester storage in the adrenal glands 
To quantify cholesterol-esters stored in the adrenal gland, Oil red O (ORO) staining was performed on 
10µm-thick frozen tissue sections. ORO is a red dye used for staining neutral lipids and therefore stains 
the cholesterol esters in the lipid droplets of the adrenal cortex. Sections were dried at room 
temperature, fixed in propylene glycol and stained overnight in 0.5% ORO (Sigma Aldrich, St.Louis, 
USA) in propylene glycol and counterstained with hematoxylin.  
Digital microscopic images of the ORO stainings were analyzed for the amount of redness per surface 
unit and the intensity of this redness with an in house developed computer algorithm from a plug-in for 
ImageJ 1.44p (Wayne Rasband). In short, the stained areas were quantified by training a classification 
algorithm to detect staining in the brightness and color saturation channels of the digitized images. This 
allows the differently stained areas to be extracted from the overall image, after which their respective 
surface areas can be calculated by the number of image pixels present in them. As a pre-processing 
step, image artifacts such as dust spots or staining drops were removed manually. For the intensity of 
the red-staining, the maximal and minimal redness (interpreted as pixel saturation) was determined for 
each individual image and labeled respectively 1 and 0. Every pixel was evaluated against this scale. 
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The mean of all values for all pixels represented the intensity of the staining. The product of the intensity 
and amount of redness per tissue surface was considered to represent the total amount of available 
cholesterol esters.  
mRNA expression of ACTH-regulated key proteins of the steroidogenic pathway 
Total mRNA was extracted from adrenal gland tissue (approximately. 30mg) using Qiazol lysis reagent 
(Qiagen, Hilden, Germany) and subsequently purified with RNAeasy Mini columns (Qiagen). Samples 
were treated with DNase to remove all genomic DNA, and 1µg total mRNA was reverse-transcribed 
using random hexamers. cDNA levels of genes regulated by ACTH signaling [for cholesterol uptake and 
synthesis (SCARB1, LDLR and HMGCR) and crucial genes for steroidogenesis (MC2R, STAR and 
CYP11A1)] were quantified in real time with the TaqMan gene expression assays using the 
StepOnePlus System (Applied Biosystems, Carlsbad, USA) (Hs00196245_m1, 4310884E, 
Hs02758991_g1, Hs03928985_g1, Hs00167984_m1, Hs00986559_g1, Hs00300820_s1, 
Hs00969821_m1, Hs00181192_m1, Hs00168352_m1). Individual samples with a copy number 
coefficient of variation greater than 20% were reanalyzed. Data were expressed relative to expression 
18S ribosomal 5 RNA (RNA18S5), a housekeeping gene of which the expression was not altered 
neither by critical illness nor by the duration of illness, and as a fold difference from the mean of the 
control subjects.  
To exclude confounding effects of RNA degradation that may have occurred during the postmortem 
period, mRNA expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was evaluated with 
two different primer sets designed to amplify fragments at two distinct exons, (exon 6-7 and exon 3). To 
evaluate the relative proportion of the adrenal gland medulla in the tissue samples, cDNA levels for 
neurofilament light-polypeptide (NEFL), a marker for neuronal elements, were also quantified.  
Statistical analyses 
Statistical analyses were performed with JMP (version10.0) (SAS Institute Inc., Cary, USA). Data are 
presented as means±SD or medians with IQR, as appropriate. All experimental results were analyzed 
with a nonparametric Wilcoxon singed rank test. Comparison of proportions was done by chi-square-
testing. Associations between parameters were analyzed with linear regression. The Pearson 
determination (R2) coefficient was calculated and its significance analyzed by Analysis of Variance. No 
corrections were made for multiple comparisons. The a priori defined primary comparison was that 
between long ICU-stay patients and control subjects, as this is where the hypothesized differences were 
expected.  Two-sided P-values <0.05 were considered statistically significant.  
107 
 
5.4 RESULTS 
The study comprised adrenal glands harvested from 13 long-stay ICU patients, 27 short ICU-stay 
patients and 13 control subjects. The characteristics of patients and control subjects are described in 
Table 1.14,15 
Weight, size and microscopic zonational structure of the adrenal glands 
The weight of the adrenal glands, corrected for body weight, was not different among the groups 
[median 0.10 IQR (0.07-0.12) g/kg in the control subjects, 0.10 (0.08-0.12) g/kg in the short ICU-stay 
patients and 0.08 (0.06-0.10) g/kg in the long ICU-stay patients (all Ps>0.08)]. Also the adrenal surface 
area was similar for all groups [10.2 (8.8-12.2) cm² in control subjects, 11.2 (9.1-13.7) cm² in the short 
ICU-stay patients and 11.1 (9.3-16.5) cm² in the long ICU-stay patients (all Ps>0.25)].  
The fraction water in adrenal glands from long ICU-stay patients [76% (IQR 72-78)] was larger than in 
those from control subjects [69% (62-74); P=0.01], while no difference was observed between short 
ICU-stay patients [72% (IQR 67-76)] and controls (P=0.22) or between the 2 ICU patient groups 
(P=0.08). There was 21% less protein per milligram tissue in adrenal glands from long ICU-stay patients 
[74µg/mg (IQR 67-78)] than in those from control subjects [94µg/mg (IQR 71-101), P=0.03]; and also 
23% less protein in short ICU-stay patients [72µg/mg (IQR 66-83)] than in control subjects (P=0.02). 
Adrenal protein content in both ICU patient groups was similar (P=0.89).  
Microscopic semi-quantitative scoring revealed disturbed adrenocortical zonational structure in both ICU 
patient groups as compared with control subjects (P<0.0001) (Figure 1). As compared with control 
subjects, indistinguishable zonational structure was significantly more often present only in the long 
ICU-stay patients (P=0.003).   
Quantification of adrenal cholesterol-ester storage 
Computerized quantification of the ORO staining revealed that in adrenal glands from long ICU-stay 
patients, there were 78% less cholesterol esters stored than in those from controls (P=0.03) and also 
78% less than in those from short ICU-stay patients (P=0.03), while short ICU-stay patients were not 
different from controls. (Figure 2) 
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Table 1: Characteristics of ICU patients and control subjects         
       
  
Controls 
(N=13) 
Short ICU- 
stay patients 
(N=27) 
Long ICU-
stay patients 
(N=13) 
P-value Controls 
versus short ICU-
stay patients 
P-value Controls 
versus long ICU-
stay patients 
P-value short 
versus long ICU-
stay patients 
Demography and anthropometry       
     Gender (no. male (%)) 9 (69) 14 (52) 9 (69) 0.29 1.0 0.29 
     Age (yr) (mean ± SD) 40.8 ± 17.5 69.7±12.6 67.6±14.1 <0.0001 0.0017 0.62 
     BMI (kg/m2) (mean ± SD) 24.9 ± 4.8 26.0 ± 5.5 25.8 ± 3.9 0.34 0.40 0.86 
Admission Characteristics       
     Diagnostic group on admission (no. (%)) N.A.         0.92 
       Cardiovascular  7 (26) 3 (23)    
       Respiratory/Esophageal-lung surgery   10 (37) 4 (31)       
       Abdominal/Gastro-intestinal/Hepatic  6 (22) 3 (23)    
       Other   4 (15) 3 (23)       
     APACHE II (mean±SD)  N.A. 34.6± 9.9 34.8± 6.0   0.70 
     SIRS (no. (%))  N.A. 27 (100) 12 (92)     0.14 
     Sepsis (no. (%)) N.A. 18 (67) 11 (85)   0.23 
Patient characteristics at study time             
     Cause of death       
         Refractory Shock N.A. 12 (44) 0 (0)     0.004 
         Therapy withdrawal for futility N.A. 15 (56) 13 (100)    
         Sudden out of hospital death* 13 (100) N.A. N.A.       
     SIRS (no. (%))  N.A. 26 (96) 12 (92)   0.58 
     Sepsis (no. (%)) N.A. 16 (59) 11 (85)     0.10 
     Duration of stay in ICU prior to death (days)  N.A. 2 (1-5) 16 (13-21)   <0.0001 
     (median (IQR))       
     Time interval between death and autopsy (h)   17.5 ± 4.5 15.0±6.8 15.4±4.8 0.28 0.31 0.79 
     (mean ± SD)             
The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Acute Physiology and Chronic Health Evaluation II (APACHE II) ranges from 0 to 71, with 
higher scores indicating a greater severity of illness.14 SIRS stands for Systemic Inflammatory Response Syndrome and is determined by the BONE criteria.15 *Sudden out-of-hospital deaths 
comprised: Trauma (N=2), Cardiac Arrest (N=4), Drowning (N=2), Electrocution (N=1), Gun Shot (N=1), Acute Hemorrhage (N=1), Pulmonary Embolism (N=1), Sudden unexpected death of 
epilepsy (N=1). 
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Figure 1: Semi-quantitative scoring of the loss of adrenocortical zonational structure 
Panel A: The fraction of patients with score 0, indicating a normal zonational structure, is depicted in white. The fraction of 
patients with score 1, indicating a moderately distorted zonational structure, is depicted in light grey.  The fraction of patients 
with score 2, indicating that the different zones were no longer distinguishable, is depicted in dark grey.  
Panel B: The illustrations are representative examples of HE staining images for each group. Photographs were taken at a 
5X magnification. 
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Figure 2: Quantification of the total amount of cholesterol esters in the adrenal glands 
Panel A: The total amount of cholesterol esters was calculated by the product of ORO staining intensity and area. Boxes 
represent medians and interquartile ranges and whiskers represent 1stquartile-1.5*IQR and 3rdquartile+1.5*IQR. P-values for 
group comparisons were determined by the Wilcoxon rank-sum test.   
Panel B: The illustrations are representative examples of ORO staining images for each group. Photographs were taken at a 
1.25 X magnification. 
mRNA expression of ACTH-regulated proteins of the steroidogenic pathway 
To assess any confounding effect of post-mortem loss of mRNA quality, the degree of mRNA 
degradation was investigated. For this purpose, GAPDH mRNA expression was measured with 2 
primers directed towards a different exon. There was a tight correlation between the expression using 
both primers (R²=0.94; P<0.0001) suggesting that RNA degradation was limited. mRNA expression of 
NEFL was similar in long ICU-stay patients [0.13 (IQR 0.06-0.77)], in short ICU-stay patients [0.13 (IQR 
0.04-1.15)] and in control subjects [0.24 (IQR 0.04-1.70)] (all Ps>0.80), indicating that tissue samples of 
all study groups contained comparable amounts of adrenal medulla. The amounts of mRNA encoding 
for MC2R, SCARB1,HMGCR, STAR, and CYP11A1 were at least 58% lower in long ICU-stay patients 
than in control subjects (all Ps<0.03) (Figure 3). Also compared with short ICU-stay patients, mRNA 
expression of MC2R, SCARB1, CYP11A1 and STAR was at least 53% lower in long ICU-stay patients 
(all Ps<0.04). No differences were observed between short ICU-stay patients and control subjects. 
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Figure 3: mRNA expression of ACTH-regulated proteins of the steroidogenic pathway 
The mRNA data are expressed, normalized to RNA18S, as a fold difference from the mean of the controls. Boxes represent 
medians and interquartile ranges and whiskers represent 1stquartile-1.5*IQR and 3rdquartile+1.5*IQR.  P-values for group 
comparisons were determined by the Wilcoxon rank-sum test.  
112 
 
5.5 DISCUSSION 
The results of this human postmortem study suggest that important alterations occur in the adrenal 
gland during the course of critical illness. In long ICU-stay patients, but not in the short stayers, severe 
cholesterol-ester depletion and substantially reduced mRNA expression of ACTH regulated key-
enzymes for steroidogenesis were observed.  These observations suggest that with extended duration 
of critical illness, a significant loss of ACTH signaling in the adrenal cortex may have important 
functional consequences.  
The loss of adrenocortical zonational structure already in the acute phase of critical illness confirmed the 
results of previous studies performed in small groups of septic patients.16,17 Although postmortem 
changes could have played a role, these should then apply to both acute out-of-hospital deaths and to 
patients who died in the ICU, which was not the case in our study. Furthermore, severe abnormalities 
were more present in the long ICU-stay patients only.  Another interesting observation was that the 
adrenal glands of long ICU-stay patients tended to weigh less, not more, than those of short ICU-stay 
patients, while the adrenal glands contained somewhat more water and less protein.  This is not what 
one would expect when the adrenal gland would receive prolonged ACTH stimulation in sustained 
critical illness, which would cause adrenal hypertrophy and hyperplasia.18 A prospective study by Jung 
et al. 19 indeed evaluated in vivo adrenal gland volume with computer tomography measurements in 
septic and non-septic critically ill patients and found increased adrenal gland volume. However, 
increased blood flow or edema could not be excluded. In post-mortem samples, swollen adrenal glands 
due to increased blood flow are no longer present which could already explain the differences in 
observations. Moreover, we only evaluate the sickest patients (those who did not survive); which were 
the ones with the lowest increase in adrenal gland volume in the study by Jung et al. Polito et al. 17 also 
evaluated post-mortem macroscopic changes in septic critically ill patients and also observed increased 
adrenal weight. However, they only evaluated 7 patients, which weakens the generalizability of these 
conclusions. Hence, as smaller adrenal glands and loss of zonational structure are also observed in 
POMC-deficient mice,3 ACTH deprivation with time in ICU could have played a role. Low plasma ACTH 
concentrations have been repeatedly reported during critical illness1,20,21 and we recently showed that 
nocturnal ACTH secretion rate was suppressed in ICU patients.22 Such ACTH suppression could in part 
be due to feedback inhibition exerted by elevated cortisol levels brought about by reduced cortisol 
breakdown.1 This situation is comparable with sustained exogenous administration of hydrocortisone, 
which is known to suppress ACTH and with time can cause adrenal atrophy.23 
Severe depletion of cholesterol esters was only observed in the adrenal glands harvested from long 
ICU-stay patients and not in those from the short stayers. Since normal adrenocortical synthesis and 
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release of cortisol relies predominantly on the availability of cholesterol stored in the adrenal cortex, the 
observed lipid depletion may theoretically contribute to the inability of long ICU-stay patients to acutely 
release enough cortisol in response to a second hit.13 Also, the gene expression of one of the 
cholesterol uptake receptors, SCARB1, as well as of HMGCR, the enzyme responsible for de novo 
cholesterol production, was not increased at all and was significantly down-regulated in the adrenal 
glands of the long ICU-stay patients only. Furthermore, the expression of genes encoding for the ACTH 
receptor (MC2R) and the steroidogenic proteins (STAR, CYP11A1) showed a comparable expression 
profile, with reduced expression levels in long ICU-stay patients only. Given that ACTH stimulates the 
expression of these genes, sustained ACTH deprivation could explain these findings.4,5,7,9,10 Indeed, the 
presentation is again highly reminiscent of the alterations observed in POMC-deficient mice.12 
Our observation that mRNA expression of the different key genes in steroidogenesis was not 
upregulated in critically ill patients, does not support a role for ACTH or ACTH-independent stimulators 
of cortisol synthesis such as neuropeptides, endothelin and cytokines,2 as all would require an activation 
of the steroidogenic genes.24  It actually further supports our previous finding that high plasma cortisol in 
critically ill patients is to a large extent due to reduced cortisol breakdown.1, 22 Unfortunately, given the 
nature of the study, blood samples were not available to correlate the adrenocortical pathology and 
gene expression findings with plasma ACTH and cortisol concentrations. It appears that especially 
ACTH pulsatility is critical for adequate transcriptional activation of steroidogenic genes.25 We recently 
showed, by serial blood sampling and deconvolution analysis, that it is specifically the pulsatile 
nocturnal ACTH release that is suppressed during critical illness, with reduced ACTH pulse mass in the 
presence of unaltered ACTH pulse frequency.22 Possibly, in the acute phase of critical illness the 
pulsatile ACTH signal is still sufficient to prevent downregulation of ACTH responsive genes in the 
adrenal cortex. However, when increased feedback-inhibition exerted by high cortisol levels is 
maintained into the prolonged phase of critical illness, and as a consequence pulsatile ACTH is 
suppressed for a longer time, this might reach a critical threshold below which steroidogenic 
transcription becomes impaired.  
The presented study has several limitations and some strengths. First, inevitably for a human study on 
this topic, the adrenal glands were harvested at the occasion of autopsy, and although this was 
performed within 24 hours after death, postmortem artifacts cannot be fully excluded. However, as the 
corpses were kept cooled until harvesting of the adrenal glands, this problem may have been limited, 
supported by the mRNA quality analysis that revealed minimal mRNA degradation.  Furthermore, not all 
studied genes were downregulated in the prolonged phase of illness, since LDLR, NEFL and RNA18S5 
were unaltered, which speaks against postmortem artifacts explaining the between group differences. 
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Cholesterol depletion could also theoretically be exacerbated by acute consumption of available 
cholesterol droplets in the agonal phase of illness.26,27 However, this would again apply to all ICU 
patients and to the sudden out-of-hospital deaths alike. Also, adrenocortical lipid depletion was 
previously observed in an animal model of sepsis-induced critical illness, a model that does not suffer 
from the above mentioned methodological issues that are inevitable in human studies.28 Second, acute 
out-of-hospital deaths used as control subjects were matched for BMI and gender but turned out to be 
younger than the ICU patients. However, research by Hornsby et al. revealed no impact of age on the 
zona fasciculata.29 Third, the lack of blood samples did not allow assessing the association between the 
observed changes in the adrenal glands and the circulating levels of ACTH and cortisol. Hence, in vivo 
animal studies are required to further study the influence of duration of critical illness, and hereby the 
duration of ACTH deprivation, on adrenocortical morphology and function during critical illness. 
However, despite these limitations, the strength of this study was that no signs of increased 
steroidogenesis could be found in the adrenal glands of a large and heterogeneous population of 
patients, being treated for a variety of illnesses in ICU, with or without sepsis.  This observation further 
corroborated our previous findings in vivo indicating that other mechanisms than ACTH drive elevated 
plasma cortisol concentrations during sustained critical illness.1,22 Also, this is the first study to 
investigate the impact of critical illness on the adrenal gland at the tissue level in such a large 
population. Most previous studies only investigated the adrenal gland indirectly, via the cortisol 
response to ACTH injection,30 a test that remains highly debated as to what it reveals about adrenal 
functional reserve.31,32 
In conclusion, the changes observed in adrenal glands harvested within 24h after death from long-stay 
and short-stay ICU patients and from sudden out-of-hospital control deaths suggest that extended 
duration of critical illness profoundly affects adrenocortical structure and function which could be related 
to ACTH deprivation. Depletion of cholesterol esters and reduced expression of ACTH-regulated genes 
involved in steroidogenesis may contribute to the risk of adrenal insufficiency in the prolonged phase of 
critical illness.  
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Despite the general agreement that an adequate HPA-axis function is essential for survival from critical 
illness, understanding of the pathophysiology of adrenal failure during critical illness is currently 
incomplete. This precludes further optimization of diagnosis and treatment of this condition which is 
prevalent among ICU patients.  This PhD project has attempted to further clarify the alterations within 
the HPA-axis as they occur during critical illness, to identify underlying mechanisms of the so-called 
“ACTH-cortisol dissociation”, and to unravel the pathophysiology of adrenal insufficiency in ICU patients.  
The classical concept of the HPA stress-response postulates that the elevated plasma cortisol 
concentrations present during critical illness are primarily, if not exclusively, brought about by a several-
fold increased adrenocortical production of cortisol, driven by elevated ACTH and CRH release. (Figure 
1)  However, published data on plasma ACTH concentrations in critically ill patients are scarce. Vermes 
et al. reported an immediate increase followed by a steep fall in plasma ACTH concentrations after 3 
days of critical illness.1 Interestingly, a small study by Polito et al. reported reduced ACTH mRNA levels 
in 9 human pituitary glands harvested postmortem from patients who died after septic shock as 
compared with patients who died suddenly from other diseases.2  This reduced ACTH expression 
occurred in the absence of a compensatory rise in expression of CRH or vasopressin in the 
hypothalamus.   
We observed in a more heterogeneous critically ill patient population that plasma ACTH concentrations 
are lower than normal already from ICU admission onward and stay below the lower limit of normality 
throughout the first week of critical illness.(Chapter 3) This apparent inconsistency in published results 
may be explained by differences in severity of illness and/or by the type of patients that were 
included/excluded for the study. Moreover, the specificity of the ACTH assays that were used in the 
different studies may have differed. Indeed, the ACTH concentrations Vermes et al observed were 
extraordinarily high as compared with other values in the literature, the latter more in the range of the 
ones we observed in our studies.3,4 Whether the expected initial ACTH rise in response to stress was 
missed in our studies and had already occurred before ICU admission, for example in the operating 
room or emergency department, remains unknown and needs to be further explored. Indeed, other 
studies performed during and immediately after elective surgery have reported that ACTH is increased 
during and immediately after surgery, while plasma ACTH concentrations were already normal within 
the first postoperative day.5,6 Patients in our studies often entered the ICU some time after the onset of 
the life-threatening illness, so that the initial rise in ACTH may have been missed. Also studies of 
children suffering from meningococcal sepsis revealed low plasma ACTH levels already within the first 
24h of admission,7,8 which suggest that tracing the initial ACTH rise presumed to be triggered by severe 
illnesses could be a major challenge.  
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The observation of low plasma ACTH concentrations in the face of elevated plasma cortisol, referred to 
as “the ACTH-cortisol dissociation”, was based on single blood sample measurements of ACTH and 
cortisol. Given that ACTH and cortisol are secreted in discrete pulses, analyzing the dynamics of the 
secretory patterns of these hormones and the interaction between ACTH and cortisol secretion must 
involve time series analyses. We therefore performed a second study (Chapter 4) in which we analyzed 
the dynamics of ACTH and cortisol secretion via nocturnal time series of repeated (every 10 minutes) 
blood samples taken from critically ill patients and from healthy controls. By deconvolving these 
concentration time series into secretion profiles, taking into account the plasma clearance, we revealed 
decreased ACTH and cortisol secretion rates in ICU patients as compared with the healthy controls, 
which was explained by a decrease in the size of the pulses but not by a change in the number of 
pulses. Surprisingly the dose-response between a given ACTH concentration and cortisol secretory 
response was preserved. These findings suggested that the term „ACTH-cortisol dissociation‟ may not 
be entirely correct. Indeed, the cortisol secretion was still “connected” to the amount of circulating 
ACTH, but both were suppressed, not increased, in the presence of high plasma cortisol concentrations. 
The observed low circulating ACTH levels in combination with reduced ACTH and cortisol secretion 
could be explained by a general suppressor of the HPA axis such as NO or orexin.2,9 Another possible 
explanation could be that the circulating high cortisol levels suppress ACTH release centrally by 
negative feedback which inhibits cortisol production. 
Moreover, our data also invalidate the possibility of an increased ACTH sensitivity as an explanation for 
low ACTH and high cortisol levels, as the preserved dose-response indicated that a given ACTH 
concentration still drives cortisol secretion during critical illness but does not lead to an increased 
cortisol response. We also observed an increase in markers of irregularity and asynchrony (ApEn and 
crossApEn) in the secretory patterns, which further suggested that alternative non-ACTH dependent 
regulators of cortisol production are involved in the „dissociation‟.  
Pro-inflammatory cytokines are known to stimulate adrenocortical cortisol production and we found both 
IL6 and TNFα concentrations to correlate positively with the morning cortisol production as determined 
with the stable isotope tracer (Chapter 3). Remarkably, morning cortisol production rate was only 
elevated in patients suffering from the „systemic inflammatory response syndrome‟ (SIRS), while cortisol 
production in other critically ill patients was indistinguishable from healthy controls, in the presence of 
elevated plasma cortisol. However, in the study of the overnight cortisol secretion rate, as determined by 
deconvolution analysis, the plasma cytokine concentrations correlated inversely with cortisol secretion 
(Chapter 4). Hence, the data do not really support a major role for circulating cytokines as key 
regulators of plasma cortisol. Other potential stimulators of cortisol production such as neuropeptides or 
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splanchnic innervation were not further investigated. Given the fact that cortisol production was only 
moderately increased in the morning (Chapter 3), and even decreased during the night (Chapter 4), one 
could question whether such alternative drivers of cortisol production play an important role during 
critical illness. This is further supported by the lack of correlation between plasma total and/or free 
cortisol concentrations and cortisol production rate during critical illness. 
Indeed the cortisol production rate during the day, documented with isotopes, was not even a doubling 
of that of healthy subjects, while the nocturnal cortisol secretion documented was only half that of 
healthy controls.  All together, 24h cortisol production rates during critical illness may not be, or at best 
only moderately, increased. Ideally, 24h profiles should be constructed in order to quantify the 24h 
differences in cortisol secretion rates between patients and controls. However, such 24h studies 
represent a major challenge in the ICU without disturbing daytime diagnostic and therapeutic activities. 
What can be concluded from our data is that the classical assumption that cortisol production rate 
during critical illness is 6-fold higher than normal, is probably a large overestimation. As a consequence, 
the therapeutic doses of 200 mg, currently used for substituting a presumed failing adrenal gland during 
critical illness, may be too high. This conclusion is supported by the observation that several-fold higher 
plasma cortisol concentrations were obtained with the treatment of 200 mg hydrocortisone per day of 
patients who were presumed to suffer from relative adrenal failure, as compared with the endogenous 
cortisol plasma concentrations in patients who have an adequate HPA-axis response.10 
 
As an alternative for increased cortisol production, hypercortisolemia could also be evoked by reduced 
plasma cortisol clearance. We indeed observed cortisol clearance to be reduced to less than half, as 
determined with a low dose tracer infusion as well as quantified via the clearance of a 100 mg bolus of 
exogenous hydrocortisone. Reduced cortisol breakdown was explained by reduced expression and 
activity of the cortisol metabolizing enzymes in liver and kidney, as suggested by urinary steroid ratios, 
tracer kinetics and assessment of liver-biopsy samples. (Chapter 3) These results were obtained via 4 
different studies, where each of these studies investigated another aspect, making these studies 
complementary and adding to the robustness of the data. Furthermore, we analyzed possible 
confounding regulators. Theoretically, as shown in literature,11,12 CBG levels influence both half-life and 
clearance of cortisol. We observed in the studied patients decreased CBG levels during critical illness. 
Low CBG levels would shorten the half-life of cortisol, and increase the plasma clearance and 
distribution volume of cortisol.  Our findings are therefore clearly not explained by alterations in CBG, as 
the opposite would be expected, which further adds to the robustness of our observations. Decreased 
plasma clearance of cortisol could also be explained by reduced renal or hepatic function or by 
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hypoperfusion.  However none of the representative clinical markers of organ function and/or perfusion 
were associated with cortisol plasma clearance. Drugs that interfere with HPA-axis function were all 
excluded except for anticoagulants and opioids, which are often required during critical illness. We could 
confidently eliminate potential confounding by such treatments, since there were no differences between 
patients who were treated with these drugs and those who were not treated. 
Importantly, we observed reduced cortisol clearance in all tested critically ill patients, irrespective of type 
and severity of illness, inflammation status and irrespective of ICU stay and prognosis, which further 
emphasized the potential key role for this mechanism to increase plasma cortisol. Such adaptation via 
reducing cortisol breakdown in response to sustained stress and low energy availability is not only 
observed in critical illness, but has also been described in patients with anorexia nervosa, posttraumatic 
stress disorders and depression, suggesting that it could be a fundamental part of the stress 
response.13-15  
The concept of reduced cortisol metabolism as a vital part of the stress response to critical illness could 
be interpreted as an attempt of the human body to save energy when energy supply is low. The concept 
of optimizing energy resources is further supported by low plasma CBG levels in critical illness, causing 
increased levels of free cortisol, the biologically active form. Importantly, elevating cortisol via the 
suppression of metabolizing enzymes predominantly in liver and kidney, where cortisol effects are 
needed for an optimal fight or flight response, could limit the exposure of immune cells and vulnerable 
target tissues such as skeletal muscle or brain to deleterious side effects of excessive cortisol. 
Regulating effects of cortisol locally also seems to occur at the level of glucocorticoid receptor (GR) 
expression. Previous work indeed showed suppressed GR expression in white blood cells of critically ill 
children, which could be a way to allow the innate immune response to effectively protect the host 
against infections in the presence of elevated circulating cortisol levels.16,17 Increasing evidence from 
animal studies shows that the regulation of the GR in other tissues is also important during critical 
illness.18,19 
 
It remains unclear from our studies, however, what is driving the downregulation of these cortisol 
metabolizing enzymes in liver and kidney during critical illness. Bile acids, both conjugated and 
unconjugated, are potent inhibitors of the cortisol metabolizing enzymes, via competitive inhibition at 
low-physiological concentrations and by suppression of gene and protein expression at elevated 
concentrations.20-22 Circulating levels of predominantly conjugated bile acids recently were shown to be 
substantially increased during critical illness.23 These elevated bile acid levels appeared to be brought 
about by ongoing bile acid synthesis, despite suppression of the nuclear receptors that function as 
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sensors. The bile acids appeared subsequently conjugated within the hepatocyte and exported back 
towards the blood rather than to the bile. This phenomenon may be adaptive and beneficial as it could 
reduce energy expenditure by not exporting bile acids against a steep concentration gradient into the 
bile.23 Furthermore, bile acids also have an immunomodulatory effect, as shown in septic mice, possibly 
mediated by their effect on hepatic GR expression.19 Increasing evidence further emphasizes the 
beneficial effect of high circulating bile acid levels, since they prevent insulin resistance, promote energy 
expenditure via increased deiodinase 2 levels in brown adipose tissue24 and may protect the liver and 
kidney from ischemia.25-27 As a strikingly tight inverse correlation was observed between the elevated 
plasma concentrations of bile acids in patients and the gene and protein expression levels of the A-ring 
reductases in liver, a role for bile acids in regulating cortisol metabolism during critical illness may likely 
be an additional beneficial effect of bile acids.23, 28  
The link between bile acids and the HPA-axis was already suggested from different clinical observations 
and animal studies. Not only are bile acids and cortisol both produced from cholesterol, they also have 
5β-reductase in common which regulates both bile acid synthesis and cortisol metabolism.  
Bile acids are suggested to regulate the HPA-axis at every level. Animal experiments showed that 
cholestasis, besides inhibiting the different cortisol metabolizing enzymes,21 also reduces both CRH and 
ACTH expression.29 Furthermore, the farnesoid X receptor (FXR), a nuclear receptor that is activated by 
bile acids and downregulated during critical illness,23 is expressed in the adrenal glands and positively 
regulates SCARB1, 3β-HSD and CYP11B1 expression, which are important for steroidogenesis.29-31 
This may suggest that besides influencing cortisol metabolism, bile acid homeostasis could also explain 
our other observations of both decreased ACTH levels and decreased cortisol production. The clinical 
observations of ACTH-cortisol dissociations in patients with cholestasis 32 as well as the high incidence 
of adrenal failure in patients with liver diseases 33 further emphasize this potential link. 
However, an inverse regulation by glucocorticoids on bile acid homeostasis was also described, since 
patients with Addison disease have increased circulating levels of bile acids and POMC-deficiency 
coincides with cholestasis.34 Moreover, mice studies with deficient hepatic GR expression showed both 
increased bile acid levels, as well as reduced FXR expression and reduced basolateral uptake of 
circulating bile acids,34 which are all findings observed in critically ill patients.23 Intervention studies are 
therefore indispensable to further explore this cause-or-consequence debate.  
 
In the last chapter of this thesis, we explored the longer term consequences of the ACTH-cortisol 
dissociation on the adrenal gland of critically ill human patients. Maintaining plasma cortisol 
concentrations high by reducing the breakdown of cortisol would cause feedback inhibition on both 
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pituitary ACTH and hypothalamic CRH release. It has been shown previously that this can 
predominantly affect pulsatility via reducing the mass per ACTH pulse, which is exactly what we 
observed in critical illness. (Chapter 4) Reduced pulsatile ACTH secretion was associated with 
suppressed pulsatile cortisol secretion. There is increasing evidence that emphasizes the importance of 
hormonal pulsatility in maintaining normal cellular function in both the adrenal gland and the target 
tissues of cortisol, by preventing desensitization of transcriptional responses. Whether the observed 
reduced pulsatility in cortisol secretion during critical illness still suffices to prevent such desensitization 
in target tissues remains unclear. One could speculate that it may indeed contribute to tissue specific 
cortisol resistance and, by inference, to „relative‟ adrenal insufficiency during critical illness. 
Whereas reduced cortisol metabolism can be interpreted as an „economic‟ way to maintain cortisol 
levels, the coinciding low plasma ACTH concentrations could negatively affect adrenal structure and 
function. Therefore, in the last chapter, we investigated post-mortem adrenal glands harvested from 
patients who died after a short or a long ICU stay, as compared with those harvested from sudden out-
of-hospital deaths. The study showed a clear depletion of adrenocortical cholesterol esters and reduced 
expression of steroidogenic genes (STAR, CYP11A1, MC2R, SCARB1, LDLR, HMGCR) in prolonged 
critically ill patients, while no changes occurred in acute critically ill patients. These alterations further 
strengthened our hypothesis that no important activation of the HPA-axis and therefore no increased 
cortisol production seems to occur during critical illness, since this would upregulate the steroidogenic 
enzymes. Since cortisol is not stored in the adrenal gland and cortisol secretion relies on immediate 
cortisol production from cholesterol, these observations instead suggested a reduced cortisol 
production.  
Theoretically, each of the observed changes in the harvested adrenal glands could either be explained 
by several independent factors or by ACTH alone, as ACTH deprivation can bring about all these 
alterations. For example, STAR is regulated by several transcription factors and the interactions with 
proteins such as the peripheral type benzodiazepine receptor (PBR) are known to be essential.35 STAR 
is also upregulated by cholesterol depletion.  Hence, the low cholesterol levels of the critically ill 
inferentially should upregulate STAR. Also, STAR knock-out mice are characterized by florid lipid 
depositions in the adrenal glands.35,36 However, these adaptations require an increase in ACTH, which 
is low during critical illness. Furthermore, the cholesterol uptake receptors and HMG-Co A reductase are 
all negatively regulated by circulating cholesterol. Again, the observed low cholesterol levels during 
critical illness would therefore rather stimulate cholesterol uptake and synthesis.37 An adequate supply 
of oxygen within the mitochondria is known to be essential for CYP11A1 function. Hypoperfusion with 
ischemia could occur in critical illness. Hypoxia has been previously shown to downregulate both 
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CYP11A1 and MC2R, however without alterations in STAR expression.38 Iatrogenic factors such as 
etomidate are also likely to affect cortisol production. Etomidate is known to inhibit CYP11B, though 
causes stimulation of STAR and CYP11A1.39  
All these different regulators cannot explain the full picture of the observed changes in the adrenal gland 
during critical illness. Since mRNA expression of all the genes correlated tightly with each other (all 
P<0.0001 and all R²>0.53) and mRNA expression of all genes except HMGCR correlated, albeit weakly, 
with ORO quantification (all P≤0.004 and all R²>0.15), this may suggest that all changes in the adrenal 
gland are determined by the same regulator during critical illness. ACTH is the only shared regulator of 
all these alterations; being suggestive that sustained lack of ACTH-effect may indeed explain these 
findings. Furthermore, predominantly ACTH pulsatility determines transcriptional activation of the 
steroidogenic genes and we demonstrated that pulsatility is reduced during critical illness. Finally, our 
results are strikingly reminiscent of the phenotype of POMC-deficient mice.40,41 Unfortunately, we did not 
have blood samples to correlate these changes to ACTH plasma concentrations. 
The observed changes in the adrenal glands of prolonged critically ill patients, possibly related to ACTH 
deprivation, may at first sight seem in contrast with our previous finding of a preserved dose-response 
relationship of ACTH and cortisol. (Chapter4)  However, the patients from the study on the dynamics of 
ACTH and cortisol time series were included early during the course of critical illness (with a median 
ICU stay at study time of 4 days (IQR 2-5)). In contrast, the observed changes in the study of the 
adrenal glands were only observed in the prolonged phase, i.e. after a median 16 (IQR 13-21) days in 
ICU, and not in the adrenal glands harvested from patients with a short ICU stay, i.e. after a median 2 
(IQR 1-5) days in ICU. This is consistent with other endocrine changes observed in critical illness, which 
are likely to be beneficial in the acute phase, but become maladaptive when illness is prolonged.42,43 
Furthermore, Barquist et al. showed a 20-fold increased incidence of adrenal failure in patients with 
ICU-stay of more than 14 days.44  
Possibly, other previously suggested regulators such as pro-inflammatory cytokines, impaired blood 
supply, oxidative stress, cholesterol deficiency or interfering medications could also play a role in the 
pathophysiology of adrenal failure. For example, since cholesterol uptake and synthesis are 
downregulated, circulating levels of cholesterol become more important. Indeed it was shown that the 
circulating HDL-levels are an important prognostic marker of adrenal failure and of adverse outcome of 
critical illness.45  
Furthermore, adrenal failure has also been described in the acute phase of sepsis-induced illness. This 
acute failure can be brought about by other causes of “absolute adrenal failure”, such as iatrogenically 
decreased adrenal cortisol production by etomidate, adrenal ischemia, adrenal hemorrhage, among 
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others. As patients often enter the ICU for an acute deterioration of a chronic illness, or were ill already 
for some time prior to ICU admission, more chronic ACTH deprivation could also play a role in this 
„acute‟ form of adrenal insufficiency. 
 
The novel findings of reduced cortisol breakdown, only moderately increased cortisol production (if at 
all) and the deleterious impact of sustained ACTH deprivation reshape the current understanding of 
HPA-axis regulation during critical illness and may have important implications for diagnosis and 
treatment of adrenal insufficiency.  
From large association studies, relative adrenal failure of the critically ill is thought to be identifiable by 
an insufficient rise (< 9 µg/dl) in plasma cortisol in response to a 250 µg ACTH bolus, irrespective of the 
baseline plasma cortisol concentration - which is usually much higher than in healthy humans.46 In such 
a condition of insufficiently increased cortisol production, a very high plasma ACTH concentration would 
be expected. However, the recent robust findings that ACTH plasma concentrations are suppressed, 
that cortisol production is not much elevated, if at all, and that instead reduced cortisol breakdown plays 
a major role during critical illness, further complicate defining correct diagnostic criteria for adrenal 
failure. Furthermore, we showed that the cortisol response to ACTH stimulation in critically ill patients 
correlated positively with both cortisol production rate and cortisol plasma clearance. We also found that 
patients who reveal a low response to ACTH, to the extent of absolute adrenal failure,47 were the ones 
with the most suppressed cortisol breakdown, whereas their cortisol production was still similar to that of 
healthy subjects. These findings suggest that a low cortisol response to an ACTH injection may simply 
reflect the degree of negative feedback inhibition exerted by the cortisol that is not broken down. This 
condition resembles that of patients treated with exogenous glucocorticoids for an extended time, who 
also reveal a suppressed response to ACTH injection.48 Whether or not such a low response in the 
presence of elevated plasma cortisol during critical illness indicates that cortisol availability would be 
„insufficient‟ to cope with the stress of illness remains unclear. Furthermore, it has been shown that the 
response to an ACTH stimulation test is poorly reproducible in critically ill patients,49 which further limits 
the use of a single ACTH stimulation test to diagnose adrenal failure and strengthens the hypothesis 
that adrenal function during critical illness is dynamic. Therefore, the use of repetitive ACTH stimulation 
tests could be recommended to both recognize adrenal recovery as well as the evolution to adrenal 
failure. It has already been suggested that the cortisol response restores after recovery of illness.50, 51 
Furthermore, a retrospective study of de Jong et al. showed that patients in whom the cortisol increment 
to a ACTH stimulation test decreased with time had the worst prognosis.52 Unfortunately, large enough 
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and well designed prospective clinical studies of systematic ACTH stimulation tests performed on 
repeated time points into the prolonged phase of critical illness and recovery are currently lacking.  
Reduced cortisol breakdown can be interpreted as a highly energy efficient way to maintain adequate 
cortisol levels. However, inhibiting cortisol metabolism can only increase plasma cortisol to a limited 
extent.  One could speculate that when a second hit occurs, an additional cortisol production is needed 
to cope with this extra need of cortisol. If ACTH deprivation was already present for some time so that 
adrenal function already became compromised, this extra required cortisol may no longer be produced. 
To detect adrenal failure, repetitive cortisol measurements are needed rather than drawing conclusions 
from a single cortisol value, taking into account the previously described limitations of total cortisol levels 
as a reflection of free cortisol and the problems with cortisol assays. Repetitive cortisol measurements in 
time showed a decrease in serum cortisol levels in the prolonged phase of illness.53 In this study 25% of 
the patients who had initial normal baseline cortisol levels evolved to low cortisol levels within a mean 
time of 8 days, which is consistent with our observation that >7days of ICU stay causes signs of 
insufficient adrenal cortisol production. It further remains to be studied how ACTH concentrations evolve 
during the course of critical illness. Whenever a second hit would imply additional cortisol production, 
high ACTH levels would then be released in an attempt to stimulate adrenal cortisol production and 
release. However, persistent feedback of high cortisol could also have affected pituitary and 
hypothalamic function and could cause low ACTH levels. Indeed, long-term administration of exogenous 
glucocorticoids is known to cause tertiary adrenal insufficiency by prolonged suppression of 
hypothalamic secretion of CRH,54 which is comparable with the continuously high cortisol levels during 
critical illness. Moreover, the observed alterations in adrenal glands from patients, who did not recover, 
but died after a prolonged phase of critical illness, are highly suggestive of being related to ACTH 
deprivation.(Chapter 5) On the other hand, by analogy with the evolution of TSH levels in critically ill 
patients,43 one could expect that ACTH levels restore when recovery of illness sets in. As such, the 
changes in circulating ACTH over time could be highly informative to understand illness evolution. 
Therefore, the combination of repetitive basal (unstimulated) ACTH and cortisol levels would be more 
informative to assess the function of the HPA-axis during critical illness. 
 
Our new insights also may have important implications for treatment strategies. The proposed dose of 
200 mg of hydrocortisone per day, referred to as “low dose” in the literature, is in fact approximately 10 
times higher than the normal amount of daily cortisol production in healthy humans 55-58 and between  
3- to 6-fold higher than the production which we observed in critically ill patients. Furthermore, the 
plasma half-life of a bolus of 100 mg hydrocortisone was documented to be at least 5-fold longer in 
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critically ill patients than in healthy control subjects, and thus hydrocortisone doses of 200 mg per day 
will likely result in accumulation of cortisol during critical illness. By regulating cortisol breakdown, 
tissue-specific cortisol levels are ensured which is believed to be beneficial by preventing high levels in 
those tissues that are susceptible to excessive glucocorticoid levels. Treatment with exogenous 
glucocorticoids overrules this adaptive response by increasing levels in all tissues, thus explaining the 
potentially deleterious effect of this treatment. Excessive glucocorticoid levels could inferentially 
aggravate lean tissue wasting, increase the risk of myopathy and prolong intensive care dependency, 
which could expose the patients to potentially lethal complications.59,60 This may further explain why the 
multi-center randomized controlled study that assessed the effect of hydrocortisone treatment could not 
confirm the benefit that was originally observed in the pioneer trial.55,58 Moreover, as glucocorticoid 
sensitivity could vary among individuals61 and among cell types 17, 62,63 the dosing issue is further 
complicated. Also single nucleotide polymorphisms in the GR gene, with an enhanced or decreased 
response to glucocorticoids, have been identified.64,65 It thus currently remains a challenge to identify 
specific clinical biomarkers of GR activation to guide optimal glucocorticoid therapy for individual 
patients and illnesses.  
Further research is urgently needed to investigate appropriate substitution therapy for adrenal failure 
based on current new insights. The stable isotope studies suggested that a dose of approximately 60 
mg of hydrocortisone, equivalent to about a doubling of the normal daily cortisol production, may be 
interesting to further explore when patients at risk can be identified.  A tapering down to the lowest 
effective dose as soon as possible should limit the adverse effects of excessive amounts of 
glucocorticoids during critical illness. Furthermore, the novel findings do not only influence treatment of 
patients with adrenal failure but must also be taken into account when treating ICU-patients with 
steroids for other indications. 
 
The novel observations described in this thesis generate additional questions which need to be further 
explored in the future.  The evolution of circulating ACTH and cortisol levels during the course of critical 
illness until recovery or death will give more insight into the evolution of the HPA-axis regulation during 
critical illness. Ideally this study should be combined with repetitive ACTH-stimulation tests and 24 hour 
urine collections to evaluate adrenal function and cortisol metabolism during the course of critical illness. 
Next, well designed clinical trials are needed to define the appropriate treatment strategy of patients with 
adrenal failure during critical illness. Quantifying the GR expression in different tissues would be of 
additional interest to explore local tissue sensitivity and further optimize glucocorticoid treatment during 
critical illness. The impact of sustained high cortisol concentrations at the level of hypothalamus and 
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pituitary must also be investigated. CRH-stimulation tests have been used to investigate HPA recovery 
after treatment of Cushing‟s disease and could be informative in an ICU setting too. Currently, only a 
limited amount of studies have been performed in critically ill patients, which yielded conflicting 
results.66,67 Moreover, also further in detail investigation of the CRH, vasopressin and ACTH expression 
in relation to reduced cortisol breakdown would be of additional value. However this would imply the 
need for brain biopsies. Finally, identifying the cause of reduced cortisol clearance and metabolism is 
indispensable to further understand pathophysiology of endocrine changes during the course of critical 
illness and recovery. 
Human studies are inevitably limited by ethical restrictions. Furthermore, studying post-mortem human 
material has important limitations. Animal studies eliminate such limitations of post-mortem analyses 
and further allow in depth investigation of target tissues. Given the possibilities of studying knock-out 
mice, investigating the HPA alterations during critical illness in a mouse model would be interesting. Our 
group recently validated a mouse model of sepsis, induced by cecal ligation and puncture.68 We already 
completed a small pilot study in 4 healthy control mice and 9 critically ill mice to assess whether the 
HPA-axis alterations during critical illness in mice are comparable to those observed in humans. Daily 
blood samples were taken and all animals were sacrificed at the third day of critical illness. ACTH levels 
were low in critically ill mice compared to controls, while corticosterone levels were always higher in ill 
mice, suggesting that the “ACTH-cortisol dissociation” is also present in critically ill mice. Furthermore, 
in liver of critically ill mice, enzyme expression of 5α reductase was markedly reduced, which is 
important as 5α reductase predominates for cortisol breakdown in mice.69,70 Though, the sample size of 
this pilot study was too small and 3 days of critical illness may not be entirely representative for 
prolonged ICU stay, which is important given that adrenal alterations only occur in the prolonged phase 
of illness. Therefore, a new larger study with a longer follow-up period is required.   
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In conclusion, (Figure1) unlike previously inferred, morning cortisol production in critically ill patients was 
found to be only moderately increased and was suppressed during the night. In the face of low plasma 
ACTH concentrations and low nocturnal ACTH secretion, these data suggest that other factors drive 
hypercortisolism during critical illness, which may suppress ACTH by feed-back inhibition. Markedly 
reduced plasma clearance of cortisol in critical illness, explained by suppressed expression and activity 
of the main cortisol-metabolizing enzymes in liver and kidney, contributes to high cortisol levels during 
critical illness. Whereas this stress response could be interpreted as an acute beneficial adaptation of 
the body to maintain hypercortisolemia in an energy efficient way, sustained low ACTH levels appear to 
negatively affect structure and function of the adrenal cortex in the prolonged phase of critical illness. 
These novel insights reshape the current understanding of the hormonal stress response to critical 
illness. Furthermore, these insights complicate the diagnosis of adrenal failure during critical illness and 
may suggest a dose adaptation when treatment with hydrocortisone is considered necessary. High 
quality clinical studies are required to address these many remaining questions. 
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Figure 1 – Overview of the novel insights and remaining questions in the HPA-axis regulation during and critical illness compared to health
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SUMMARY 
 
 
Critical illness is defined as any condition that requires support of failing vital organ functions, without 
which death would rapidly ensue. As such, it represents an extreme example of physical stress, where 
“stress” comprises the normal physical response of the human body that arises when confronted with a 
threat. In healthy individuals, experiencing stress causes an immediate activation of the hypothalamic-
pituitary-adrenal axis, which induces secretion of the hypothalamic corticotropin-releasing hormone, 
followed by the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. ACTH 
causes production of cortisol from cholesterol in the adrenal gland. Cortisol itself exerts feedback 
inhibition at the pituitary and the hypothalamic level, as such regulating its own release. Under normal 
conditions, these hormones are secreted in a pulsatile manner according to a fixed daily rhythm. 
Whenever stress occurs, activation of the hypothalamic-pituitary-adrenal axis causes an additional 
episodic release of cortisol. 
Critical illness is therefore hallmarked by the presence of high circulating cortisol levels, proportionate to 
the severity of illness. This was traditionally attributed to activation of the hypothalamic-pituitary-adrenal 
axis and increased ACTH-driven cortisol production. However, ACTH levels were observed to be low, 
suggesting that non-ACTH dependent regulators of cortisol production are important during critical 
illness. Cortisol production has even never been quantified during critical illness. Furthermore, it is 
assumed that activation of the hypothalamic-pituitary-adrenal axis can sometimes be insufficient to cope 
with severe illness. In the presence of high plasma cortisol, this condition has been labeled “relative 
adrenal insufficiency”. However, the underlying mechanisms remain unknown. Also, it remains 
controversial whether treating such patients with corticosteroids is required, as interventional studies 
provided conflicting results.  
The main objective of this doctoral thesis was to explore the regulation of cortisol secretion and 
metabolism during critical illness in order to gain more insight in the pathophysiology of adrenal 
insufficiency. The general hypothesis of this doctoral thesis postulated that during critical illness reduced 
cortisol breakdown, rather than continuously stimulated cortisol secretion, contributes to maintain the 
elevated plasma cortisol concentrations. Negative feedback inhibition, exerted by high circulating 
cortisol levels would then explain low ACTH levels. When ACTH deprivation sustains, adrenal integrity 
and function could be negatively affected, predominantly in the prolonged phase of critical illness. 
In a first part, we investigated in critically ill patients and matched healthy control subjects daily ACTH 
and cortisol levels in plasma during the first week of illness; plasma cortisol clearance and production 
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during infusion of cortisol isotopes as tracers; plasma clearance of 100 mg of synthetic cortisol and the 
urinary cortisol metabolites and enzyme expression at tissue level to assess the major cortisol-
metabolizing enzymes. This showed that while circulating cortisol levels were consistently higher in 
patients than in controls, ACTH levels were decreased during critical illness. Cortisol production was 
less than doubled in patients. Furthermore, critically ill patients showed a more than 50% reduction in 
cortisol clearance during tracer infusion and after the administration of exogenous cortisol. All these 
factors accounted for the 4-fold increased plasma cortisol levels in patients, as compared with controls. 
Reduced cortisol metabolism was explained by reduced inactivation of cortisol in the liver and kidney of 
patients. 
In the first study, only single sample ACTH and cortisol concentrations were reported. Since both ACTH 
and cortisol are secreted in pulses, this precludes analysis of their secretory dynamics and their relation 
during critical illness. In a second study, we therefore analyzed the dynamics of ACTH and cortisol 
secretion in critically ill patients and matched healthy control subjects, via nocturnal time series of 
repeated blood samples.  We documented that hypercortisolemia during critical illness coincided with 
suppressed pulsatile ACTH and cortisol secretion, whereas the cortisol secretory response to a given 
plasma ACTH concentration was unaltered. These findings speak against the classical dogma of an 
activated hypothalamic-pituitary-adrenal axis in critical illness and instead suggest feedback-inhibition 
on ACTH exerted by circulating cortisol.  
Considering the important function of ACTH in ensuring adrenal structure and function, the observed 
low ACTH levels could negatively affect the adrenal glands, possibly predominantly in patients who 
stayed in the ICU for a prolonged time. In the third part of this thesis, we therefore investigated post-
mortem adrenal glands from patients who died in the intensive care unit compared to adrenal glands 
from sudden out-of-hospital deaths as controls. Adrenal glands from patients who stayed long in the 
intensive care unit were clearly more distorted in structure. Furthermore, the amount of stored 
cholesterol droplets was reduced in the adrenal glands from these patients. We also showed that the 
genes responsible for cholesterol uptake and synthesis as well as crucial genes for the production of 
cortisol were downregulated only in prolonged critically ill patients. Since cortisol cannot be stored in the 
adrenal gland and its production is dependent on rapid synthesis from cholesterol, these alterations limit 
cortisol production. Given that all the observed alterations are regulated by ACTH, one could speculate 
that the observed low ACTH levels might play a role and, when ACTH deprivation sustains, may help to 
explain the increased incidence of adrenal failure in the prolonged phase of critical illness. 
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In conclusion, reduced cortisol metabolism contributes to high cortisol levels during critical illness. 
Consequently, these high cortisol levels could suppress pulsatile ACTH secretion by negative feedback 
inhibition, causing acutely a reduced pulsatile cortisol secretion. Maintaining cortisol by not breaking it 
down seems a highly energy efficient way. However, the concurrent low ACTH levels could explain the 
observed disruption in structure and function of the adrenal gland in the prolonged phase of critical 
illness. These novel insights help to understand adrenal failure during critical illness and may have 
important implications for its diagnosis and treatment. 
  
142 
 
 
  
143 
 
SAMENVATTING 
 
 
Kritieke ziekte wordt gedefinieerd als een toestand waarbij de functie van vitale organen moet 
ondersteund worden om een snel volgende dood te voorkomen. Het lichaam ervaart deze toestand dan 
ook als een extreme stress situatie. Bij gezonde personen reageert het lichaam op stress door een 
onmiddellijke activatie van de hypothalame-hypofysaire-bijnier-as, waardoor corticotropine releasing 
hormoon uit de hypothalamus wordt vrijgesteld. Dit zorgt voor de secretie van het adrenocorticotroop 
hormoon (ACTH) uit de hypofyse. ACTH stimuleert vervolgens de productie van cortisol in de bijnier. 
Door negatieve feedback op het corticotropine releasing hormoon en ACTH regelt cortisol zijn eigen 
vrijzetting. In normale omstandigheden worden deze hormonen vrijgezet in pulsen met een vast 
dagelijks ritme. In stress situaties zorgt een extra activatie van de hypothalame-hypofysaire-bijnier-as 
voor een bijkomende vrijzetting van cortisol.  
Kritieke ziekte wordt dan ook gekenmerkt door hoge cortisol spiegels, evenredig met de ernst van 
ziekte. Traditioneel werd dit toegeschreven aan een activatie van de hypothalame-hypofysaire-bijnier-as 
en een gestegen cortisol productie. ACTH bloedwaarden zijn echter verlaagd in kritieke ziekte, wat lijkt 
te wijzen op een ACTH onafhankelijke cortisol productie. De cortisol productie werd echter nooit eerder 
gemeten in kritieke ziekte. Bovendien lijkt de activatie van de hypothalame-hypofysaire-bijnier-as soms 
tekort schieten tijdens kritieke ziekte, en dit terwijl de cortisol waarden nog steeds hoger liggen dan bij 
gezonde personen. Deze toestand wordt “relatief bijnierfalen” genoemd. De onderliggende 
mechanismen van dit falen zijn echter tot op heden onbekend. Aangezien interventionele studies 
tegengestelde resultaten gaven, is het bovendien onvoldoende geweten hoe men deze patiënten moet 
behandelen.  
Het algemene doel van deze doctoraatsthesis is de regulatie van cortisol secretie en metabolisme 
tijdens kritieke ziekte te onderzoeken om zo een beter inzicht te krijgen in de pathofysiologie van bijnier-
falen. Als algemene hypothese stelden we dat een gedaalde cortisol afbraak, eerder dan een 
gestimuleerde cortisol productie, de verhoogde cortisol niveaus tijdens kritieke ziekte verklaart. Deze 
verhoogde cortisol waarden zouden vervolgens een negatieve feedback op ACTH uitoefenen, wat, door 
een langdurig ACTH tekort, de structuur en functie van de bijnier kan beïnvloeden, vermoedelijk in de 
verlengde fase van kritieke ziekte. 
In het eerste deel van dit doctoraatsproject, onderzochten we bij  kritiek zieke patiënten en gezonde 
vrijwilligers naast de dagelijkse ACTH en cortisol waarden in het plasma tijdens de eerste week van 
kritieke ziekte, ook de klaring en productie van cortisol aan de hand van een cortisol tracer, de klaring 
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van 100 mg synthetisch cortisol en de cortisol metabolieten in de urine alsook de enzym expressie in 
weefsels om zo de belangrijkste cortisol metaboliserende enzymen te onderzoeken. Hieruit bleek dat 
patiënten steeds verhoogde cortisol waarden hadden ondanks dat ACTH verlaagd was. De cortisol 
productie was bijna verdubbeld bij patiënten. Bovendien, was de klaring van cortisol uit het bloed meer 
dan gehalveerd zowel wanneer bepaald na tracer-infusie als na een synthetische cortisol dosis. Samen 
bepalen ze de viervoudige stijging in plasma cortisol waarden bij patiënten. Een gedaalde afbraak van 
cortisol in de lever en nieren van patiënten verklaarde het gedaalde cortisol metabolisme. 
In de eerste studie werden enkel eenmalige waarden van ACTH en cortisol gerapporteerd. Aangezien 
zowel ACTH als cortisol in pulsen worden gesecreteerd, verhindert dit de analyse van de secretie 
dynamiek en hun onderlinge relatie. In een tweede studie analyseerden we daarom de dynamiek van 
ACTH en cortisol secretie bij zowel kritiek zieke patiënten als gezonde vrijwilligers aan de hand van een 
serie bloedstalen. We toonden aan dat de hoge cortisol waarden tijdens kritieke ziekte samengaan met 
een onderdrukte pulsatiele secretie van ACTH en cortisol, terwijl het antwoord in cortisol secretie op een 
ACTH stimulus onveranderd bleef. Deze observaties staan in sterk contrast met de klassieke 
veronderstelling dat de hypothalame-hypofysaire-bijnier-as geactiveerd is in kritieke ziekte en 
suggereren dat de verhoogde circulerende cortisol waarden een negatieve feedback uitoefenen met de 
verlaagde ACTH secretie tot gevolg. 
Gezien de belangrijke functie van ACTH voor de bijnier structuur en functie zouden lage ACTH waarden 
de bijnieren negatief kunnen beïnvloeden en dit dan vooral bij die langdurig kritiek zieke patiënten. 
Daarom onderzochten we in een derde deel van deze thesis, post-mortem bijnieren van patiënten die 
overleden waren op de intensieve zorgenafdeling en vergeleken deze met bijnieren van mensen die 
onverwacht overleden buiten het ziekenhuis. De bijnieren van langdurig kritiek zieke patiënten hadden 
duidelijk een meer verstoorde structuur. Verder was het aantal opgeslagen cholesterol druppels in de 
bijnieren van deze patiënten verlaagd. We konden ook aantonen dat zowel de genen die 
verantwoordelijk zijn voor de cholesterol opname en synthese als de genen belangrijk voor cortisol 
productie onderdrukt zijn bij deze patiënten. Aangezien cortisol niet opgeslagen zit in de bijnier en de 
productie dus afhankelijk is van de snelle omzetting van cholesterol, zorgen deze veranderingen voor 
een beperking in de cortisol productie. Aangezien al deze veranderingen door ACTH geregeld zijn, doet 
dit vermoeden dat de aangetoonde lage ACTH waarden een rol spelen en zeker, wanneer deze 
onderdrukking aanhoudt, mee kunnen verklaren waarom bijnierfalen meer voorkomt in de verlengde 
fase van kritieke ziekte. 
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Uit deze studies kunnen we besluiten dat een gedaald cortisol metabolisme bijdraagt tot de hoge 
cortisol waarden tijdens kritieke ziekte. Hieruit volgt dat deze hoge cortisol waarden door negatieve 
feedback de pulsatiele ACTH secretie onderdrukken, waardoor acuut de pulsatiele cortisol secretie 
wordt verminderd. Het behouden van cortisol door het niet af te breken lijkt een zeer energie 
besparende reactie van het menselijk lichaam op kritieke ziekte. De hierdoor veroorzaakte lage ACTH 
waarden kunnen bovendien de vastgestelde verstoring van de bijnier structuur en functie verklaren bij 
patiënten die langdurig op intensieve zorgen verblijven. Deze nieuwe zichten dragen daarom in 
belangrijke mate bij tot het begrijpen van bijnierfalen tijdens kritieke ziekte en hebben mogelijks 
belangrijke diagnostische en therapeutische implicaties. 
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